UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

[X]	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~September~~March 3031, ~~2017~~2018

[ ]	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________ to ___________

Commission File Number: 001-33297

POSITIVEID CORPORATION

(Exact name of registrant as specified in its charter)

DELAWARE		06-1637809
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

1690 South Congress Avenue, Suite 201
Delray Beach, Florida 33445		(561) 805-8000
(Address of principal executive offices, including zip code)		(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer [ ] Accelerated filer [ ] Non-accelerated filer [ ] Smaller reporting company [X] Emerging growth company [ ] ~~[ ] [ ] [X] [ ]~~ (Do not check if a smaller reporting company)

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [ ] No [X]

The number of shares outstanding of each of the issuer’s classes of common stock as of the close of business on ~~November~~May 716, ~~2017~~2018 is as follows:

Class		Number of Shares
Common Stock: $0.0001 Par Value		9,393,339	~~150,931,461~~

TABLE OF CONTENTS

PART I — FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
Condensed Consolidated Balance Sheets — September 30, 2017 (unaudited) and December 31, 2016	3
Condensed Consolidated Balance Sheets — March 31, 2018 (unaudited) and December 31, 2017	3
Unaudited Condensed Consolidated Statements of Operations — Three and Nine Months Ended September 30, 2017 and 2016	4
Unaudited Condensed Consolidated Statements of Operations — Three Months Ended March 31, 2018 and 2017	4
Unaudited Condensed Consolidated Statement of Changes in Stockholders’ Deficit — Nine Months Ended September 30, 2017	5
Unaudited Condensed Consolidated Statement of Changes in Stockholders’ Deficit — Three Months Ended March 31, 2018	5
Unaudited Condensed Consolidated Statements of Cash Flows — Nine Months Ended September 30, 2017 and 2016	6
Unaudited Condensed Consolidated Statements of Cash Flows — Three Months Ended March 31, 2018 and 2017	6
Unaudited Notes to Unaudited Condensed Consolidated Financial Statements	7
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS	3436
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	3538
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	3940
ITEM 4. CONTROLS AND PROCEDURES	3940
PART II — OTHER INFORMATION	40
ITEM 1. LEGAL PROCEEDINGS	4041
ITEM 1A. RISK FACTORS	4041
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	41
ITEM 3. DEFAULTS UPON SENIOR SECURITIES	4142
ITEM 4. MINE SAFETY DISCLOSURES	4142
ITEM 5. OTHER INFORMATION	4142
ITEM 6. EXHIBITS	4142
SIGNATURES	4243

PART I — FINANCIAL INFORMATION

Item 1. Financial Statements

POSITIVEID CORPORATION AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(In thousands, except share data)

	September 30, 2017			December 31, 2016
	March 31, 2018			December 31, 2017
	(Unaudited)
Assets
Current Assets:
Cash	$	2549		$	40181
Accounts receivable, net		~~259~~57			~~307~~75
Inventories		~~693~~12			~~678~~433
Prepaid expenses and other current assets		4840			97102
Total Current Assets		~~1,025~~158			~~1,122~~791
Equipment, net		117			129
Investment in ENG Mobile Systems		249			—
Goodwill		800			800
Equipment, net		27			120
Intangibles, net		376			492
Goodwill		601			601
Other assets		58			19
Intangibles, net		167			194
Total Assets	$	2,376		$	2,562
Other assets		11			19
Total Assets	$	1,213		$	1,725
Liabilities and Stockholders’ Deficit
Current Liabilities:
Accounts payable	$	~~251~~206		$	~~394~~295
Accrued expenses and other current liabilities		~~994~~965			~~807~~1,183
Deferred revenue		~~623~~—			~~353~~154
Notes and loans payable, net of discounts		~~372~~408			~~469~~309
Line of credit		~~250~~—			~~150~~350
Short-term convertible debt and accrued interest, net of discounts and premiums		6,~~148~~652			46,~~808~~377
Embedded conversion option liability		23,~~614~~592			42,~~284~~650
Tax liability		~~110~~99			~~142~~100
Total Current Liabilities		11,~~362~~922			11,~~407~~418
Long Term Liabilities:
Loan payable		10—			188
Total Liabilities		11,~~372~~922			11,~~425~~426
Commitments and contingencies (Note 7)
Commitments and contingencies (Note 9)
Stockholders’ Deficit:
Preferred stock, 5,000,000 shares authorized, $0.001 par value:
Series J Convertible Preferred – 1,700 shares authorized, 71 shares issued and outstanding at September 30, 2017 and December 31, 2016, (liquidation preference of $71,000 at September 30, 2017 and December 31, 2016).		—			—
Series J Convertible Preferred – 1,700 shares authorized, 71 shares issued and outstanding at March 31, 2018 and December 31, 2017, (liquidation preference of $71,000 at March 31, 2018 and December 31, 2017).		—			—
Series II Convertible Preferred – 4,000 shares authorized, 3,097 and 2,262 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively; (liquidation preference of $3,281,728 and $2,315,293, at September 30, 2017 and December 31, 2016, respectively).		—			—
Series II Convertible Preferred – 4,000 shares authorized, 3,097 shares issued and outstanding at March 31, 2018 and December 31, 2017; (liquidation preference of $3,381,144 and $3,332,479, March 31, 2018 and December 31, 2017, respectively)		—			—
Common stock, 19,995,000,000 shares authorized, $0.0001 par value; 84,856,216 and 894,909 shares issued and outstanding at September 30, 2017 and December 31, 2016.		8			—
Common stock, 19,995,000,000 shares authorized, $0.0001 par value; 5,333,246 and 359,075 shares issued and outstanding at March 31, 2018 and December 31, 2017, respectively		—			—
Additional paid-in capital		~~154~~157,~~822~~938			~~148~~156,~~359~~186
Accumulated deficit		(~~163~~168,~~913~~647	)		(~~157~~165,~~222~~789	)
Total PositiveID Corporation Stockholders’ Deficit		(910,~~083~~709	)		(89,~~863~~603	)
Non-controlling interest in consolidated subsidiary (Note 3)		87—			—(98	)
Total Stockholders’ Deficit		(810,~~996~~709	)		(89,~~863~~701	)
Total Liabilities and Stockholders’ Deficit	$	21,~~376~~213		$	21,~~562~~725

See accompanying unaudited notes to unaudited condensed consolidated financial statements.

POSITIVEID CORPORATION AND SUBSIDIARIES

Condensed Consolidated Statements of Operations

(In thousands, except share and per share data)

(Unaudited)

	Three Months Ended						Nine Months Ended
	Three Months Ended March 31,
	September 30,						September 30,
	2018			2017
	2017			2016			2017			2016
Revenues	$	420		$	1,227
Revenue	$	1,467		$	1,065		$	3,919		$	4,578
Cost of revenues		228			804
Cost of revenue		942			527			2,497			2,874
Gross profit		192			423
Gross Profit		525			538			1,422			1,704
Operating expenses:
Operating expenses:
Selling, general and administrative		1,063			2,155
Selling, general and administrative		1,277			3,755			4,652			7,342
Research and development		158			101
Research and development		138			187			391			409
Total operating expenses		1,221			2,256
Total operating expenses		1,415			3,942			5,043			7,751
Operating (loss)		(1,029	)		(1,833	)
Operating loss		(890	)		(3,404	)		(3,621	)		(6,047	)
(Loss) on investment in ENG Mobile Systems		(45	)		—
Other income (expense):
Interest expense		(558	)		(2,263	)		(3,042	)		(5,852	)
Gain on deconsolidation of ENG Mobile Systems		388			—
Change in acquisition obligations, net		—			107			—			107
Interest expense		(768	)		(1,451	)
Change in fair value of embedded conversion option liability		(~~459~~1,441	)		~~1,077~~(571	)		~~(103~~	)		~~1,424~~
Gain (loss) on extinguishment of debt		—			(6	)		57			(6	)
Loss on extinguishment of debt		(22	)		—
Other income, net		6			6			37			57
Other income		14			6
Total other expense, net		(1,~~011~~829	)		(12,~~079~~016	)		~~(3,051~~	)		~~(4,270~~	)
Net loss		(12,~~901~~903	)		(43,~~483~~849	)		~~(6,672~~	)		~~(10,317~~	)
Preferred stock dividends		(4950	)		(34	)		~~(131~~	)		~~(100~~	)
Net loss attributable to common stockholders before allocation to non-controlling interest	$	(12,~~950~~953	)	$	(43,~~517~~883	)		~~(6,803~~	)		~~(10,417~~	)
Less net (income) loss allocated to non-controlling interest in consolidated subsidiary		6			—			(19	)		—
Less net loss allocated to non-controlling interest in consolidated subsidiary		45			—
Net loss applicable to PositiveID Corporation common stockholders	$	(12,~~944~~908	)	$	(43,~~517~~883	)	$	~~(6,822~~	)	$	~~(10,417~~	)
Loss per common share attributable to common stockholders – basic and diluted	$	(0.05	)	$	(578.21	)	$	(0.48	)	$	(1,884.75	)
Net loss per common share attributable to common stockholders – basic and diluted	$	(1.90	)	$	(2,646.89	)
Weighted average shares outstanding – basic and diluted		351,~~537~~528,~~930~~126			71,~~812~~467			~~14,143,169~~			~~5,527~~

See accompanying unaudited notes to unaudited condensed consolidated financial statements.

POSITIVEID CORPORATION AND SUBSIDIARIES

Condensed Consolidated Statement of Changes in Stockholders’ Deficit

For the ~~Nine~~Three Months Ended ~~September~~March 3031, ~~2017~~2018

(In thousands, except share data)

(Unaudited)

	Preferred Shares				Common Shares				Additional Paid-in			Accumulated			Non- controlling			Total Stockholders’
	Shares		Amount		Shares		Amount		Capital			Deficit			Interest			Deficit
Balance at December 31, 2016		2,333	$	—		894,909	$	—	$	148,359		$	(157,222	)	$	—		$	(8,863	)
Balance at December 31, 2017		3,168	$	—		359,075	$	—	$	156,186		$	(165,789	)	$	(98	)	$	(9,701	)
Net (loss) income		—		—		—		—		—			(6,691	)		19			(6,672	)
Net loss after allocation to non-controlling interest		—		—		—		—		—			(2,858	)		(45	)		(2,903	)
Stock based compensation - employees		—		—		—		—		~~181~~22			—			—			~~181~~22
Other Stock based compensation - Series II Preferred shares		835		—		—		—		852			—			—			852
Common Stock issued pursuant to convertible note conversions		—		—		4,974,171		—		1,042			—			—			1,042
Common Stock issued pursuant to convertible note conversions		—		—		82,661,307		8		1,849			—			—			1,857
Reclassification of derivative liability upon debt conversion and debt extinguishment		—		—		—		—		525			—			—			525
Reclassification of derivative liability upon debt conversion		—		—		—		—		2,245			—			—			2,245
Reclassification of premium upon debt conversion		—		—		—		—		199			—			—			199
Reclassification of premium upon debt conversion and extinguishment		—		—		—		—		147			—			—			147
Preferred stock dividends		—		—		—		—		(50	)		—			—			(50	)
Preferred stock dividends		—		—		—		—		(131	)		—			—			(131	)
Sale of interest in subsidiary		—		—		—		—		—			—			143			143
Sale of non-controlling interest		—		—		1,300,000		—		1,320			—			68			1,388
Gain on settlement of balance due to equity method investee		—		—		—		—		14			—			—			14
Balance at September 30, 2017		3,168	$	—		84,856,216	$	8	$	154,822		$	(163,913	)	$	87		$	(8,996	)
Balance at March 31, 2018		3,168	$	—		5,333,246	$	—	$	157,938		$	(168,647	)	$	—		$	(10,709	)

See accompanying unaudited notes to unaudited condensed consolidated financial statements.

POSITIVEID CORPORATION AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

	Nine Months Ended September 30,
	Three Months Ended March 31,
	2017			2016
	2018			2017
Cash flows from operating activities:
Net loss	$	(62,~~672~~903	)	$	(103,~~317~~849	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		151			251
Gain on deconsolidation		(388	)		—
Stock-based compensation		1,033			2,908
Depreciation and amortization		33			50
Convertible debt discounts and premium amortization		2,647			5,306
Stock-based compensation		22			922
(Gain) loss on extinguishment of debt		(57	)		6
Convertible debt discounts and premium amortization		641			1,316
Change in fair value of embedded conversion option liability		103			(1,424	)
Loss on extinguishment of debt		22			2
Change in acquisition obligations		—			(107	)
Change in fair value of embedded conversion option liability		1,441			571
Gain on disposal of property & equipment		(2—	)		—(2	)
Note issued as consideration for services		15			145
Note issued as penalty		—			15
Bad debt		2			—
Foreign exchange transaction loss		10(2	)		—
Loss on investment in ENG Mobile Systems		45			—
Changes in operating assets and liabilities:
Decrease (increase) in prepaid expenses and other current assets		56			456
(Increase) decrease in:
Decrease (increase) in inventory		(15	)		1,214
Account receivable		(31	)		(98	)
Increase (decrease) in accounts payable and other current liabilities		(87	)		(39	)
Prepaid expenses and other current assets		30			45
Increase in accrued interest		245			471
Inventories		79			210
(Decrease) increase in deferred revenue		271			(1,724	)
Increase (decrease) in:
Decrease in tax liability		(47	)		(58	)
Accounts payable and other accrued expense		(43	)		66
Net cash used in operating activities		(2,347	)		(2,912	)
Accrued interest		122			76
Deferred revenue		(94	)		363
Tax liability		—			1
Net cash used in operating activities		(1,024	)		(312	)
Cash flows from investing activities:
Proceeds on sale of non-controlling interest in consolidated subsidiary		1,495			—
Bank overdraft liability held by deconsolidated subsidiary		99			—
Transaction costs related to sale of non-controlling interest		(107	)		—
Purchase of property & equipment		(2	)		(15	)
Purchase of property and equipment		(26	)		(8	)
Proceeds on disposal of property & equipment		—			4
Proceeds on disposal of property & equipment		4			—
Net cash (used in) provided by investing activities		97			(11	)
Net cash (used in) provided by investing activities		1,366			(8	)
Cash flows from financing activities:
Proceeds from debt financing, net of fees		1,886			3,076
Proceeds from convertible debt financing, net of fees		829			868
Payments on short-term debt		(1,020	)		(189	)
Proceeds from note payable, net of discounts		48			—
Proceeds from line of credit, net of payments		100			—
Principal payments of short-term debt		(82	)		(136	)
Net cash provided by financing activities		966			2,887
Payment of line of credit		—			(150	)
Net (decrease) in cash		(15	)		(33	)
Net cash provided by financing activities		795			582
Cash, beginning of period		40			173
Net increase (decrease) in cash		(132	)		259
Cash, end of period	$	25		$	140
Cash, beginning of period		181			40
Cash, end of period	$	49		$	299
Supplementary Cash Flow Information:
Cash paid for interest	$	~~127~~3		$	7042
Cash paid for income tax	$	—		$	—
Non-cash financing and investing activities:
Conversion of promissory notes into common stock	$	1,~~857~~042		$	~~3,270~~846
Stock issued for prepaid services	$	—		$	159
Reclassification of embedded conversion option liability to equity upon conversion of debt and extinguishment of debt	$	525		$	945
Reclassification of embedded conversion option liability upon conversion of debt	$	2,245		$	3,026
Reclassification of stock settle debt premium to equity upon conversion of debt	$	199		$	38
Premium recorded on debt	$	735		$	447
Discounts recorded for loan fees and original issue discount	$	56		$	173
Reclassification of stock settled debt premium to equity upon conversion of debt	$	147		$	28
Premium recorded on debt	$	507		$	274
Discounts recorded for loan fees and original issue discount	$	202		$	320
Embedded conversion option liability recorded as debt discount	$	26		$	328
Embedded conversion option liability recorded as debt discount	$	472		$	2,270
Note issued in settlement of amounts due to ENG	$	54		$	—

See accompanying unaudited notes to unaudited condensed consolidated financial statements.

POSITIVEID CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements

~~September~~March 3031, ~~2017~~2018

(Unaudited)

1. Organization and Basis of Presentation

PositiveID Corporation, including its wholly-owned subsidiaries PositiveID Diagnostics Inc. (“PDI”) and Thermomedics, Inc. (“Thermomedics”), and its majority -owned ~~subsidiaries E-N-G Mobile Systems~~subsidiary, ~~Inc. (“ENG”) and~~ ExcitePCR Corporation (“ExcitePCR”) , (collectively, the “Company” or “PositiveID”), develops molecular diagnostic systems for bio-threat detection and rapid medical testing; ~~manufactures specialty technology vehicles;~~ and markets the Caregiver® non-contact clinical thermometer. The Company’s fully automated pathogen detection systems are designed to detect a range of biological threats. The Company’s M-BAND (Microfluidic Bio-agent Autonomous Networked Detector) system is an airborne bio-threat detection system developed for the homeland defense industry to detect biological weapons of mass destruction. The Company is developing the FireflyDX family of products, which are automated pathogen detection ~~system~~systems for rapid diagnostics, in both portable and handheld forms, for clinical and point-of-need applications. The ~~Company~~ ~~also manufactures specialty technology vehicles focused primarily on mobile laboratory and communications applications. The~~ Company’s Caregiver® thermometer is an FDA-cleared infrared thermometer for the professional healthcare market. Through its investment in ENG Mobile Systems, which was a majority owned subsidiary through January 30, 2018 (see Note 3), the Company manufactures specialty technology vehicles focused primarily on mobile laboratory and communications applications.

~~Authorized~~Reverse ~~Common~~ Stock Split

On ~~January~~April 3013, ~~2017~~2018, the Company filed ~~the~~an ~~First~~amendment ~~Amendment~~ to ~~the~~its ~~Company’s~~ Third Amended and Restated Certificate of Incorporation ~~with the State of Delaware~~, to increase the Company’s authorized capital stock from 3.9 billion shares to 20 billion shares (19.995 billion common) and to change the par value of the Company’s common stock from $0.001 to $0.0001 (the “Common Stock”). On May 19, 2017, the Company filed the Second Amendment to the Third Amended and Restated Certificate of Incorporation, as amended, with the State of Delaware, to implement a 1-for-31,000 reverse stock split (the “Reverse Stock Split”) of the Company’s outstanding Common Stock, which became effective on ~~May~~April 2318, ~~2017~~2018. The reverse stock split affected the outstanding Common Stock as well as all outstanding Common Stock underlying convertible notes, warrants, convertible preferred stock and stock options ~~outstanding~~ immediately prior to the reverse stock split. The number of authorized shares was not adjusted. All share and per share amounts in the accompanying historical consolidated financial statements have been retroactively adjusted to reflect the ~~change~~Reverse ~~in the par value of the Common~~ Stock ~~and the 1-for-3,000 reverse stock split~~Split.

Going Concern

The Company’s unaudited consolidated financial statements have been prepared assuming the Company will continue as a going concern. As of ~~September~~March 3031, ~~2017~~2018, we had a working capital deficit, stockholders’ deficit and accumulated deficit of approximately $1011.3 8 million, $910.07 million and $~~164~~168.6 million, respectively, compared to a working capital deficit, stockholders’ deficit and accumulated deficit of approximately $10.36 million, $9.07 million and $~~157~~165.8 million, respectively, as of December 31, ~~2016~~ 2017. The increase in the working capital deficit iswas primarily ~~the~~due ~~result~~to ofcapital ~~the~~raised ~~Company’s~~through convertible debt financings that was spent on operations.

We have incurred operating losses and net cash used in operating activities since the merger that created PositiveID in 2009. The current ~~2017~~2018 operating losses are the result of research and development expenditures, ~~and~~ selling, general and administrative ~~expenses~~ expenses related to our molecular diagnostics and detection and Caregiver products. We expect our operating losses to continue through ~~2017.~~ 2018. It’s management’s opinion that these conditions raise substantial doubt about our ability to continue as a going ~~concern~~ concern for a period of one year from the date of this filing.

Our ability to continue as a going concern is dependent upon our ability to obtain financing to fund the continued development of our products and to support working capital requirements. Until we are able to achieve operating profits, we will continue to seek to access the capital markets. In fiscal ~~2016~~2017 and for the first ~~nine~~three months of ~~2017~~2018, we raised approximately $32.87 and $10.9 million, respectively primarily from the issuance of convertible debt. In addition, during the nine months ended September 30, 2017, we received approximately $1.4 million of net proceeds from the sale to a strategic investor of a non-controlling interest in one of our subsidiaries (see Note 3).

The Company intends to continue to access capital to provide funds to meet its working capital requirements for the near-term future. In addition, and if necessary, the Company could reduce and/or delay certain discretionary research, development and related activities and costs. However, there can be no assurances that the Company will be able to negotiate additional sources of equity or credit for its long-term capital needs. The Company’s inability to have continuous access to such financing at reasonable costs could materially and adversely impact its financial condition, results of operations and cash flows, and result in significant dilution to the Company’s existing stockholders. The Company’s consolidated financial statements do not include any adjustments relating to recoverability of assets and classifications of assets and liabilities that might be necessary should the Company be unable to continue as a going concern.

Basis of Presentation

The accompanying condensed consolidated balance sheet as of December 31, 2017 has been derived from the Company’s audited financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2017. The accompanying unaudited condensed consolidated financial statements for the three months ended March 31, 2018 and 2017 have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and pursuant to the rules and regulations of the Securities Exchange Commission (“SEC”). Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures made are adequate to make the information not misleading. In the opinion of the Company’s management, all adjustments (including normal recurring adjustments) necessary for a fair presentation for the periods presented have been reflected as required by Regulation S-X, Rule 10-01.

POSITIVEID CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements

~~September~~March 3031, ~~2017~~2018

(Unaudited)

~~Basis~~The unaudited condensed consolidated statements of ~~Presentation~~operations for the three months ended March 31, 2018 are not necessarily indicative of the results that may be expected for the entire year. These statements should be read in conjunction with the consolidated financial statements and related notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.

The accompanying condensed consolidated balance sheet as of December 31, 2016 has been derived from the Company’s audited financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2016. The accompanying unaudited condensed consolidated financial statements for the nine months ended September 30, 2017 and 2016 have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and pursuant to the rules and regulations of the Securities Exchange Commission (“SEC”). Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures made are adequate to make the information not misleading. In the opinion of the Company’s management, all adjustments (including normal recurring adjustments) necessary for a fair presentation for the periods presented have been reflected as required by Regulation S-X, Rule 10-01.

The unaudited condensed consolidated statements of operations for the three and nine months ended September 30, 2017 are not necessarily indicative of the results that may be expected for the entire year. These statements should be read in conjunction with the consolidated financial statements and related notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016.

2. Summary of Significant Accounting Policies

Principles of Consolidation

The ~~unaudited~~ consolidated financial statements include the accounts of the Company and its wholly-owned and majority- owned subsidiaries of of which all are inactive except for PDI, Thermomedics and ~~ENG~~ExcitePCR. All intercompany balances and transactions have been eliminated in the consolidation.

On July 17, 2017, ExcitePCR Corporation, a majority-owned subsidiary of the Company, was ~~formed~~incorporated toin the State of Delaware, to own and further the development of the FireflyDX family of products. As of March 31, 2018, ExcitePCR ~~was~~is ~~incorporated~~operating inand doing the business ~~State~~ of ~~Delaware~~ PDI under the ExcitePCR name, while focusing on the potential strategic partnership(s) and isfinancing ~~inactive~~that aswill complete the sale of ~~September~~all ~~30,~~PDI ~~2017~~and FireflyDX related assets to ExcitePCR (see Note 3).

Investment in ENG Mobile Systems

On January 30, 2018, ENG, in order to raise working capital, sold additional ownership of ENG to a strategic investor who previously held the non-controlling interest in ENG. As a result of this transaction the Company’s ownership and voting interest in ENG decreased to approximately 24% and the Company deconsolidated the balance sheet, results of operations and cash flows of ENG in its consolidated financial statements and now accounts for ENG under the equity method of accounting in accordance with ASC 323. At December 31, 2017 the Company owned 50.2% of ENG and controlled ENG’s assets, and therefore consolidated its balance sheet and results of operations (see Note 3 and Note 5).

Non-Controlling Interest

On June 12, 2017, the Company sold 49.2% ownership of ENG, to a strategic investor. Accordingly, ~~the~~as ~~Company~~of isthat ~~presenting~~date, ~~noncontrolling~~the Company presented noncontrolling interests as a component of equity on its consolidated balance sheets under the heading “Non-controlling interest in consolidated subsidiary” and ~~reports~~reported noncontrolling interest net income or loss under the heading “Net (income) loss allocated to noncontrolling interest in consolidated subsidiary” in the consolidated statements of operations based on its 5150.2% ownership (see Note 3), through January 30, 2018.

~~Use~~Accounting offor ~~Estimates~~Investment in ENG Mobile Systems – Equity Method

The ~~preparation~~Company ofaccounts ~~financial~~for ~~statements~~investments in ~~conformity~~which ~~with~~the ~~GAAP~~Company ~~requires~~owns ~~management~~more tothan ~~make~~20% ~~estimates~~of ~~and~~the ~~assumptions~~investee, ~~that~~using ~~affect~~ the ~~reported~~equity ~~amounts~~method ofin ~~assets~~accordance with ~~and~~ASC ~~liabilities~~Topic 323, Investments—Equity Method and ~~disclosure~~Joint ofVentures. ~~contingent~~Under ~~assets~~the ~~and~~equity ~~liabilities~~method, atan investor initially records an investment in the ~~date~~stock of ~~the~~an ~~financial statements~~investee at cost and adjusts the ~~reported~~carrying ~~amounts~~amount of ~~revenue~~the ~~and~~investment ~~expenses~~to ~~during~~recognize the ~~reporting~~investor’s share ~~period.~~of ~~Actual~~the ~~results~~earnings ~~could~~or ~~differ~~losses ~~from~~of ~~those estimates~~the investee after the date of acquisition. ~~Significant~~The ~~estimates~~amount ~~during~~of the ~~reported~~adjustment ~~periods~~is ~~include~~included ~~valuation~~in the determination of ~~assets~~net ~~acquired~~income by the investor, and ~~liabilities~~such ~~assumed~~amount reflects adjustments similar to those made in ~~business~~preparing consolidated ~~combinations,~~statements ~~allowance~~including ~~for~~adjustments ~~doubtful~~to ~~accounts~~eliminate ~~receivable~~intercompany gains and losses, ~~inventories~~and ~~valuation~~to amortize, ~~estimates~~if ofappropriate, ~~depreciable~~any ~~lives~~difference between investor cost and ~~valuation~~ underlying equity in net assets of ~~property~~the ~~and~~investee ~~equipment,~~at ~~valuation~~the date of ~~goodwill~~investment. ~~and~~The ~~intangible~~investment ~~assets~~of ~~and~~an ~~related~~investor ~~amortization~~is also ~~period,~~adjusted ~~valuation~~to reflect the investor’s share of ~~loss~~changes ~~and~~in the investee’s capital. Dividends received from an investee ~~other~~reduce ~~contingencies,~~the ~~product~~carrying ~~warranty~~amount ~~liabilities,~~of ~~valuation~~the investment. A series of ~~derivatives,~~operating ~~valuation~~losses of ~~beneficial~~an ~~conversion~~investee ~~features,~~or ~~estimate~~other factors may indicate that a decrease in value of ~~contingent~~the ~~earn-out~~investment ~~liabilities~~has occurred which is other than temporary, ~~valuation~~and which should be recognized even though the decrease in value is in excess of ~~stock-based~~what ~~compensation~~would ~~and~~otherwise anbe ~~estimate~~recognized by application of the ~~deferred~~equity ~~tax~~method ~~asset~~(see ~~valuation allowance~~Note 5).

Inventories

Inventories consist of finished goods of our Caregiver non-contact thermometers, and in our Mobile Lab Segment consists of finished goods, standard and manufactured frames and bodies of vehicles, components of mobile units and other materials and is stated at lower of cost and net realizable value on average basis. The Company early adopted ASU 2015-11 “Simplifying the Measurement of Inventory” on January 1, 2016, and there was no material impact. Reserves, if necessary, are recorded to reduce inventories to net realizable value based on assumptions about consumer demand, current inventory levels and product life cycles for the various inventory items. These assumptions are evaluated periodically and are based on the Company’s business plan and from feedback from customers and the product development team; however, estimates can vary significantly. As of September 30, 2017 and December 31, 2016, inventory reserves were not material.

POSITIVEID CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements

~~September~~March 3031, ~~2017~~2018

(Unaudited)

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates during the reported periods include valuation of assets acquired and liabilities assumed in business combinations, allowance for doubtful accounts receivable, inventories valuation, valuation of equity method investments, estimates of depreciable lives and valuation of property and equipment, valuation of goodwill and intangible assets and related amortization period, valuation of loss and other contingencies, product warranty liabilities, valuation of derivatives, valuation of beneficial conversion features, estimate of contingent earn-out liabilities, valuation of stock-based compensation and an estimate of the deferred tax asset valuation allowance.

Inventories

Inventories consist of finished goods of our Caregiver® non-contact thermometers as of March 31, 2018 and December 31, 2017, and as of December 31, 2017, in our Mobile Lab Segment inventory, finished goods, standard and manufactured frames and bodies of vehicles, components of mobile units and other materials and is stated at lower of cost and net realizable value. The Company early adopted ASU 2015-11 “Simplifying the Measurement of Inventory” on January 1, 2016, and there was no material impact. Reserves, if necessary, are recorded to reduce inventories to net realizable value based on assumptions about consumer demand, current inventory levels and product life cycles for the various inventory items. These assumptions are evaluated periodically and are based on the Company’s business plan and from feedback from customers and the product development team; however, estimates can vary significantly. As of March 31, 2018 and December 31, 2017, inventory reserves were not material.

Inventories consisted of the following (in thousands):

	September 30, 2017		December 31, 2016
	March 31, 2018		December 31, 2017
Finished goods of Caregiver® non-contact thermometers	$	4112	$	2827
Materials inventory		~~652~~—		~~462~~315
Mobile vehicle inventory		—		~~188~~91
	$	~~693~~12	$	~~678~~433

Intangible Assets and Goodwill

Intangible assets are carried at cost less accumulated amortization, computed using the straight-line method over the estimated useful lives. Customer contracts and relationships are being amortized over a period of 3 years, patents and other intellectual property are being amortized over a period of 5 years, and non-compete agreements are being amortized over 2 years.

The Company continually evaluates whether events or circumstances have occurred that indicate the remaining estimated useful lives of its definite-lived intangible assets may warrant revision or that the remaining balance of such assets may not be recoverable. The Company uses an estimate of the related undiscounted cash flows attributable to such asset over the remaining life of the asset in measuring whether the asset is recoverable.

The Company records goodwill as the excess of the purchase price over the fair values assigned to the net assets acquired in business combinations. Goodwill is allocated to reporting units as of the acquisition date for the purpose of goodwill impairment testing. The Company’s reporting units are those businesses for which discrete financial information is prepared. ASC 350, “Intangibles — Goodwill and Other” requires that intangible assets with indefinite lives, including goodwill, be evaluated on an annual basis for impairment or more frequently if an event occurs or circumstances change that could potentially result in impairment. The goodwill impairment test requires the allocation of goodwill and all other assets and liabilities to reporting units. If the fair value of the reporting unit is less than the book value (including goodwill), then goodwill is reduced to its implied fair value and the amount of the write-down is charged to operations. We are required to test our goodwill and intangible assets with indefinite lives for impairment at least annually.

InThe ~~assessing~~Company ~~potential~~performed ~~impairment~~its ofannual ~~the~~impairment ~~intangible~~test ~~assets~~of ~~recorded~~goodwill inas ~~connection~~of ~~with~~December ~~PDI~~31, ~~ENG~~2017. ~~and~~As ~~Thermomedics,~~a asresult of ~~September 30,~~our ~~2017~~analysis, wewhich ~~considered~~ included the ~~likelihood~~information ofavailable ~~future~~in ~~cash~~January ~~flows~~2018, ~~attributable~~resulting toin ~~such~~the ~~assets~~dilution onof athe ~~per~~Company’s ~~segment~~interest ~~basis.~~in ~~Based on our analysis~~ENG, we ~~have~~ concluded based on information ~~currently~~ available, at that notime, ~~impairment~~the carrying value of the ENG intangible ~~assets~~asset ~~exists~~and asgoodwill ofwere ~~September 30, 2017~~impaired. ~~The~~An ~~Company~~aggregate amount ~~performed~~of ~~its~~$342,327, ~~annual~~representing ~~impairment~~the ~~test~~full impairment of ENG goodwill asand ofintangible ~~December 31~~assets, ~~2016~~was charged to impairment expense in fiscal 2017. AsIn aassessing ~~result~~potential impairment of ~~this~~the ~~annual~~intangible ~~test, it~~assets ~~was~~recorded ~~determined~~in ~~that~~connection with the ~~goodwill~~PDI ~~balance~~and Thermomedics, as of ~~December~~March 31, ~~2016~~2018, ~~was~~we ~~not~~considered ~~impaired.~~the ~~The~~likelihood ~~amortization~~of ~~expense~~future ~~was~~cash ~~approximately $39,000~~flows ~~and~~attributable ~~$39,000~~to ~~for~~such ~~the~~assets ~~three~~on ~~months~~a ~~ended~~per ~~September~~segment ~~30,~~basis. ~~2017~~Based on ~~and~~our ~~2016~~analysis, ~~respectively~~we ~~and~~have ~~was~~concluded ~~approximately~~based ~~$116,200~~on ~~and~~information ~~$218~~currently available,~~000 for~~ that no impairment of the ~~nine~~intangible ~~months~~assets ~~ended~~or ~~September~~goodwill existed ~~30,~~as ~~2017~~of ~~and~~March ~~2016~~31, ~~respectively~~2018.

Revenue Recognition

Revenue is recognized when persuasive evidence of an arrangement exists, collectability of arrangement consideration is reasonably assured, the arrangement fees are fixed or determinable and upon completion and delivery in accordance with the customer contract or purchase order.

If at the outset of an arrangement, the Company determines that collectability is not reasonably assured, revenue is deferred until the earlier of when collectability becomes probable or the receipt of payment. If there is uncertainty as to the customer’s acceptance of the Company’s deliverables, revenue is not recognized until the earlier of receipt of customer acceptance or expiration of the acceptance period. If at the outset of an arrangement, the Company determines that the arrangement fee is not fixed or determinable, revenue is deferred until the arrangement fee becomes estimable, assuming all other revenue recognition criteria have been met.

To date, the Company has generated revenue from three sources: (1) professional services, (2) technology licensing, and (3) product sales.

POSITIVEID CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements

~~September~~March 3031, ~~2017~~2018

(Unaudited)

Intangible amortization expense was approximately $27,000 and $39,000 for the three months ended March 31, 2018 and 2017, respectively.

Revenue Recognition

On January 1, 2018, we adopted ASC 606 — Revenue from Contracts with Customers (Topic 606), which supersedes the revenue recognition requirements in Accounting Standards Codification (ASC) Topic 605, Revenue Recognition. ASC 606 is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASC 606 also requires additional disclosure about the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer purchase orders, including significant judgments. Our adoption of ASC 606 did not result in cumulative adjustments and does not have any impact on our results of operations, cash flows or financial condition in 2018.

If at the outset of an arrangement, the Company determines that collectability of the consideration for the transferred goods or services is not probable, revenue is deferred until the earlier of when collectability becomes probable or the receipt of payment. If there is uncertainty as to the transfer of goods or services, revenue is not recognized until the earlier of the transfer or expiration of the obligation. If at the outset of an arrangement, the Company determines that the transaction price is not determinable, revenue is deferred until the consideration becomes estimable, assuming all other revenue recognition criteria have been met.

To date, the Company has generated revenue from three sources: (1) professional services, (2) technology licensing, and (3) product sales.

Specific revenue recognition criteria for each source of revenue is as follows:

	(1)	Revenues for professional services, which are of short term duration, are recognized ~~when~~as the entity satisfies a performance obligation by transferring the promised services ~~are~~to ~~provided~~a customer;
	(2)	Technology license revenue is recognized upon the completion of all terms of that license. Payments received in advance of completion of the license terms are recorded as deferred revenue; and
	(3)	Revenue from sales of the Company’s products is recorded when risk of loss has passed to the buyer and criteria for revenue recognition discussed above is met. Payments received in advance of delivery and revenue recognition are recorded as deferred revenue.

If these criteria are not met, the arrangement is accounted for as one unit of accounting which would result in revenue being recognized ratably over the contract term or being deferred until the earlier of when such criteria are met or when the ~~last~~performance ~~undelivered~~obligation ~~element~~ is ~~delivered~~satisfied. If these criteria are met for each element and there is a relative ~~selling~~transaction price for all units of accounting in an arrangement, the ~~arrangement~~ consideration is allocated to the separate units of accounting based on each unit’s relative ~~selling~~transaction price.

Concentrations

Concentration of Deferred Revenue

As of ~~September~~March 3031, ~~2017~~2018, the Company had deferred revenue of ~~approximately $0~~nil.6 ~~million of which 30%, 17% and 16% were from three of the Company’s customers.~~ As of December 31, ~~2016~~2017, the Company had deferred revenue of approximately $0.42 million of which 54 61% and 2039% were from two of the Company’s customers.

Concentration of Revenues

During the three months ended ~~September~~March 3031, ~~2017~~2018, the Company generated revenue of approximately $10.54 million of which 4230%, 29% and 2418% were from ~~two~~three of the Company’s customers. During the ~~nine~~three months ended ~~September~~March 3031, 2017, the Company generated revenue of approximately $31.92 million of which 3229%, 1020% and 914% were from three of the Company’s customers.

Concentration of Accounts Receivable

As of ~~September~~March 3031, ~~2017~~2018, the Company had accounts receivable of approximately $~~0.3~~57,000 ~~million~~ of which 7030%, ~~was~~24% and 22% were from athree ~~single~~of ~~customer.~~the Company’s customers. As of December 31, ~~2016~~2017, the Company had accounts receivable of approximately $~~0.3~~75,000 ~~million~~ of which 5530% and 1424% were from two of the Company’s customers.

Concentration of Manufacturer

We currently buy our primary Thermomedics products from one third-party, sole source supplier who produces our products in its plant in Taiwan. Although we have the right to engage other manufacturers, we have not done so. Accordingly, our reliance on this supplier involves certain risks, including:

POSITIVEID CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements

March 31, 2018

(Unaudited)

	●	The cost of our products might increase, for reasons such as inflation and increases in the price of the precious metals, if any, or other internal parts used to make them, which could cause our cost of goods to increase and reduce our gross margin and profitability if any; and
	●	Poor quality could adversely affect the reliability and reputation of our products.

Any of these uncertainties also could adversely affect our business reputation and otherwise impair our profitability and ability to compete.

Fair Value of Financial Instruments and Fair Value Measurements

The Company measures its financial and non-financial assets and liabilities, as well as makes related disclosures, in accordance with ASC Topic 820, Fair Value Measurements and Disclosures (“ASC Topic 820”). For certain of our financial instruments, including cash, accounts receivable, accounts payable and accrued liabilities, the carrying amounts approximate fair value due to their short maturities. Amounts recorded for notes payable, net of discount, also approximate fair value because current interest rates available to the Company for debt with similar terms and maturities are substantially the same.

ASC Topic 820 provides guidance with respect to valuation techniques to be utilized in the determination of fair value of assets and liabilities. Approaches include, (i) the market approach (comparable market prices), (ii) the income approach (present value of future income or cash flow), and (iii) the cost approach (cost to replace the service capacity of an asset or replacement cost). ASC Topic 820 utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:

	Level 1:	Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.

	Level 2:	Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.

	Level 3:	Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.

Stock-Based Compensation

Stock-based compensation expenses are reflected in the Company’s consolidated statements of operations under selling, general and administrative expenses and research and development expenses.

POSITIVEID CORPORATION

Notes to the Condensed Consolidated Financial Statements

September 30, 2017

(Unaudited)

The Company estimates the fair value of stock-based compensation awards on the date of grant using the Black-Scholes-Merton (“BSM”) option pricing model, which was developed for use in estimating the value of traded options that have no vesting restrictions and are freely transferable. In addition, option valuation models require the input of highly subjective assumptions including the expected stock price volatility. The BSM option pricing model considers, among other factors, the expected term of the award and the expected volatility of the Company’s stock price. Expected terms are calculated using the Simplified Method, volatility is determined based on the Company’s historical stock price trends and the discount rate is based upon treasury rates with instruments of similar expected terms. Warrants granted to non-employees are accounted for in accordance with the measurement and recognition criteria of ASC Topic 505-50, Equity Based Payments to Non-Employees.

Compensation expense for all stock-based employee and director compensation awards granted is based on the grant date fair value estimated in accordance with the provisions of ASC Topic 718, Stock Compensation (“ASC Topic 718”). The Company recognizes these compensation costs on a straight-line basis over the requisite service period of the award, which is generally the vesting term. Vesting terms vary based on the individual grant terms.

Segments

The Company follows the guidance of ASC 280-10 for “Disclosures about Segments of an Enterprise and Related Information.” The Company operated in three business segments ~~as of September 30, 2017~~: Molecular Diagnostics, Medical Devices and Mobile Labs (through January 30, 2018) (see Note 911).

POSITIVEID CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements

March 31, 2018

(Unaudited)

Loss per Common Share

The Company presents basic net income (loss) per common share and, if applicable, diluted net income (loss) per share. Basic income (loss) per common share is based on the weighted average number of common shares outstanding during the year and after preferred stock dividends. The calculation of diluted income (loss) per common share assumes that any dilutive convertible preferred shares outstanding at the beginning of each year or the date issued were convertible at those dates, with preferred stock dividend requirements and outstanding common shares adjusted accordingly. It also assumes that outstanding common shares were increased by shares issuable upon exercise of those stock options and warrants for which the average period market price exceeds the exercise price, less shares that could have been purchased by the Company with related proceeds. Additionally, shares issued upon conversion of convertible debt are included.

The following potentially dilutive equity securities outstanding as of ~~September~~March 3031, ~~2017~~2018 and as of December 31, ~~2016~~2017 were not included in the computation of dilutive loss per common share because the effect would have been anti-dilutive:

	September 30, 2017		December 31, 2016
	March 31, 2018		December 31, 2017
Common shares issuable under:
Convertible notes		~~516~~93,~~232~~017,~~731~~368		4,~~429~~615,~~144~~455
Convertible Series II Preferred Stock		~~187~~551,~~527,314~~671		1543,~~102,798~~570
Convertible Series J Preferred Stock		~~4,057,143~~55		~~33,810~~55
Stock options, restricted stocks and warrants		2,105		2,105
		93,569,094		5,159,080
		707,819,293		5,567,857

The ~~Common~~common shares issuable under the convertible notes, ~~convertible~~as ~~Series~~of IIDecember ~~and~~31, ~~Series~~2017 Jand ~~Preferred~~March ~~Stock~~31, ~~was~~2018 were calculated using the ~~closing~~ closing bid prices at ~~September~~December 3031, 2017 and ~~December~~March 31, ~~2016~~2018 which were $02.~~0175~~10 and $20.10, respectively. The prices used to calculate the common shares issuable under the convertible Series II and Series J Preferred Stock as of December 31, 2017 and March 31, 2018 were as follows: (i) fixed conversion prices of $16.80 and $2.20 for Series II as determined by the agreements;(ii) fixed conversion price of $1,280 for Series J (based on Series J stated value of $1,000 per share) as determined by the agreement.

Recent Accounting Pronouncements

There are no new accounting pronouncements during the ~~nine~~three months ended ~~September~~March 3031, ~~2017~~2018 other than those described below that affect the consolidated financial position of the Company or the results of its operations. Accounting Standard Updates which are not effective until after ~~September~~March 3031, ~~2017~~2018, and the potential effects on the Company’s consolidated financial position or ~~results~~ results of its operations are discussed below.

ASU 2017-11:

In July 2017, FASB issued Accounting Standards Update (“ASU”), 2017-11 —Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments.

POSITIVEID CORPORATION

Notes to the Condensed Consolidated Financial Statements

September 30, 2017

(Unaudited)

As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS.

Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other Options), including related EPS guidance (in Topic 260).

The amendments in Part II of this Update recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect.

For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. For all other entities, the amendments in Part I of this Update are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The amendments in Part II of this Update do not require any transition guidance because those amendments do not have an accounting effect. The Company is currently evaluating the impact of this accounting standard.

ASU 2017-09:

In May 2017, FASB issued Accounting Standards Update (“ASU”), 2017-09 —Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting. The amendments in this Update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. An entity should account for the effects of a modification unless all the following are met:

1. The fair value (or calculated value or intrinsic value, if such an alternative measurement method is used) of the modified award is the same as the fair value (or calculated value or intrinsic value, if such an alternative measurement method is used) of the original award immediately before the original award is modified. If the modification does not affect any of the inputs to the valuation technique that the entity uses to value the award, the entity is not required to estimate the value immediately before and after the modification. 2. The vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified. 3. The classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified.

The current disclosure requirements in Topic 718 apply regardless of whether an entity is required to apply modification accounting under the amendments in this Update.

Effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including adoption in any interim period, for (1) public business entities for reporting periods for which financial statements have not yet been issued and (2) all other entities for reporting periods for which financial statements have not yet been made available for issuance. This updated guidance is not expected to have a material impact on our results of operations, cash flows or financial condition.

ASU 2017-08:

In March 2017, FASB issued Accounting Standards Update (“ASU”), 2017-08—Receivables—Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities. The amendments in this Update more closely align the amortization period of premiums and discounts to expectations incorporated in market pricing on the underlying securities. In most cases, market participants price securities to the call date that produces the worst yield when the coupon is above current market rates (that is, the security is trading at a premium) and price securities to maturity when the coupon is below market rates (that is, the security is trading at a discount) in anticipation that the borrower will act in its economic best interest. As a result, the amendments more closely align interest income recorded on bonds held at a premium or a discount with the economics of the underlying instrument.

POSITIVEID CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements

~~September~~March 3031, ~~2017~~2018

(Unaudited)

ASU 2017-08:

For public business entities, the amendments in this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. This updated guidance is not expected to have a material impact on our results of operations, cash flows or financial condition.

ASU 2017-04:

In January 2017, FASB issued Accounting Standards Update (“ASU”), 2017-04 — Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. Under the amendments in this Update, an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. Additionally, an entity should consider income tax effects from any tax-deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if applicable. The Board also eliminated the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. Therefore, the same impairment assessment applies to all reporting units. An entity is required to disclose the amount of goodwill allocated to each reporting unit with a zero or negative carrying amount of net assets.

A public business entity that is an SEC filer should adopt the amendments in this Update for its annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. This updated guidance is not expected to have a material impact on our results of operations, cash flows or financial condition.

ASU 2016-20:

In December 2016, FASB issued Accounting Standards Update (“ASU”), 2016-20 — Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers. The amendments in this Update affect the guidance in Update 2014-09, which is not yet effective. The effective date and transition requirements for the amendments are the same as the effective date and transition requirements for Topic 606 (and any other Topic amended by Update 2014-09). Accounting Standards Update No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, defers the effective date of Update 2014-09 by one year. This updated guidance is not expected to have a material impact on our results of operations, cash flows or financial condition (see ASU 2016-12 and ASU 2014-09 below).

ASU 2016-15:

In August 2016, FASB issued Accounting Standards Update (“ASU”), 2016-15 — Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. The amendments in this Update provide guidance on the following eight specific cash flow issues:

1. Debt Prepayment or Debt Extinguishment Costs 2. Settlement of Zero-Coupon Debt Instruments or Other Debt Instruments with Coupon Interest Rates That Are Insignificant in Relation to the Effective Interest Rate of the Borrowing 3. Contingent Consideration Payments Made after a Business Combination 4. Proceeds from the Settlement of Insurance Claims 5. Proceeds from the Settlement of Corporate-Owned Life Insurance Policies, including Bank-Owned Life Insurance Policies 6. Distributions Received from Equity Method Investees 7. Beneficial Interests in Securitization Transactions 8. Separately Identifiable Cash Flows and Application of the Predominance Principle

Effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2018, and interim periods within fiscal years beginning after December 15, 2019. Early adoption is permitted, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. An entity that elects early adoption must adopt all of the amendments in the same period. This updated guidance is not expected to have a material impact on our results of operations, cash flows or financial condition.

POSITIVEID CORPORATION

Notes to the Condensed Consolidated Financial Statements

September 30, 2017

(Unaudited)

ASU 2016-12:

In May 2016, FASB issued Accounting Standards Update (“ASU”), 2016-12— Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients. The amendments in this Update affect the guidance in Accounting Standards Update 2014-09, Revenue from Contracts with Customers (Topic 606), which is not yet effective. The effective date and transition requirements for the amendments in this Update are the same as the effective date and transition requirements for Topic 606 (and any other Topic amended by Update 2014-09). Accounting Standards Update 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, defers the effective date of Update 2014-09 by one year to December 15, 2017. This updated guidance is not expected to have a material impact on our results of operations, cash flows or financial condition (see ASU 2016-20, 10 and ASU 2014-09 below).

ASU 2016-10:

In April 2016, FASB issued Accounting Standards Update (“ASU”), 2016-10—Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing. The amendments in this Update affect the guidance in Accounting Standards Update 2014-09, Revenue from Contracts with Customers (Topic 606), which is not yet effective. The effective date and transition requirements for the amendments in this Update are the same as the effective date and transition requirements in Topic 606 (and any other Topic amended by Update 2014-09). Accounting Standards Update 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, defers the effective date of Update 2014-09 by one year to annual reporting periods beginning after December 15, 2017. This updated guidance is not expected to have a material impact on our results of operations, cash flows or financial condition (see ASU 2016-20, 12 above and ASU 2014-09 below).

ASU 2016-02:

In February 2016, FASB issued Accounting Standards Update (“ASU”), 2016-02— “Leases (Topic 842), Section A—Leases: Amendments to the FASB Accounting Standards Codification; Section B—Conforming Amendments Related to Leases: Amendments to the FASB Accounting Standards Codification; Section C—Background Information and Basis for Conclusions”. ~~The~~Effective ~~amendment in this update are effective~~ for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, for any of the following:

	1.	A public business entity

	2.	A not-for-profit entity that has issued, or is a conduit bond obligor for, securities that are traded, listed, or quoted on an exchange or an over-the-counter market

	3.	An employee benefit plan that files financial statements with the U.S. Securities and Exchange Commission (SEC).

For all other entities, the amendments in this Update are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early application of the amendments in this Update is permitted for all entities. This updated guidance is not expected to have a material impact on our results of operations, cash flows or financial condition.

~~ASU 2014-09:~~13

InPOSITIVEID ~~June~~CORPORATION ~~2014,~~AND FASB issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers”. The update gives entities a single comprehensive model to use in reporting information about the amount and timing of revenue resulting from contracts to provide goods or services to customers. The proposed ASU, which would apply to any entity that enters into contracts to provide goods or services, would supersede the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific guidance throughout the Industry Topics of the Codification. Additionally, the update would supersede some cost guidance included in Subtopic 605-35, Revenue Recognition – Construction-Type and Production-Type Contracts. The update removes inconsistencies and weaknesses in revenue requirements and provides a more robust framework for addressing revenue issues and more useful information to users of financial statements through improved disclosure requirements. In addition, the update improves comparability of revenue recognition practices across entities, industries, jurisdictions, and capital markets and simplifies the preparation of financial statements by reducing the number of requirements to which an entity must refer (see ASU 2016-20, 12 and 10 above).SUBSIDIARIES

POSITIVEID CORPORATION

Notes to the Condensed Consolidated Financial Statements

~~September~~March 3031, ~~2017~~2018

(Unaudited)

3. Non-Controlling ~~Interest in Consolidated Subsidiary~~Interests

ExcitePCR

On August 24, 2017, the Company and its wholly-owned subsidiary ~~PositiveID~~PDI ~~Diagnostics, Inc.~~ (collectively, the “Seller”), entered into an Asset Purchase Agreement (“APA”) with its majority-owned subsidiary, ExcitePCR ~~Corporation~~ (the “Buyer”). Pursuant to the APA, at closing, the Seller will sell and deliver to the Buyer all right, title and interest in all assets used or useful in connection with the operation of the FireflyDX technology, which consists of the FireflyDX intellectual property and that of its predecessor, the Dragonfly Dx technology and products, along with patents, the applicable know how used in the development of the FireflyDX and Dragonfly Dx technology, and breadboard prototypes of both products (the “~~Firefly~~FireflyDX Technology”). The consideration to be paid by the Buyer to the Seller pursuant to the APA, will be 10,500,000 shares of common stock of the Buyer, and the Company will own approximately 91% of the ~~Buyer~~outstanding shares of ExcitePCR post-closing of the sale (prior to any financing). As a condition to the Seller’s obligation to close the transaction, the Buyer shall have completed a financing transaction with net proceeds to the Buyer of at least $3 million. Additional conditions and deliverables at closing include a patent assignment agreement, accounting services agreement, license agreement, and certain required consents from third parties.

The Company believes that the ~~Firefly~~FireflyDX Technology has significant potential value to stockholders. The parties have entered into ~~the~~ the APA so the Buyer can secure financing and then independently pursue the development, improvement and commercialization of ~~the~~ ~~Firefly~~the FireflyDX Technology. The current stockholders of the Buyer include two third-party individuals, who are working with the ~~Buyer~~ Buyer to develop and execute the business plan of the Buyer. Lyle L. Probst (the Company’s President) is the Chief Executive ~~Officer~~ Officer of the Buyer, ~~Dr.~~and ~~Kimothy~~William ~~Smith~~J. Caragol (the Company’s ~~Chief~~Chairman ~~Technology~~and ~~Advisor~~CEO), is the ~~Chief~~Chairman ~~Science Officer~~ of the Buyer. ~~William~~As of March J.31, ~~Caragol~~2018, (the ~~Company’s~~Buyer ~~Chairman~~ and ~~CEO),~~Company ishad ~~the~~not ~~Chairman~~yet ofclosed the ~~Buyer~~transaction.

As of September 30, 2017, the Buyer and the Company had not yet closed the transaction.

ENG Mobile Systems

On June 12, 2017, the Company entered into a Stock Purchase Agreement (“SPA”) with ENG, a California corporation and Holdings ENG, LLC, a Florida limited liability company, and an affiliate of East West Resources Corporation (the “Purchaser”), pursuant to which (i) the Company sold 49.8%, or two hundred ninety nine (299) shares of Series A Convertible Preferred Stock (the “Purchased Shares”), of ENG, (ii) the Company granted Purchaser an option to purchase up to an additional 10%, or or sixty (60) shares of Series A Convertible Preferred Stock, of ENG from the Company’s holdings (the “Option Shares”) and (iii) ENG, pursuant to a stock option agreement (the “Stock Option Agreement”), granted Purchaser an option to purchase 1%, or three (3) shares of Series A Convertible Preferred Stock, of ENG directly from ENG (collectively, the “Transaction”). The Company received one million four hundred ninety-five thousand dollars ($1,495,000) or $5,000 per share of Series A Convertible Preferred Stock, in exchange for the Purchased Shares. The exercise price payable to the Company or ENG for each of the Company’s Option Shares is five thousand dollars ($5,000) ~~(subject to adjustment)~~. ~~The Purchaser options are not exercisable until June 12, 2018.~~

Immediately prior to the closing of the Transaction, ENG effected a recapitalization so that there are two classes of its stock as follows: (i) 2,000 authorized shares of common stock, $0.001 par value, with 241 shares, issued and outstanding and held by the Company; and (ii) 1,000 authorized shares of Series A Convertible Preferred Stock, $0.001 par value (the “Series A Convertible Stock”), with 359 shares of Series A Convertible Stock issued and outstanding and held by the Company prior to the closing of the Transaction. After the closing of the transaction, the Company owned 60 shares of Series A Convertible Stock. Immediately following the closing of the Transaction, the Company owned 241 shares of common ~~shares~~stock and 60 shares of Series A Convertible Preferred Stock of ENG, or 50.2% of the voting interest in ENG; immediately following the closing of the Transaction, the Purchaser owned 299 shares of ~~Series~~ Series A Convertible Preferred Stock of ENG, or 49.8% of the voting interest in ENG.

A summary of the Series A Convertible Stock of ENG is set forth below:

Voting and Protective Provisions. The Series A Convertible Stock shall vote together with the common stock of ENG, except as required by law. The Series A Convertible Stock contain protective provisions such that the vote of a majority of the outstanding shares of Series A Stock is required to engage in certain acts, including (i) file a petition in bankruptcy; (ii) create, authorize, authorize the creation of, issue or sell any equity security, any security convertible into or exercisable for any equity security or option; (iii) permit any consolidation, reorganization or merger of ENG with or into any other person; (iv) acquire all or substantially all of the properties, assets or capital stock of any other corporation or entity; (v) sell, lease or otherwise dispose of assets or properties of ENG in an aggregate amount in excess of $100,000 in any calendar year, other than in the ordinary course of business; (vi) grant any lien on or security interest in any of ENG’s assets other than in the ordinary course of business; (vii) incur any indebtedness for borrowed funds, excluding any draws on any line of credit in the ordinary course of business; (viii) create or authorize the creation of any debt security; (ix) approve or execute any contract, agreement or lease giving rise to a financial commitment or obligation of ENG other than in the ordinary course of business; (x) purchase or redeem or pay any dividend on any capital stock, make any distribution or authorize a stock split or split-up; (xi) increase or decrease the size of the Board of Directors of ENG; (xii) create, or authorize the creation of, a subsidiary; (xiii) make any loan or advance to any person, except advances in the ordinary course of business; (xiv) guarantee any indebtedness except for trade accounts of ENG arising in the ordinary course of business; (xv) make any investment inconsistent with any investment policy approved by the Board of Directors of ENG; (xvi) enter into or be a party to any transaction with (A) any director, officer or employee of ENG or any “associate” (as defined in Rule 12b-2 promulgated under the Exchange Act) of any such person or (B) any “affiliate” (as defined in Rule 12b-2 promulgated under the Exchange Act); (xvii) change the principal business of ENG, enter new lines of business, or exit the current line of business; (xviii) sell, assign, license, pledge or encumber material technology or intellectual property, other than licenses granted in the ordinary course of business; (xix) amend the Articles of Incorporation or the Bylaws of ENG (xx) purchase, option or otherwise acquire any real property or any interest therein; (xxi) dissolve, wind-up or cease operations of ENG; or (xxii) enter into any corporate strategic relationship, joint venture or partnership.

1514

POSITIVEID CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements

~~September~~March 3031, ~~2017~~2018

(Unaudited)

Dividends. Dividends may not be declared on any class of stock unless paid pro rata on all classes of stock.

Liquidation. Upon on any liquidation, dissolution or winding up of ENG, after payment or provision for payment of debts and other liabilities of ENG, before any distribution or payment is made to the holders common stock or any junior securities, the holders of Series A Convertible Stock shall first be entitled to be paid out of the assets of the Company available for distribution to its stockholders an amount equal to $5,000 per share (subject to adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series A Convertible Stock), plus any dividends declared but unpaid on such shares. The occurrence of a merger or consolidation or sale of substantially all of the assets of ENG shall be deemed to be a liquidation of ENG.

In addition, in connection with the Transaction, the Company entered into an Executive Services Agreement, dated June 12, 2017, with Purchaser and Mr. Lyle Probst, the Company’s President (the “Executive Services Agreement”), pursuant to which the Company has agreed to provide ENG the services of Mr. Probst to continue to act as President of ENG (the “Services”). As compensation for the Services, ENG will pay the Company nine thousand five hundred twenty-five dollars ($9,525) per month, for a twelve-month period.

~~The~~As a result of the June 12, 2017 sale, the Company retained control over ENG and accounted for sale of the non-controlling interest as an equity transaction in accordance with ASC 810-10-42-23. No gain or loss was recognized in the accompanying ~~unaudited~~ consolidated statement of operations. The difference between the fair value of consideration, transaction costs and carrying amount of the non-controlling interest resulted in “net gain” in the amount of $1,242,083 which was recorded in the in the equity section of the accompanying ~~unaudited~~ balance sheet in additional paid in capital. The carrying amount of the non-controlling interest was recorded separate from the Company’s total equity under “non-controlling interest in consolidated subsidiaries” and was adjusted to reflect the change in ownership interest in the subsidiary as of June 3012, 2017. The net gain and adjustment to the carrying amount of the non-controlling interest as of ~~September~~December 3031, 2017 are detailed below:

Sale of non-controlling interest reconciliation:
Fair value of consideration	$	1,495,000
Transaction costs		(107,255	)
Cash received		1,387,745
Equity allocated to non-controlling interest		(67,662	)
PSID common stock issued as fee (transaction cost)		(78,000	)
Net gain on sale of non-controlling interest	$	1,242,083

Non-controlling interest balance reconciliation:
Beginning balance, January 1, 2017	$	—
Equity allocated to non-controlling interest, June 12, 2017		67,662
Income allocated to non-controlling interest		19,157
Ending balance, September 30, 2017	$	86,819

On January 30, 2018, ENG entered into a Stock Purchase Agreement (“SPA II”) with the Purchaser, pursuant to which (i) ENG sold six hundred forty one (641) shares (the “Shares”) of Series A Convertible Preferred Stock of ENG for a purchase price of approximately $312 per share, for an aggregate purchase price of $200,000; and (ii) the Company declined to exercise its right to purchase a pro rata portion of the Shares and has approved the issuance and sale of the Shares by ENG to the Purchaser, and waived all rights it may have with respect to ENG’s purchase of the Shares. In connection with the transaction, the Company also issued a promissory note in the amount of $54,000 to ENG for settlement of past and current intercompany transactions and liabilities. As a result of this transaction the Company’s equity interest in ENG decreased to approximately 24% and the Company deconsolidated the balance sheet, results of operations and cash flows of ENG in its consolidated financial statements and accounted for ENG under the equity method of accounting in accordance with ASC 323 (see Note 4 and Note 5). At December 31, 2017 the Company owned 50.2% of ENG and controlled ENG’s assets. These assets represented between 50% and 55% of the Company’s overall assets. As the result of the Company owning approximately 24% of ENG as of January 30, 2018 and no longer controlled ENG’s assets, the Company deconsolidated the results of ENG, as of January 30, 2018. The non-controlling interest balance between December 31, 2017 and January 30, 2018 (the date of deconsolidation) are detailed below:

Non-controlling interest balance reconciliation:
Beginning balance, January 1, 2017	$	—
Equity allocated to non-controlling interest, June 12, 2017		67,662
Loss allocated to non-controlling interest during 2017		(166,216	)
Ending balance, December 31, 2017	$	(98,554	)
Loss allocated to non-controlling interest during January 2018		(44,958	)
Ending balance, January 30, 2018	$	(143,512	)
Deconsolidation effect on non-controlling interest		143,512
Ending balance, March 31, 2018	$	—

POSITIVEID CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements

March 31, 2018

(Unaudited)

4. Gain on Deconsolidation of Subsidiary

As a result of the dilution of the Company’s interest in ENG on January 30, 2018 (see note 3), the Company recognized a gain on deconsolidation of ENG of $387,692 during the three months ended March 31, 2018, consisting of the following:

Retained investment at fair value	$	293,604
Carrying value of non-controlling interest		(143,512	)
Net (assets) liability of ENG		237,600
Gain on deconsolidation	$	387,692

5. Investment in ENG Mobile Systems

As a result of the dilution of the Company’s interest in ENG on January 30, 2018 (see note 3), the Company deconsolidated ENG and accounted for its investment in ENG using the equity method of accounting in accordance with ASC 323 (see Note 2). The fair value of the ENG investment was recorded as a separate line item in the Company’s consolidated balance sheet under “Investment in ENG Mobile Systems” and was adjusted to reflect the “Loss on investment in ENG Mobile Systems”, recorded as a separate line item in the statement of operations, during the quarter ended March 31, 2018. The adjustments to “Investment in ENG Mobile Systems” of as of March 31, 2018 are detailed below:

Investment in ENG Mobile Systems balance reconciliation:
Beginning balance, January 1, 2018	$	—
Retained investment at fair value		293,604
Balance on January 30, 2018	$	293,604
Loss on investment in ENG Mobile Systems from January 31, 2018 through March 31, 2018		(45,088	)
Ending balance, March 31, 2018	$	248,516

Financial information for ENG Mobile Systems for the period from January 31, 2018 through March 31, 2018, is summarized below in accordance with Regulation S-X rule 8-03:

ENG Mobile Systems

Summary of Statement of Operations

(In thousands)

	For the period January 31, 2018 through March 31, 2018
Revenues	$	147
Cost of revenues		81
Gross profit		66
Operating expenses		250
Operating (loss)		(184	)
Other income (expense)		(4	)
Net loss	$	(188	)

Ownership interest		24.19	%
Share of Net loss	$	(45,088	)
Total equity interest loss recorded	$	(45,088	)

POSITIVEID CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements

~~September~~March 3031, ~~2017~~2018

(Unaudited)

46. Equity and Debt Financing Agreements and Fair Value Measurements

Convertible Note Financings

Short-term convertible debt as of ~~September~~March 3031, ~~2017~~2018 is as follows (In thousands):

	Notes			Accrued Interest		Total
Convertible notes with accrued interest accounted for as stock settled debt	$	12,~~374~~108		$	85108	$	12,~~459~~216
Conversion premiums		~~817~~1,244			—		~~817~~1,244
		2,191			85		2,276
		3,352			108		3,460
Convertible notes with embedded derivatives		32,~~258~~817			~~922~~768		43,~~180~~585
Derivative discounts		(~~217~~280	)		—		(~~217~~280	)
		3,041			922		3,963
		2,537			768		3,305
Original issue discounts and loan fee discounts		(91113	)		—		(91113	)
	$	5,~~141~~889		$	~~1,007~~876	$	6,~~148~~652

Dominion Convertible Debt Financings

On November 25, 2014, the Company closed a financing transaction by entering into a Securities Purchase Agreement dated November 25, 2014 (the “Note I SPA”) with Dominion Capital LLC (the “Purchaser”) for an aggregate subscription amount of $4,000,000 (the “Purchase Price”). Pursuant to the Note I SPA, the Company issued a series of 4% Original Issue Discount Senior Secured Convertible Promissory Notes (collectively, the “Note I”) to the Purchaser. The Purchase Price will be paid in eight equal monthly payments of $500,000. Each individual Note was issued upon payment and will be amortized beginning six months after issuance, with amortization payments being 1/24^th of the principal and accrued interest, made in cash or common stock at the option of the Company, subject to certain conditions contained in the Note I SPA. The Company also reimbursed the Purchaser $25,000 for expenses from the proceeds of the first tranche and the Purchaser’s counsel $25,000 from the first tranche.

On August 14, 2015, the Company closed a financing transaction by entering into a Securities Purchase Agreement dated August 14, 2015 (the “Note II SPA”) with Dominion Capital LLC (the “Purchaser”) for an aggregate subscription amount of $2,400,000 (the “Purchase Price”). Pursuant to the Note II SPA, the Company issued a series of 4% Original Issue Discount Senior Secured Convertible Promissory Note (collectively, the “Note II”) to the Purchaser. The Purchase Price was paid in six equal monthly payments of $400,000. Each individual Note was issued upon payment and is amortized beginning six months after issuance, with amortization payments being 1/24^th of the principal and accrued interest, made in cash or common stock at the option of the Company, subject to certain conditions contained in the Note II SPA. The Company also reimbursed the Purchaser $20,000 for expenses from the proceeds of the first tranche and the Purchaser’s counsel $10,000 from the first tranche.

The aggregate principal amount of both Notes I and II are issued with a 4% original issue discount whereby the aggregate principal amount of Notes I and II is $6,400,000 but the actual purchase price of Notes I and II is $6,144,000. Each of Notes I and II accrue interest at a rate equal to 12% per annum and with maturity dates, depending on the date funded, between June 26, 2016 and June 30, 2017. Notes I and II are convertible any time after the issuance date of the notes. The Purchasers have the right to convert Note I into shares of the Company’s common stock at a conversion price equal to 95% of the daily VWAP on the trading day immediately prior to the closing of each tranche. The Purchasers have the right to convert Note II into shares of the Company’s common stock atas adefined ~~conversion~~in ~~price~~the ~~equal~~Notes toI ~~$4,200~~and II. Additionally, under certain conditions defined in Notes I and II, the notes ~~would~~ would be convertible into common stock at a price equal to 62.5% of the lowest VWAP during the 15 Trading Days immediately prior to to the applicable amortization date. In the event that there is an Event of Default or certain conditions are not met, the conversion price will be adjusted to equal to 55% of the lowest VWAP during the thirty (30) Trading Days immediately prior to the applicable Conversion Date. Notes I and II can be prepaid at any time upon five days’ notice to the Holder by paying an amount in cash equal to the outstanding principal and interest and a 120% premium.

During 2015, the Company had received all eight tranches under the Note I SPA ($500,000 principal in 2014 and $3,650,000 principal in 2015 which includes an additional $150,000 added to one of the agreed $500,000 monthly funding as requested by the Company), with maturity dates, depending on the date funded, between June 26, 2016 and December 29, 2016, pursuant to a convertible note. Under the agreement, the Company received $3,540,600, which was net of the $448,400 Purchaser’s expenses and legal fees and $166,000 which represents the 4% original issue discount. As of June 30, 2016, the Company has received, all six tranches under the Note II SPA ($2,281,250 in principal in 2015 and $208,333 in 2016) with maturity dates of February 15, 2017 and June 30, 2017, pursuant to a convertible note. Under the agreement, the Company received $2,143,000, which was net of Purchaser’s expenses, legal fees of $247,000 and a 4% original issue discount of $99,583. The notes might be accelerated if an event of default occurs under the terms of the note, including the Company’s failure to pay principal and interest when due, certain bankruptcy events or if the Company is delinquent in its SEC filings. In connection with the issuance of Notes I and II, the Company recorded a debt discount of $387,000 in 2014, $5,116,600 in 2015 and $180,000 in 2016, totaling to $5,683,600 of debt discount recorded, related to the embedded conversion option derivative liability. The amortization expense related to that discount recorded ~~during~~were ~~the~~approximately ~~six~~$161,000 ~~months~~during ~~ended~~2017 ~~June~~which ~~30,~~fully ~~2017~~amortize ~~was~~the ~~approximately~~total recorded debt discount. In 2017, $~~161~~549,~~000~~670 of the outstanding principal and asinterest ofon ~~June~~Notes ~~30,~~I ~~2017,~~and ~~the~~II ~~total~~was ~~debt~~converted ~~discount~~into ~~recorded~~99,846 ~~has~~shares ~~been fully~~of ~~amortized~~common stock. During the ~~nine~~three months ended ~~September 30~~March 31, ~~2017~~2018, $~~341~~161,~~615~~778 of the outstanding principal and interest on Notes I and II was converted into 18891,~~442,220~~259 shares of common stock. The ~~As of September 30, 2017, the~~ outstanding principal and interest on Notes I and II were $1,~~787~~579,361 for the year ended December 31, 2017 and $1,417,583 for the three months ended March 31, 2018. As the note conversion includes a “lesser of” pricing provision, a derivative ~~liability~~ liability of $8,936,405 was recorded when Notes I and II were entered into. The derivative liability is re-measured at each balance ~~sheet~~ sheet date and reclassified to equity on a pro-rata basis upon conversion of the note, the derivative liability balance for Notes I I and II at ~~September~~March 3031, ~~2017~~2018 was $1,~~109~~418,~~291~~238.

POSITIVEID CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements

~~September~~March 3031, ~~2017~~2018

(Unaudited)

On December 22, 2015, in order to finance the acquisition of ENG, the Company closed a financing transaction by entering into a Securities Purchase Agreement dated December 22, 2015 (the “Note III SPA”) for an aggregate principal amount of $904,042 and subscription amount of $865,000, net of OID (the “Purchase Price”). The Company also reimbursed the Purchaser $30,000 for legal fees and expenses from the proceeds of the Note. Pursuant to the Note III SPA, the Company shall issue a 4% Original Issue Discount Senior Secured Convertible Promissory Note (the “Note III”) to Dominion. Note III was issued upon payment and will be amortized beginning six months after issuance, with amortization payments being 1/24th of the principal and accrued interest, made in cash or common stock, on a semi-monthly basis, subject to certain conditions contained in the Note III SPA. The amortization payments will begin to be due starting on the 15th day of the month immediately following the six-month anniversary of the Closing Date. The Company received funding for Note III on December 24, 2015, net proceeds of $751,500 (net of the $152,542 of legal fees, expenses and OID). Note III accrues interest at a rate equal to 12% per annum (interest is guaranteed for the first twelve months) and has a maturity date of June 15, 2017. Note III is convertible any time after its issuance date and Dominion has the right to convert any or all of Note III into shares of the Company’s common stock at a conversion price equal to $3,300 per share, subject to adjustment as described in Note III. Additionally, under certain conditions defined in Note III, it may also be convertible into common stock at a price equal to 62.5% of the lowest VWAP during the 15 Trading Days immediately prior to the applicable amortization date. In the event that there is an Event of Default or certain conditions are not met, the conversion price will be adjusted to equal to 55% of the lowest VWAP during the thirty (30) Trading Days immediately prior to the applicable Conversion Date. Note III can be prepaid at any time upon five days’ notice to the Dominion by paying an amount in cash equal to the outstanding principal and interest, and a 20% premium. In connection with the issuance of the Note III, the Company recorded a debt discount of $751,500 when Note III was entered into, related to the embedded conversion option derivative liability. The amortization expense related to that discount recorded ~~during~~were ~~the~~approximately ~~six months ended June 30, 2017 was~~ $231,963 ~~and~~during as2017 ofwhich fully ~~June~~amortize ~~30, 2017,~~ the total recorded debt discount ~~record has been fully amortized~~. ~~During~~In ~~the quarter ended June 30,~~ 2017, $450,000 of the outstanding principal and interest was paid from the proceeds received as discussed in Note 3. AsThe ~~of September 30, 2017, the~~ outstanding principal and interest on Note III ~~was~~were $562,527 for the year ended December 31, 2017 and $562,527 for the three months ended March 31, 2018. As the note conversion includes a “lesser of” pricing provision, a derivative liability of $1,267,800 was recorded when Note III was entered into. The derivative liability is re-measured at each balance sheet date, the derivative liability balance for Note III at ~~September~~March 3031, ~~2017~~2018 was $~~349~~562,~~110~~787.

On January 28, 2016, the Company closed a financing transaction by entering into a Securities Purchase Agreement dated January 28, 2016 (the “Note IV SPA”) with Dominion Capital LLC (the “Purchaser”) for an aggregate principal amount of $2,187,500 and subscription amount of $2,100,000 (the “Purchase Price”), net of OID. Pursuant to the Note IV SPA, the Company shall issue a series of 4% Original Issue Discount Senior Secured Convertible Promissory Notes (collectively, the “Note IV”) to the Purchaser. The Purchase Price is scheduled to be paid in six equal monthly tranches of $350,000, subject to the discretion of the Purchaser. Each individual Note will be issued upon payment and will be amortized beginning six months after issuance, with amortization payments being 1/24th of the principal and accrued interest, made in cash or common stock at the option of the Company, on a semi-monthly basis, subject to certain conditions and limitations contained in the Note IV SPA. The amortization payments will begin on the 15th day of the month immediately following the six-month anniversary of the Closing Date. The Company also reimbursed the Purchaser $20,000 for expenses from the proceeds of the first tranche and the Purchaser’s counsel $10,000 from the first tranche. During ~~the year ended December 31,~~ 2016, the Company has received a total of $604,763 net proceeds under Note IV (net of the $93,153 of legal fees, expenses and OID). During ~~the three months ended September 30~~, ~~2017,~~ the Company received a total of $96288,000 net proceeds (net of the $824,~~167~~ 498 of legal fees, expenses and OID) and ~~subsequent to the three months ended September 30, 2017, the Company received a total of~~ $~~144~~24,000 of net proceeds (net of the $82,~~167~~042 of legal fees, expenses and OID) ~~under~~was ~~Note~~received during IVthe ~~(see~~three months ended March 31, 2018, under Note ~~10)~~IV. Note IV accrues interest at a rate equal to 12% per annum (interest is guaranteed for the first twelve months) and has a maturity dates between July 15, 2017 and ~~April~~June 2730, 2019. Note IV is convertible any time after its issuance date and Dominion has the right to convert any or all of Note IV into shares of the Company’s ~~common~~ common stock ~~at a conversion price equal to $3,300 per share, subject to adjustment~~ as described in Note IV. Additionally, under certain conditions defined in Note IV, it may also be convertible into common stock at a price equal to 62.5% of the lowest VWAP during the 15 Trading Days immediately prior to the applicable amortization date. In the event that there is an Event of Default or certain conditions are not met, the conversion price will be adjusted to equal to 55% of the lowest VWAP during the thirty (30) Trading Days immediately prior to the applicable Conversion Date. Note IV can be prepaid at any time upon five days’ notice to the Dominion by paying an amount in cash equal to the outstanding principal and interest, and a 20% premium. Subsequent to the funding of the first tranche the Purchaser and the Company agreed to delay further tranches, until such time as the Purchaser and Company mutually agree, both as to timing and amount. In connection with the issuances of Note IV, the Company recorded a debt discount of $~~669~~874,~~446~~415 when the notes were entered into, related to the embedded conversion option derivative liability. The amortization expense related to that discount recorded during the ~~nine~~year ~~months~~ ended December ~~September 30~~31, 2017 was approximately $~~276~~347,~~963~~667 and $44,286 during the three months ended March 31, 2018. As the note conversion includes a “lesser of” pricing provision, a derivative liability of $1,~~006~~242,~~446~~562 was recorded when the issuances of Note IV was entered into. The derivative liability is re-measured at each balance sheet date, the derivative liability balance for Note IV at ~~September~~March 3031, ~~2017~~2018 was $~~455~~965,~~521~~603. During 2017, $161,317 of the ~~nine~~outstanding principal and interest was converted into 6,825 shares of common stock. During the three months ended ~~September~~March 3031, ~~2017~~2018, $~~161~~107,~~317~~752 of the outstanding principal and interest was converted into 6104,~~825,225~~707 shares of common stock. As of ~~September~~March 3031, ~~2017~~2018, the outstanding principal and interest on Note IV was $~~722~~924,~~537~~618.

POSITIVEID CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements

~~September~~March 3031, ~~2017~~2018

(Unaudited)

Pursuant to the Company’s obligations under Notes I, II, III and IV, the Company entered into a Security Agreement with the Purchaser, pursuant to which the Company granted a lien on all assets of the Company, subject to existing security interests, (the “Collateral”) for the benefit of the Purchaser, to secure the Company’s obligations under the Note. In the event of a default as defined in Notes I, II, III and IV, the Purchaser may, among other things, collect or take possession of the Collateral, proceed with the foreclosure of the security interest in the Collateral or sell, lease or dispose of the Collateral.

Other Convertible Debt ~~Financing~~Financings

On March 9, 2016, the Company closed a Securities Purchase Agreement (“SPA”) with a lender, providing for the purchase of two Convertible Redeemable Notes in the aggregate principal amount of $270,400 (the “Notes”), with the first note being in the amount of $135,200 (“Note I”) and the second note being in the amount of $135,200 (“Note II”) with a maturity date of March 9, 2017. Pursuant to Note I, the Company received $125,000 of proceeds, net of original issue discount of $5,200 and legal fees of $5,000. Note II was initially paid for by the issuance of an offsetting $130,000 secured note issued by the Lender to the Company (“Secured Note”). The Notes bear an interest rate of 12%; and may be at any time after 180 days of the date of closing converted into shares of Company common stock convertible at the lesser of a 37.5% discount to the common stock price on the date of the note or a 37.5% discount to the price of our common stock price at the time of conversion. The Notes also contain certain representations, warranties, covenants and events of default, and increases in the amount of the principal and interest rates under the Notes in the event of such defaults. In connection with the issuance of Note I, the Company recorded a debt discount of $125,000, related to the embedded conversion option derivative liability which was fully amortized ~~during~~in ~~the year ended December 31,~~ 2016. As of December 31, 2016, the outstanding principal and interest on Note I was fully converted into ~~40,968~~41 shares of common stock. During ~~the year ended December 31,~~ 2016, the Company received $125,000 pursuant to Note II, net of original issue discount of $5,200 and legal fees of $5,000. In connection with the issuance of Note II, the Company recorded a debt discount of $125,000, related to the embedded conversion option derivative liability which was fully amortized asin ~~of December 31,~~ 2016. As of ~~September~~December 3031, ~~2017~~2016, $129,980 of the outstanding principal and interest on Note II was converted into ~~51,684~~52 shares of common stock. As of ~~September~~December 3031, 2017 and March 31, ~~Note~~2018, Note II had an outstanding balance of $2226,~~348~~437 and $30,437, respectively. As the note conversion includes a “lesser of” pricing provision, a derivative liability of $306,000 was recorded when Notes were entered into. The derivative liability is re-measured at each balance sheet date and reclassified to equity on a pro-rata basis upon conversion of the note, the derivative ~~liability~~ liability balance for Note II at ~~September~~March 3031, ~~2017~~2018 was $1330,~~869~~451.

On April 1, 2016, the Company closed a Securities Purchase Agreement (“SPA”) with a lender, providing for the purchase of two Convertible Redeemable Notes in the aggregate principal amount of $270,400 (the “Notes”), with the first note being in the amount of $135,200 (“Note I”) and the second note being in the amount of $135,200 (“Note II”). Note I was funded on April 1, 2016, with a maturity date of April 1, 2017, pursuant to Note I, the Company received $125,000 of net proceeds, net of original issue discount of $5,200 and legal fees of $5,000. Note II was initially paid for by the issuance of an offsetting $130,000 secured note issued by the Lender to the Company (“Secured Note”). Note II was funded on August 2, 2016, with a maturity date of April 1, 2017, pursuant to Note II, the Company received $125,000 of net proceeds, net of original issue discount of $5,200 and legal fees of $5,000. The Notes bear an interest rate of 12%; and may be at any time after 180 days of the date of closing converted into shares of Company common stock convertible at the lesser of a 37.5% discount to the common stock price on the date of the note or a 37.5% discount to the price of our common stock price at the time of conversion. In connection with the issuance of Notes, the Company recorded a debt discount of $250,000, related to the embedded conversion option derivative liability. The amortization expense related to that discount recorded was approximately $77172,~~859~~000 ~~during~~in ~~the~~2016 ~~six months ended~~and ~~June 30~~$77,859 in 2017. ~~and~~The ~~the~~ total debt discount recorded has been fully amortized as of June 30, 2017. During ~~the three months ended June 30,~~ 2017, $27,114 of the outstanding principal and interest on the notes was converted into ~~402,827~~403 shares of common stock. As of ~~September~~December 3031, 2017 and March 31, 2018 the outstanding principal and interest on the Notes were $~~286~~294,~~446~~625 and $302,626, respectively. As the note conversion includes a a “lesser of” pricing provision, a derivative liability of $311,756 was recorded when Notes were entered into. The ~~derivative~~ derivative liability is re-measured at each balance sheet date and reclassified to equity on a pro-rata basis upon conversion of the note, the derivative liability balance for the Notes at ~~September~~March 3031, ~~2017~~2018 was $~~177~~302,~~772~~766.

On April 28, 2016, the Company closed a Securities Purchase Agreement (“SPA”) with a lender, providing for the purchase of two Convertible Redeemable Notes in the aggregate principal amount of $437,500 (the “Notes”), with the first note being in the amount of $218,750 (“Note I”) and the second note being in the amount of $218,750 (“Note II”). Note I was funded on April 28, 2016, with a maturity date of April 27, 2017, pursuant to Note I, the Company received $190,000 of net proceeds, net of original issue discount of $8,750 and legal fees of $20,000. Note II was initially paid for by the issuance of an offsetting $210,000 secured note issued by the Lender to the Company (“Secured Note”). Note II was funded on September 7, 2016, with a maturity date of April 27, 2017, pursuant to Note II, the Company received $200,000 of net proceeds, net of original issue discount of $8,750 and legal fees of $10,000. The Notes bear an interest rate of 12%; and may be at any time after 180 days of the date of closing converted into shares of Company common stock convertible at the lesser of a 37.5% discount to the common stock price on the date of the note or a 37.5% discount to the price of our common stock price at the time of conversion. In connection with the issuance of the Notes, the Company recorded a debt discount of $390,000, related to the embedded conversion option derivative liability. The amortization expense related to that discount recorded was approximately $~~143~~247,000 ~~during~~in ~~the~~2016 ~~three~~and ~~months~~$143,000 ~~ended~~in ~~March~~2017. ~~31,~~The ~~2017~~recorded ~~and~~debt discount was fully amortized as of March 31, 2017. ~~During~~In 2016, $21,453 of the ~~nine~~outstanding ~~months~~principal and interest of the note was converted into 13 shares of common stock. During the year ended ~~September~~ 30December 31, 2017, $424,426 of the outstanding principal and interest of the notes was converted into 4,455~~,017~~ shares of common stock. As of ~~September~~December 3031, 2017 and March 31, 2018, the outstanding principal and interest on the Notes were $3845,~~902.~~518 and $51,991, respectively. As the note conversion includes a “lesser of” pricing provision, a derivative liability of $499,800 was recorded when Notes were entered into. The derivative liability is re-measured at each balance sheet date and reclassified to equity on a pro-rata basis upon conversion of the note, the derivative liability balance for the Notes at ~~September~~March 3031, ~~2017~~2018 was $2752,~~612~~051.

POSITIVEID CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements

~~September~~March 3031, ~~2017~~2018

(Unaudited)

On June 3, 2016, the Company closed a Securities Purchase Agreement (“SPA”) with a lender, providing for the purchase of two Convertible Redeemable Notes in the aggregate principal amount of $624,000 (the “Notes”), with the first note being in the amount of $312,000 (“Note I”) and the second note being in the amount of $312,000 (“Note II”). Note I was funded on June 3, 2016, with a maturity date of June 2, 2017, pursuant to Note I, the Company received $285,000 of net proceeds, net of original issue discount of $12,000 and legal fees of $15,000. Note II was initially paid for by the issuance of an offsetting $300,000 secured note issued by the Lender to the Company (“Secured Note”). Note II was funded in two tranches during the year ended December 31, 2016, with a maturity date of June 2, 2017, pursuant to Note II, the Company received $285,000 of net proceeds, net of original issue discount of $12,000 and legal fees of $15,000. The Notes bear an interest rate of 12%; and may be at any time after 180 days of the date of closing converted into shares of Company common stock convertible at the lesser of a 35% discount to the common stock price on the date of the note or a 35% discount to the price of our common stock price at the time of conversion. The Notes also contain certain representations, warranties, covenants and events of default, and increases in the amount of the principal and interest rates under the Notes in the event of such defaults. In connection with the issuance of the Notes, the Company recorded a debt discount of $570,000, related to the embedded conversion option derivative liability. ~~During~~The amortization expense related to that discount recorded was approximately $288,000 in 2016 and $282,000 in 2017 and the ~~nine~~total ~~months~~debt ~~ended~~discount ~~September~~recorded was fully amortized as of June 30, 2017. In 2016, $~~301~~129,~~537~~298 of the outstanding principal and interest of the notes was converted into ~~12,383,428~~120 shares of common stock. ~~The~~During ~~amortization~~the ~~expense~~year ~~related~~ended toDecember ~~that~~31, ~~discount~~2017, ~~recorded was~~ $~~282~~301,~~000~~537 ~~for~~ of the outstanding ~~six~~principal ~~months~~and ~~ended~~interest ~~June~~of ~~30, 2017 and~~ the ~~total~~notes ~~debt discount recorded~~ was ~~fully~~converted ~~amortized~~into as12,383 shares of ~~June~~common ~~30, 2017~~stock. As of ~~September 30~~December 31, 2017, the outstanding principal and interest on the Notes were $~~246~~256,~~744~~181. During the three months ended March 31, 2018, $260,799 of the outstanding principal and interest was fully converted into 1,145,465 shares of common stock. The Notes had no remaining balance as of March 31, 2018. As the note conversion includes a “lesser of” pricing provision, a derivative liability of $755,690 was recorded when Notes was entered into. The derivative liability is re-measured at each balance sheet date and ~~reclassified~~was reclassified to equity on a pro-rata basis upon conversion of the note~~, the derivative liability balance for the Notes at September 30, 2017 was $153,132~~.

On July 5, 2016, the Company closed a Securities Purchase Agreement (“SPA”) with a lender, providing for the purchase of two Convertible Redeemable Notes in the aggregate principal amount of $416,000 (the “Notes”), with the first note being in the amount of $208,000 (“Note I”) and the second note being in the amount of $208,000 (“Note II”) with a maturity date of July 30, 2017. Pursuant to Note I, the Company received $190,000 of proceeds, net of original issue discount of $8,000 and legal fees of $10,000. Note II was initially paid for by the issuance of an offsetting $200,000 secured note issued by the Lender to the Company (“Secured Note”). Pursuant to Note II, the Company received $190,000 of proceeds, net of original issue discount of $8,000 and legal fees of $10,000 Note II during the three months ended March 31, 2017. The Notes bear an interest rate of 12%; and may be at any time after 180 days of the date of closing converted into shares of Company common stock convertible at the lesser of a 37.5% discount to the common stock price on the date of the note or a 37.5% discount to the price of our common stock price at the time of conversion. The Notes also contain certain representations, warranties, covenants and events of default, and increases in the amount of the principal and interest rates under the Notes in the event of such defaults. In connection with the issuance of the Notes, the Company recorded a debt discount of $380,000, related to the embedded conversion option derivative liability. The amortization expense related to that discount recorded was approximately $~~282~~97,~~939~~000 ~~for~~in ~~the~~2016 ~~nine months ended~~and ~~September 30~~$282,939 in 2017 and the total debt discount recorded was fully amortized as of September 30, 2017. During the ~~nine~~year ~~months~~ ended ~~September~~ 30December 31, 2017, $~~200~~248,~~180~~793 of the outstanding principal and interest of the note was converted into 1829,~~359,790~~130 shares of common stock. As of ~~September~~December 3031, 2017, the outstanding principal and interest on the notes was $~~262~~226,~~576~~546. During the three months ended March 31, 2018, $101,784 of the outstanding principal and interest of the note was converted into 298,491 shares of common stock. As of March 31, 2018, the outstanding principal and interest on the notes was $136,651. As the note conversion includes a “lesser of” pricing provision, a derivative liability was also recorded in the amount of $360,552. The derivative liability at ~~September 30~~March 31, ~~2017~~2018 for the Notes was $~~162~~136,~~957~~741.

On July 6, 2016, the Company closed a Securities Purchase Agreement (“SPA”) with a lender, providing for the purchase of two Convertible Redeemable Notes in the aggregate principal amount of $132,300 (the “Notes”), with the first note being in the amount of $66,150 (“Note I”) and the second note being in the amount of $66,150 (“Note II”) with a maturity date of July 7, 2017. Pursuant to Note I, the Company received $60,000 of net proceeds, net of original issue discount of $3,150 and legal fees of $3,000. Note II was initially paid for by the issuance of an offsetting $63,000 secured note issued by the Lender to the Company (“Secured Note”). The Notes bear an interest rate of 10%; and maybe converted into shares of Company common stock, convertible at variable conversion price at a 35% discount of the lowest closing bid price of the common stock for the 15 trading days prior to conversion. The Notes also contain certain representations, warranties, covenants and events of default, and increases in the amount of the principal and interest rates under the Notes in the event of such defaults. In connection with the issuance of Note I, the Company recorded a premium of $35,619 as the note is considered stock settled debt under ASC 480, which was fully accreted as of September 30, 2016. As of ~~September~~December 3031, 2017 and March 31, 2018, the outstanding principal and interest on the note ~~was~~were $7476,~~419~~073 and $77,726, respectively.

POSITIVEID CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements

~~September~~March 3031, ~~2017~~2018

(Unaudited)

On August 1, 2016, the Company closed a Securities Purchase Agreement (“SPA”) with a lender, providing for the purchase of a Convertible Redeemable Note with a principal amount of $52,500 (the “Note”) and maturity date of April 29, 2017, pursuant to Note, the Company received $50,000 of net proceeds, net of original issue discount of $2,500. The Note bears an interest rate of 10%; and maybe converted into shares of Company common stock, convertible at variable conversion price at a 37.5% discount of the three lowest closing bid prices of the common stock for the 20 trading days prior to conversion. The Note also contain certain representations, warranties, covenants and events of default, and increases in the amount of the principal and interest rates under the Note in the event of such defaults. In connection with the issuance of the note, the Company recorded a premium of $31,500 as the note is considered stock settled debt under ASC 480, which was fully accreted as of September 30, 2016. During the ~~three~~year ~~months~~ ended ~~March~~December 31, 2017, $6,250 of the outstanding principal and interest of the note was converted into 8~~,333~~ shares of of common stock. As of ~~September~~December 3031, 2017, the outstanding principal and interest on the note was $5355,~~600~~175. During the three months ended March 31, 2018, $48,994 of the outstanding principal and interest of the note was converted into 783,900 shares of common stock. As of March 31, 2018, the outstanding principal and interest on the notes was $7,756.

On August 11, 2016, the Company closed a Securities Purchase Agreement (“SPA”) with a lender, providing for the purchase of a Secured Convertible Promissory Note in the aggregate principal amount of up to $330,000, which shall be funded in six tranches, each amounting to $50,000. The Note has a 10% original issuance discount to offset transaction, diligence and legal costs. The Note bears an interest rate of 10% and the maturity date for each funded tranche will be 12 months from the date on which the funds are received by the Company. Then note is convertible into shares of Company’s common stock at a 37.5% discount to the lowest volume-weighted average price for the Company’s common stock during the 15 trading days immediately preceding a conversion date. The Note also contain certain representations, warranties, covenants and events of default, and increases in the amount of the principal and interest rates under the Note in the event of such defaults. In 2016, the Company had received three of the six tranches amounting to $150,000 of net proceeds, net of the original issue discount of $15,000. The funded tranches have maturity dates between August 17, 2017 and September 13, 2017. In connection with the issuance of the note, the Company recorded a premium of $99,000 as the note is considered stock settled debt under ASC 480, which was fully accreted during as of September 30, 2016. During the ~~six~~year ~~months~~ ended ~~June~~December 3031, 2017, ~~$132,938 of~~ the outstanding principal and interest of ~~the~~$186,453 ~~note~~ was converted into ~~609~~31,~~000~~ 126 shares of common stock. AsDuring ofthe ~~September~~three 30months ended March 31, ~~2017~~2018, the remaining outstanding principal and interest onof ~~the~~$16,208 was fully converted into 12,966 shares of common stock. The note ~~was~~has ~~$45~~no outstanding balance as of March 31,~~835~~ 2018.

On ~~August~~November 1730, 2016, the Company closed a Securities Purchase Agreement (“SPA”) with a lender, providing for the purchase of ~~two~~ three Convertible Redeemable Notes in the aggregate principal amount of $~~105~~183,~~264~~750 (the “Notes”), with the first note ~~being~~ being in the amount of $52,~~632~~500 (“Note I”), ~~and~~ the second note being in the amount of $52,~~632~~500 (“Note II”)., and the third note being in the amount of $78,750 (“Note III”). Note I was funded on ~~August~~November 1730, 2016, with a maturity date of ~~August~~December 1730, 2017, pursuant to Note I, the Company received $45,000 of net proceeds, net of original issue discount of $23,~~632~~150 and legal fees of $53,000. Note II was initially paid for by the issuance of an offsetting $50,000 secured note issued byto the ~~Lender~~Company toby the ~~Company~~lender (“Secured Note”). and Note IIIII was ~~funded~~initially ~~on February~~be ~~17,~~paid ~~2017,~~for ~~with~~by the aissuance ~~maturity date~~ of ~~August~~an ~~17,~~offsetting ~~2017~~$75,000 ~~pursuant~~secured tonote ~~Note~~issued ~~II,~~to the Company ~~received~~by ~~$45,000~~the oflender. ~~net~~Funding ~~proceeds, net~~ of ~~original~~Note ~~issue~~II ~~discount~~and ofNote ~~$2,632~~III ~~and~~is ~~legal~~subject to ~~fees~~the ofmutual ~~$5,000.~~agreement ~~The~~of ~~Notes~~the ~~bear~~lender anand ~~interest~~the ~~rate~~Company. ofThe ~~10%;~~lender ~~and~~ is ~~convertible into~~required ~~shares~~to ofpay ~~Company~~the ~~common~~principal ~~stock~~amount atof the ~~lesser~~Secured ofNotes in acash ~~37.5%~~and ~~discount~~in tofull ~~the~~prior ~~common~~to ~~stock~~executing ~~price~~any onconversions ~~the~~under ~~date~~Note ofII ~~the~~and ~~note~~Note orIII. aThe ~~37.5% discount~~Notes tobear ~~the~~an ~~price~~interest rate of ~~our~~10% ~~common~~and Notes ~~stock~~II ~~price~~and atIII ~~the~~has ~~time~~not ofyet ~~conversion~~been funded. The Notes ~~also~~may ~~contain~~be ~~certain~~converted ~~representations,~~by ~~warranties, covenants~~the ~~and~~lender ~~events~~at ofany ~~default,~~time ~~and~~into ~~increases~~shares ~~in the amount~~ of ~~the~~Company’s common ~~principal~~stock ~~and~~(as ~~interest~~determined ~~rates~~in ~~under~~ the Notes) incalculated at the ~~event~~ time of ~~such~~conversion, ~~defaults.~~except Infor ~~connection~~Note ~~with~~II ~~the~~and ~~issuance~~Note ~~of the Notes~~III, ~~the~~which ~~Company~~require full ~~recorded~~payment aof ~~debt~~the ~~discount~~Secured ofNotes ~~$76,189~~by ~~related~~the tolender ~~the embedded~~before ~~conversion~~conversions ~~option~~may ~~derivative~~be ~~liability~~made. The ~~amortization~~Notes ~~expense~~(subject ~~related~~ to ~~that~~funding ~~discount~~in ~~recorded~~the ~~was~~case ~~$60,229~~of ~~for the~~Note ~~six~~II ~~months ended June 30, 2017~~ and ~~the~~Note ~~total~~III) ~~debt~~is ~~discount~~convertible ~~recorded~~into ~~was~~shares ~~fully~~of ~~amortized~~Company’s ascommon ofstock ~~June~~at ~~30,~~a ~~2017~~37.5% ~~During~~discount to the ~~six months~~lowest ~~ended~~closing ~~June~~bid ~~30,~~price ~~2017,~~of the ~~remaining~~common ~~balance~~stock of15 ~~the~~prior ~~outstanding~~trading ~~principal~~days ~~and~~including ~~interest~~the ~~was~~day ~~fully~~upon ~~converted~~which ~~into~~a ~~441,619~~notice ~~shares~~ of ~~common~~ ~~stock~~conversion ~~and~~is received by the ~~note~~Company. ~~had~~In noconnection ~~outstanding~~with ~~balance~~the asissuance of ~~June~~the 30note, ~~2017. As~~ the ~~note~~Company ~~conversion~~recorded ~~includes~~ a ~~“lesser~~premium of~~” pricing~~ ~~provision, a derivative liability of~~ $~~112~~31,~~277~~500 ~~was~~as ~~recorded when~~ the ~~notes~~note ~~were~~is ~~entered into. The derivative liability~~considered isstock ~~re-measured~~settled atdebt ~~each~~under ~~balance~~ASC ~~sheet~~480, ~~date~~which ~~and~~was ~~reclassified~~fully toaccreted ~~equity~~as onof aDecember ~~pro-rata~~31, ~~basis~~2016. ~~upon~~As ~~conversion~~ of ~~the~~December ~~note~~31, ~~the~~2017 ~~derivative liability~~and ~~balance~~March ~~for~~31, 2018, the ~~Notes~~outstanding atprincipal ~~June~~and ~~30,~~interest ~~2017~~on ~~was~~the ~~fully~~note ~~reclassified~~were to$58,625 ~~equity~~and $59,938, respectively.

On ~~November~~January 3031, ~~2016~~2017, the Company closed a Securities Purchase Agreement (“SPA”) with a lender, dated January 30, 2017, providing for the purchase of ~~three~~a Secured Convertible ~~Redeemable~~Promissory ~~Notes~~Note ~~in the aggregate principal amount of $183,750~~ (the “~~Notes~~Note”), ~~with the first note being~~ in the ~~amount~~aggregate ofprincipal ~~$52,500 (“Note I”), the second note being in the~~ amount of $52412,500. ~~(“Note~~The ~~II”), and the third note being in the amount of $78,750 (“~~Note ~~III”). Note I~~ was ~~funded~~fully ~~on November 30, 2016, with a maturity~~funded ~~date~~as of ~~December~~March 3031, 2017, ~~pursuant~~with ~~to Note I,~~ the Company ~~received~~receiving $45375,000 of net proceeds, (net of ~~original issue discount of $3,150 and legal fees of $3,000~~OID). The Note IIhas ~~was~~a ~~initially~~10% ~~paid~~original ~~for by the~~ issuance ~~of an offsetting~~discount ~~$50,000 secured note issued~~ to ~~the~~offset ~~Company by the lender (“Secured Note”)~~transaction, ~~and~~diligence ~~Note III was initially be paid for by the issuance of an offsetting $75,000 secured note issued to the Company by the lender. Funding of Note II~~ and ~~Note~~legal ~~III is subject to the mutual agreement of the lender and the Company~~costs. The ~~lender is required to pay the principal amount of the Secured Notes in cash and in full prior to executing any conversions under~~ Note IIbears ~~and Note III. The Notes bear~~ an interest rate of 10%~~, and~~ ~~are due~~ and ~~payable~~matures12 onmonths ~~November~~after ~~30,~~the ~~2017~~tranches are funded. The ~~Notes~~Note may be converted by the lender at any time into shares of Company’s common stock ~~(as~~at ~~determined~~a inprice ~~the~~equal ~~Notes)~~to 62.5% ~~calculated~~of at the ~~time~~lowest ofclosing ~~conversion,~~bid ~~except~~price for ~~Note~~the IICompany’s ~~and~~common ~~Note~~stock ~~III,~~during ~~which~~the ~~require full~~20 ~~payment~~trading ofdays ~~the~~immediately ~~Secured~~preceding ~~Notes~~a conversion bydate. In connection with the ~~lender~~issuance ~~before~~of ~~conversions~~the ~~may~~note, bethe ~~made.~~Company ~~The~~recorded ~~Notes~~a ~~(subject~~premium toof ~~funding~~$247,500 inas the ~~case~~note ~~of Note~~is IIconsidered ~~and~~stock ~~Note~~settled ~~III)~~debt isunder ~~convertible~~ASC ~~into~~480, ~~shares~~which ofwas ~~Company’s~~fully ~~common~~accreted ~~stock~~as atof aMarch 3731, 2017.5% ~~discount~~During to the ~~lowest closing~~year ~~bid~~ended ~~price~~December 31, 2017, $262,181 of the ~~common~~outstanding ~~stock~~principal 15and ~~prior~~interest ~~trading~~of ~~days including~~ the ~~day~~note ~~upon~~was ~~which~~converted ainto ~~notice~~62,425 shares of ~~conversion~~common isstock. ~~received~~As byof December ~~the~~31, ~~Company.~~2017, Inthe ~~connection~~outstanding ~~with~~principal ~~the~~and ~~issuance~~interest ofon the note was $183,776. During the ~~Company~~three ~~recorded~~months aended ~~premium~~March ~~of $~~31,~~500~~ as2018, $184,439 of the ~~note~~remaining isoutstanding ~~considered stock~~principal ~~settled~~and ~~debt~~interest ~~under~~of ~~ASC~~the ~~480,~~note ~~which~~ was fully ~~accreted~~converted asinto ~~of December 31~~696,867 ~~2016.~~shares As of ~~September~~common ~~30,~~stock. ~~2017,~~The ~~the outstanding~~note ~~principal~~has ~~and~~no ~~interest~~outstanding onbalance ~~the~~as ~~note~~of ~~was~~March ~~$57~~31,~~313~~ 2018.

POSITIVEID CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements

~~September~~March 3031, ~~2017~~2018

(Unaudited)

On ~~January~~February 1815, 2017, the Company ~~closed a~~entered ~~Securities~~into ~~Purchase~~an ~~Agreement~~agreement ~~(“SPA”)~~ with a lender, providing for the ~~purchase~~issuance of a ~~two~~non-cash Convertible Redeemable ~~Notes in~~Note ~~the aggregate principal amount of $200,000 (the “Notes”),~~ with the ~~first~~principal ~~note being in the~~ amount of $~~100~~15,000 (~~“Note I”), and~~ the ~~second note being in the amount of $100,000 (“Note II”). Note I was funded on January 18, 2017,~~ with the Company receiving $70,000 of net proceeds (net of legal fees and OID). Note II will initially be paid for by the issuance of an offsetting $88,000 secured note issued to the Company by the lender (the “~~Secured~~ Note”). ~~The~~as ~~funding~~penalty ~~of Note II is subject to the mutual agreement of the lender and the Company~~interest. The ~~lender is required to pay the principal amount of the Secured~~ Note inbears ~~cash and in full prior to executing any conversions under Note II. The Notes bear~~ an interest rate of 10%, and ~~are~~ ~~due~~matures ~~and payable~~ on ~~January~~February 1317, 2018. The Note may be converted by the lender at any time into shares of Company’s common stock at a stock at a price equal to the lesser of a 37.5% discount to the common stock price on the date of the note or a 37.5% discount of of the lowest trading price for the Company’s common stock 2015 days prior trading days including the day upon which a notice of conversion is received by the Company. The ~~Notes~~Note also contain certain representations, warranties, covenants and events of default, and increases in the amount of the principal and interest rates under the Notes in the event of such defaults. In connection with the issuance of ~~Note~~the INote, the Company recorded a debt discount of $708,~~000~~976 related to the embedded conversion option derivative liability. The amortization expense related to that discount recorded was ~~approximately~~ $608,~~794~~259 for the ~~nine~~year ~~months~~ ended ~~September~~December 3031, 2017 and ~~the~~$717 ~~total~~for ~~debt discount recorded was fully amortized as of September 30, 2017. During~~ the three months ended ~~September~~March 3031, ~~2017,~~2018. ~~$25,764~~As of ~~the~~December ~~outstanding~~31, ~~principal~~2017 and ~~interest~~March ~~of the note was converted into 3~~31,~~445,000~~ ~~shares of common stock. As of September 30~~2018, ~~2017,~~ the outstanding principal and interest on the Note Iwere ~~was~~ $8116,~~222~~303 and $16,673, respectively. As the note conversion includes a “lesser of” pricing provision, a derivative liability of $998,~~742~~976 was recorded when the Note I was entered into. The derivative liability is re-measured at each balance sheet date and reclassified to equity on a pro-rata basis upon conversion of the note, the derivative liability balance for the ~~Notes~~Note at ~~September~~March 3031, ~~2017~~2018 was $6016,~~251~~680.

On ~~January~~March 3114, 2017, the Company closed a Securities Purchase Agreement (“SPA”) with a lender, ~~dated January 30, 2017,~~ providing for the purchase of atwo ~~Secured~~ Convertible ~~Promissory~~Redeemable ~~Note~~Notes in the aggregate principal amount of $104,000 (the “~~Note~~Notes”), with the first note being in the ~~aggregate~~amount ~~principal~~of $52,000 (“Note I”) and the second note being in the amount of $~~412~~52,~~500.~~000 ~~The~~(“Note II”) with a maturity date of March 14, 2018. Note I was ~~fully~~ funded as ofon March 3114, 2017, with the Company receiving $~~375~~47,~~000~~500 of ~~net~~ proceeds, (net of OID). ~~The~~of $2,000 and legal fees of $2,500. Note ~~has~~II awas ~~10%~~initially ~~original~~paid for by the issuance ~~discount~~of an offsetting $52,000 secured note issued by the lender to ~~offset~~the ~~transaction~~Company (“Secured Note”). Note II was funded on May 3, ~~diligence~~2017, with the Company receiving $47,500 of proceeds, net of OID of $2,000 and legal ~~costs~~fees of $2,500. The ~~Note~~Notes ~~bears~~bear an interest rate of 1012%; and ~~matures12~~may ~~months after the tranches~~converted ~~are~~be ~~funded.~~at ~~The~~any ~~Note~~time ~~may~~after be180 ~~converted~~days byof the ~~lender~~date atof ~~any~~closing ~~time~~converted into shares of Company’s common stock convertible at athe ~~price~~lesser ~~equal to~~of 62a 37.5% discount to the common stock price on the date of the ~~lowest~~note ~~closing~~or ~~bid~~a ~~price~~37.5% ~~for~~discount to the ~~Company’s~~price of our common stock ~~during~~price at the 20time ~~trading~~of ~~days~~conversion. ~~immediately~~The ~~preceding~~Notes aalso contain certain representations, warranties, covenants and events of default, and increases ~~conversion~~in ~~date~~the amount of the principal and interest rates under the Notes in the event of such defaults. In connection with the issuance of ~~the note~~Notes, the Company recorded a ~~premium~~debt discount of $~~247~~86,~~500~~964 asrelated to the ~~note~~embedded isconversion option derivative liability. The ~~considered~~amortization ~~stock~~expense ~~settled~~related ~~debt~~to ~~under~~that ~~ASC~~discount ~~480~~recorded was approximately $81,179 ~~which~~and ~~was~~$5,785, ~~fully~~during ~~accreted~~the asyear ofended December 31, 2017 and three months ended March 31, ~~2017~~2018, respectively. During the ~~three~~year ~~months~~ ended ~~September 30~~December 31, 2017, $8555,~~916~~774 of the outstanding principal and interest of the note was converted into 1312,~~025,000~~277 shares of common stock. As of ~~September~~December 3031, 2017 and March 31, 2018, the outstanding principal and interest on the Notes was $57,407 and $60,484, respectively. As the note conversion includes a “lesser of” pricing provision, a derivative liability of $97,555 was recorded when the Notes were entered into. The derivative liability is re-measured at each balance sheet date and reclassified to equity on a pro-rata basis upon conversion of the notes, the derivative liability balance for the Notes at March 31, 2018 was $~~351~~60,~~334~~512.

On ~~February~~March 1524, 2017, the Company ~~entered~~closed ~~into~~a anSecurities Purchase ~~agreement~~Agreement (“SPA”) with a lender, providing for the ~~issuance~~purchase of a ~~non-cash~~two Convertible Redeemable ~~Note~~Notes ~~with~~in the aggregate principal amount of $1589,~~000~~150 (the “~~Note~~Notes”), aswith ~~penalty~~the ~~interest.~~first ~~The~~note being in the amount of $44,575 (“Note ~~bears~~I”), anand ~~interest~~the ~~rate~~second note being in the amount of ~~10%~~$44,575 ~~and~~(“Note ~~matures~~II”). Note I was funded on ~~February~~March 1727, ~~2018.~~2017, ~~The~~with the Company receiving $35,000 of net proceeds (net of legal fees and OID). Note ~~may~~II will initially be ~~converted~~paid for by the ~~lender~~issuance atof ~~any~~an ~~time~~offsetting ~~into~~$39,250 ~~shares~~secured ofnote issued to the Company’s ~~common~~by ~~stock~~the atlender a(the ~~stock~~“Secured atNote”). aThe ~~price~~funding ~~equal~~of Note II is subject to the ~~lesser~~mutual agreement of athe ~~37.5%~~lender ~~discount~~and to the ~~common~~Company. ~~stock~~The ~~price~~lender onis required to pay the ~~date~~principal amount of the ~~note~~Secured orNote ain ~~37.5%~~cash ~~discount~~and ofin full prior ~~the~~to ~~lowest~~executing ~~trading~~any ~~price~~conversions ~~for~~under ~~the~~Note ~~Company’s~~II. ~~common~~The ~~stock~~Notes 15bear ~~days~~an ~~prior~~interest ~~trading~~rate ~~days~~of ~~including~~10% ~~the~~and ~~day~~are ~~upon~~due ~~which~~and apayable ~~notice~~December 24, of2017. ~~conversion~~The isNote ~~received~~may be converted by the ~~Company.~~lender ~~The~~at ~~Note~~any ~~also~~time ~~contain~~into ~~certain~~shares ~~representations,~~of ~~warranties,~~Company’s common ~~covenants~~stock ~~and~~at ~~events~~ a price equal to 62.5% of ~~default,~~the ~~and~~lowest ~~increases~~closing inbid price for the ~~amount~~Company’s ofcommon stock during the ~~principal~~20 ~~and~~days prior ~~interest~~trading ~~rates~~days ~~under~~including the ~~Notes~~day inupon ~~the~~which ~~event~~a notice of ~~such~~conversion ~~defaults~~is received by the Company. In connection with the issuance of the ~~Note~~note, the Company recorded a ~~debt~~premium ~~discount~~ of $826,~~976~~746 ~~related~~as to the ~~embedded~~note ~~conversion~~is ~~option derivative~~considered ~~liability.~~stock ~~The~~settled ~~amortization~~debt ~~expense~~under ~~related~~ASC to480, ~~that discount recorded~~ which was ~~$6,015~~fully ~~for~~accreted ~~the~~as ~~nine~~of ~~months~~March ~~ended September 30~~31, 2017. AsDuring ofthe ~~September~~year 30ended December 31, 2017, $24,906 of the outstanding principal and interest of on the ~~Note~~note was ~~$15,925.~~converted Asinto ~~the~~20,500 ~~note~~shares ~~conversion~~of ~~includes a~~common ~~“lesser~~stock. As of” ~~pricing~~December ~~provision~~31, a2017, ~~derivative~~the ~~liability~~outstanding ofprincipal ~~$8,976~~and ~~was~~interest on ~~recorded when~~ the ~~Note~~note was ~~entered into~~$23,012. ~~The derivative~~During ~~liability~~the isthree ~~re-measured~~months atended ~~each~~March ~~balance~~31, ~~sheet~~2018, ~~date~~$23,140 ~~and~~of ~~reclassified~~the toremining ~~equity~~outstanding onprincipal aand ~~pro-rata basis upon conversion~~interest of the note was fully converted into 19,486 ~~the~~shares ~~derivative~~of ~~liability~~common ~~balance~~stock. ~~for~~The ~~the~~note ~~Note~~had atno ~~September~~outstanding ~~30,~~balance ~~2017~~as ~~was~~of $9March 31,~~652~~ 2018.

On ~~March~~April 1417, 2017, the Company closed a Securities Purchase Agreement (“SPA”) with a lender, providing for the purchase of ~~two~~a Secured Convertible ~~Redeemable~~Promissory ~~Notes~~Note in the aggregate principal amount of ~~$104,000~~up ~~(the~~to ~~“Notes”), with the first note being in the amount of~~ $52165,000 (“Note I”) ~~and the second note being in the amount of $52~~,~~000~~ The (“Note ~~II”) with~~was afully ~~maturity~~funded ~~date~~as of ~~March~~December 1431, ~~2018. Note I was funded on March 14,~~ 2017, with the Company receiving $47150,~~500~~000 of ~~proceeds,~~ net of ~~OID~~total ofproceeds ~~$2,000~~(net ~~and legal fees~~ of ~~$2,500~~10% OID). The Note IIbears ~~was~~an ~~initially~~interest ~~paid~~rate ~~for by the issuance~~ of ~~an offsetting $52~~10%,~~000~~ ~~secured~~which ~~note~~is ~~issued~~payable byin the ~~lender to the~~ Company’s ~~(“Secured~~common ~~Note”).~~stock ~~Note~~based IIon ~~was~~the ~~funded~~conversion onformula ~~May~~(as 3,defined ~~2017~~below), ~~with~~and the ~~Company~~maturity ~~receiving $47,500~~date offor ~~proceeds,~~each funded ~~net~~tranche ofwill ~~OID~~be of12 ~~$2,000~~months ~~and~~from ~~legal~~the ~~fees~~date ofon ~~$2,500.~~which ~~The~~the ~~Notes~~funds ~~bear~~are anreceived ~~interest~~by ~~rate~~the ofCompany. ~~12%;~~The ~~and~~Note may be converted by the belender at any time ~~after 180 days of the date of closing converted~~ into shares of Company’s common stock ~~convertible~~ at ~~the lesser of~~ a 37.5% discount off to the ~~common~~lowest ~~stock~~closing bid price onfor the ~~date~~Company’s ~~of the note or a 37.5% discount to the price of our~~ common stock ~~price at~~during the ~~time~~20 oftrading ~~conversion.~~days ~~The~~immediately ~~Notes~~preceding ~~also~~a ~~contain certain representations, warranties, covenants and events of default, and increases~~conversion ~~in the amount of the principal and interest rates under the Notes in the event of such defaults~~date. In connection with the issuance of ~~Notes~~the note, the Company recorded a ~~debt~~premium ~~discount~~ of $8699,~~964~~000 ~~related~~as to the ~~embedded~~note ~~conversion~~is ~~option~~considered ~~derivative~~stock ~~liability. The~~settled ~~amortization~~debt ~~expense~~under ~~related~~ASC to480, ~~that~~which ~~discount recorded~~ was ~~approximately~~fully ~~$37,298~~accreted ~~during~~as ~~the~~of ~~nine months ended~~ September 30, 2017. ~~During~~ ~~the~~As ~~three~~of ~~months~~December ~~ended September 30~~31, 2017, ~~$5,324 of the outstanding principal~~ and ~~interest~~March ~~of the note was converted into 851~~31,~~814~~ ~~shares of common stock. As of September 30~~2018, ~~2017,~~ the outstanding principal and interest on the ~~Notes was $104,711. As the~~ note ~~conversion~~were ~~includes a “lesser of” pricing provision, a derivative liability of~~ $97175,~~555~~054 ~~was recorded when the Notes were entered into. The derivative liability is re-measured at each balance sheet date~~ and ~~reclassified to equity on a pro-rata basis upon conversion of the notes~~$179, ~~the derivative liability balance for the Notes at September 30~~179, ~~2017 was $65,924~~respectively.

POSITIVEID CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements

~~September~~March 3031, ~~2017~~2018

(Unaudited)

On ~~March~~May 242, 2017, the Company ~~closed~~entered into a Securities Purchase Agreement (“SPA”) with a lender, providing for the purchase of two Convertible Redeemable Notes in the aggregate principal amount of $8964,~~150~~205 (the “Notes”), with the first note being in the amount of $4432,~~575~~102 (“Note I”), and the second note being in the amount of $4432,~~575~~ 102 (“Note II”). Note I was funded on ~~March~~May 273, 2017, ~~with the Company receiving $35,000 of net proceeds (net of legal fees~~ and ~~OID).~~ Note II ~~will~~ ~~initially~~was befunded ~~paid~~on ~~for~~October by31, ~~the~~2017, ~~issuance~~with ofthe anCompany ~~offsetting~~ receiving $3951,250 ~~secured~~of ~~note issued~~net tototal ~~the~~proceeds ~~Company by the lender~~ (~~the~~net ~~“Secured Note”). The funding~~ of ~~Note~~OID ~~II is subject to the mutual agreement of the lender~~ and ~~the~~legal ~~Company~~fees). The ~~lender is required to pay the principal amount of the Secured Note in cash and in full prior to executing any conversions under Note II. The~~ Notes bear an interest rate of 10%, and are due and payable ~~December~~on ~~24,~~February ~~2017~~2, 2018. The ~~Note~~Notes may be converted by the lender at any time into shares of Company’s common stock at a price equal to 62.5% of the lowest closing bid price ~~for~~of the ~~Company’s~~ common stock ~~during~~for the 20 ~~days~~ prior trading days including the day upon which a notice of conversion is received by the Company. In connection with the issuance of the note, the Company recorded a premium of $2638,~~746~~522 as the ~~note~~notes isare considered stock settled debt under ASC 480, which was fully accreted asupon note inception. As of ~~March~~December 31, 2017. Asand ofMarch ~~September 30~~31, ~~2017~~2018, the outstanding principal and interest on the note ~~was~~were $4666,~~804~~879 and $68,484.

On ~~April~~May 1023, 2017, the Company ~~closed~~entered into a Securities Purchase Agreement ~~(“SPA”)~~ with a lender ~~providing~~ for the purchase of ~~two~~a Convertible ~~Redeemable~~Promissory ~~Notes~~Note in the aggregate principal amount of $7753,~~792~~000 (the “~~Notes”), with the first note being in the amount of $38,896 (“~~Note I”),. ~~and~~The ~~the second note being in the amount of $38,896 (“~~Note has ~~II”).~~been ~~Note I was~~ funded ~~April 10~~, ~~2017,~~ with the Company receiving $3450,~~250~~000 of net proceeds (net of ~~original issue discount~~fees). ~~Note II will initially be paid for by the issuance of an offsetting $34,250 secured note issued to the Company by the lender (the “Secured Note”).~~ The ~~funding of~~ Note IIbears is subject to the mutual agreement of the lender and the Company. The lender is required to pay the principal amount of the Secured Note in cash and in full prior to executing any conversions under Note II. The Notes bear an interest rate of 108%, and ~~are~~ is due and payable on ~~January~~May 1023, 2018. The ~~Notes~~Note may be converted by the lender at any time into shares of Company’s common stock (as determined in ~~the~~ ~~Notes) calculated at~~ the ~~time of conversion, except for~~ Note ~~II, which requires full payment of the Secured Note by the lender before conversions may be made. The Notes (subject to funding in the case of Note II~~) ~~may be converted by the lender~~ at ~~any time into shares of Company’s common stock at~~ a price equal to ~~62.5~~65% of the average of the lowest five closing bid ~~price~~prices ~~for~~ of the ~~Company’s~~ common stock ~~during~~for the 2010 ~~days~~ prior trading days ~~including the day~~ upon which a notice of conversion is received by the Company. In connection with the issuance of the note, the Company recorded a premium of $2328,~~338~~538 as the ~~notes~~ note is considered stock settled debt under ASC 480, which was fully accreted as of June 30, 2017. As of ~~September~~December 3031, 2017 and March 31, 2018, the outstanding principal and interest on the note ~~was~~were $4055,~~841~~562 and $56,622, respectively.

On ~~April~~June 176, 2017, the Company ~~closed~~entered into a Securities Purchase Agreement (“SPA”) with a lender, providing for the purchase of atwo ~~Secured~~ Convertible ~~Promissory~~Redeemable ~~Note~~Notes in the aggregate principal amount of ~~up to~~ $~~165~~104,000 (the “~~Note~~Notes”), with the first ~~tranche~~note ~~funded~~ being in the amount of $5052,000. ~~Subsequent~~(“Note ~~tranches~~I”), ~~will~~and ~~be delivered to~~ the ~~Company~~second ~~approximately bi-weekly~~note ~~and~~being atin the ~~sole~~amount ~~discretion~~ of ~~the~~$52,000 (“Note ~~lender~~II”). ~~During~~Note ~~the~~I ~~six~~was ~~months~~funded ~~ended~~on ~~September 30~~June 6, 2017, ~~all~~and ~~three~~Note ~~tranches~~II ~~were~~was funded on August 10, 2017, with the Company receiving $~~150~~95,000 of aggregate net proceeds (net of ~~10%~~ OID and fees). The ~~Note~~Notes ~~bears~~bear an interest rate of 1012%, ~~which~~and isare ~~payable~~due ~~in the Company’s common stock based on the conversion formula (as defined below),~~ and ~~the~~payable ~~maturity date for each funded tranche will be 12 months from the date~~ on ~~which~~June ~~the~~6, ~~funds are received by the Company~~2018. The ~~Note~~Notes may be converted by the lender at any time into shares of Company’s common stock at a 37price equal to 62.5% ~~discount~~of ~~off~~ the lowest closing bid price ~~for~~of the ~~Company’s~~ common stock ~~during~~for the 2015 prior trading days ~~immediately~~including the ~~preceding~~day upon which a notice of conversion ~~date~~is received by the Company. In connection with the issuance of the ~~note~~Notes, the Company recorded a premium of $9962,~~000~~400 as the ~~note~~notes isare considered stock settled debt under ASC 480, which was fully accreted as upon issuance of ~~September~~the 30Notes. During the year ended December 31, 2017, $55,256 of the outstanding principal and interest on the note was converted into 40,318 shares of common stock. As of ~~September~~December 3031, 2017 and March 31, 2018, the outstanding principal and interest on the note ~~was~~were $~~170~~54,~~929~~600 and $56,160, respectively.

On ~~May~~July 217, 2017, the Company entered into a Securities Purchase Agreement (“SPA”) with a lender~~, providing~~ for the purchase of a ~~two~~ Convertible ~~Redeemable~~Promissory ~~Notes~~Note in the aggregate principal amount of $6453,~~205~~000 (the “~~Notes”), with the first note being in the amount of $32,102 (“~~Note I”),. ~~and~~The ~~the second note being in the amount of $32,102 (“~~Note ~~II”).~~has ~~Note~~been ~~I was~~ funded ~~on May 3~~, ~~2017~~ with the Company receiving, $2550,000 of net proceeds (net of ~~OID and legal~~ fees) ~~and Note II was funded subsequent to the three months ended September 30, 2017, with the Company receiving, $26,250 of net proceeds (net of OID and legal fees)~~. The ~~Company~~Note ~~received~~bears an ~~aggregate amount of $51,250 of net proceeds (net of OID and legal fees). The Notes bear an~~ interest rate of 108%, and ~~are~~is due and payable on ~~February~~April 230, 2018. The ~~Notes~~Note may be converted by the lender at any time into shares of Company’s common stock (as determined in the Note) at a price equal to ~~62.5~~65% of the average of the lowest five closing bid ~~price~~prices of the common stock for the 2010 ~~prior~~ trading days ~~including~~ending on the ~~day~~latest ~~upon~~complete ~~which~~trading aday ~~notice of~~prior ~~conversion~~to ~~is received by~~ the ~~Company~~conversion date. In connection with the issuance of the note, the Company recorded a premium of $1928,~~261~~ 538 as the ~~notes~~note is considered stock settled debt under ASC 480, which was fully accreted asupon issuance of ~~June~~the ~~30, 2017~~Note. As of ~~September~~December 3031, 2017, the outstanding principal and interest on the note was $3354,~~440~~943. During the three months ended March 31, 2018, $55,189 of the outstanding principal and interest on the note was fully converted into 43,174 shares of common stock. The note had no outstanding balance as of March 31, 2018.

On August 8, 2017, the Company entered into a Securities Purchase Agreement (“SPA”) with a lender for the purchase of a Convertible Promissory Note in the aggregate principal amount of $55,000 (the “Note”). The Note has been funded, with the Company receiving $50,000 of net proceeds (net of fees). The Note bears an interest rate of 12% and is due and payable on August 8, 2018. The Note may be converted by the lender at any time into shares of Company’s common stock (as determined in the Note) at a price equal to 62.5% of the lowest closing bid prices of the common stock for the 20 prior trading days including the day upon which a notice of conversion is received by the Company. In connection with the issuance of the note, the Company recorded a premium of $33,000 as the note is considered stock settled debt under ASC 480, which was fully accreted upon note inception. As of December 31, 2017 and March 31, 2018, the outstanding principal and interest on the note were $57,750 and $59,400, respectively.

POSITIVEID CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements

~~September~~March 3031, ~~2017~~2018

(Unaudited)

On ~~May~~August 2211, 2017, the Company ~~entered~~closed ~~into~~ a Securities Purchase Agreement (“SPA”) with a lender , providing for the purchase of atwo Convertible Redeemable ~~Note~~Notes in the aggregate principal amount of $5094,~~000~~500 (the “Notes”), with the first note being in the amount of $47,250 (“Note I”). ~~The~~and the second note being in the amount of $47,250 (“Note II”) ~~was~~with a maturity date of August 11, 2018. Note I and Note II were funded on ~~May~~September 2511, 2017 and October 19, 2017, respectively, with the Company receiving ~~$45~~,~~000~~ offor each note, net proceeds of $40,000 (net of OID and legal fees). ~~The~~and ~~Note~~an ~~bears~~aggregate annet proceeds of ~~interest~~$80,000 ~~rate~~(net of ~~10%,~~OID and islegal ~~due~~fees). ~~and~~The ~~payable~~Notes onbear ~~May~~an ~~22,~~interest ~~2018.~~rate ~~The~~of ~~Note~~12%; and may be converted bybe ~~the lender~~ at any time into shares of Company’s common stock, ~~(as~~convertible ~~determined~~at in the ~~Note)~~lesser atof a ~~price~~37.5% ~~equal~~discount to ~~65%~~the common stock price on the date of the ~~lowest~~note or a 37.5% discount ~~closing~~to ~~bid~~the price of ~~the~~our common stock ~~for~~price at the 20time ~~prior~~of ~~trading~~conversion. ~~days~~The ~~including~~Notes ~~the~~also ~~day~~contain ~~upon~~certain ~~which~~representations, awarranties, covenants ~~notice~~and events of ~~conversion~~default, isand ~~received by~~increases in the ~~Company~~amount of the principal and interest rates under the Notes in the event of such defaults. In connection with the issuance of ~~the~~ note, the Company recorded a ~~premium~~debt discount of $2646,~~923~~588 asrelated to the ~~note~~embedded conversion isoption ~~considered stock~~derivative ~~settled~~liability. ~~debt~~The ~~under~~amortization ~~ASC~~expense ~~480,~~related ~~which~~to that discount recorded was ~~fully~~$18,128 ~~accreted~~and as$5,516, ofduring the ~~June~~year 30ended December 31, 2017 and three months ended March 31, 2018, respectively. As of ~~September~~December 3031, 2017, the outstanding principal and interest on the Notes was $98,011. During the three months ended March 31, 2018, $25,558 of outstanding principal and interest on Note I was converted into 93,345 shares of common stock and the Company exercised its right to prepay the outstanding principal and interest for a total redemption amount of $72,000. The Company recorded a loss on extinguishment of approximately $22,000. Note II had no outstanding balance as of March 31, 2018. As March 31, 2018, the outstanding principal and interest on Note I was $25,467. As the note conversion includes a “lesser of” pricing provision, a derivative liability of $46,588 was recorded when the Notes were entered into. The derivative liability is re-measured at each balance sheet date and reclassified to equity on a pro-rata basis upon conversion or redemption of the notes, the derivative liability balance for the note at Marc 31, 2018 was $5115,~~771~~229.

On ~~May~~August 2321, 2017, the Company entered into a Securities Purchase Agreement (“SPA”) with a lender for the purchase of a Convertible Promissory Note in the aggregate principal amount of $53,000 (the “Note”). The Note was funded on ~~May 23~~August 22, 2017, with the Company receiving $50,000 of net proceeds (net of fees). The Note bears an interest rate of 8%, and is due and payable on May 2330, 2018. The Note may be converted by the lender at any time into shares of Company’s common stock (as determined in the Note) at a price equal to 65% of the average of the lowest five closing bid prices of the common stock for the 10 ~~prior~~ trading days ~~upon~~ending ~~which~~on athe ~~notice~~latest ofcomplete ~~conversion~~trading isday ~~received by~~prior to the ~~Company~~conversion date. In connection with the issuance of the note, the Company recorded a premium of $28,538 as the note is considered stock settled debt under ASC 480, which was fully accreted asupon note inception. As of ~~June~~December 3031, 2017. Asand ofMarch ~~September 30~~31, ~~2017~~2018, the outstanding principal and interest on the note ~~was~~were $54,~~502~~590 and $55,650, respectively.

On ~~June~~September 611, 2017, the Company entered into a Securities Purchase Agreement (“SPA”) with a lender, providing for the purchase of ~~two~~a Secured Convertible ~~Redeemable~~Promissory ~~Notes~~Note in the aggregate principal amount of up to $~~104~~137,~~000~~ 500 (the “~~Notes~~Note”), with the first ~~note being in the amount of $52,000 (“Note I”),~~ and ~~the~~ second ~~note~~tranche ~~being in the amount of $52,000 (“Note II”). Note I was~~ funded on ~~June~~September 615, 2017 and ~~Note~~October ~~II was funded on Augusts 10~~16, 2017, ~~with~~respectively, with the Company receiving $47125,~~500~~000 of net proceeds (net of OID). ~~and~~The Note ~~legal~~has ~~fees)~~a ~~for~~10% ~~each~~original ~~note~~issuance ~~and~~discount ~~aggregate~~to ~~net~~offset ~~proceeds~~transaction, ofdiligence ~~$95,000~~and legal costs. The ~~Notes~~Note ~~bear~~bears an interest rate of 12 10%, and ~~are~~matures ~~due~~twelve ~~and~~months ~~payable~~after onthe ~~June~~tranches 6,are ~~2018~~funded. The ~~Notes~~Note may be converted by the lender at any time into shares of Company’s common stock at a price equal to 62.5% of the lowest closing bid price offor the Company’s common stock ~~for~~ during the 1520 ~~prior~~ trading days ~~including~~immediately ~~the~~preceding ~~day upon which~~ a ~~notice of~~ conversion ~~is received by the Company~~date. In connection with the issuance of the ~~Notes~~note, the Company recorded a premium of $6282,~~400~~500 as the ~~note~~Note is considered stock settled debt under ASC 480, which was fully accreted upon ~~issuance~~note ~~of the Notes~~inception. As of ~~September~~December 3031, 2017 and March 31, 2018, the outstanding principal and interest on the note ~~was~~were $~~107~~141,~~120~~070 and $144,508, respectively.

On ~~July~~September 1712, 2017, the Company entered into a Securities Purchase Agreement (“SPA”) with a lender, providing for the purchase of a two Convertible ~~Promissory~~Redeemable ~~Note~~Notes in the aggregate principal amount of $53104,000 (the “Notes”), with the first note being in the amount of $52,000 (“Note I”), and the second note being in the amount of $52,000 (“Note II”). ~~The~~Note I was funded on September 12, 2017 and Note ~~has~~II ~~been~~was funded on September 27, 2017, with the Company receiving $5047,~~000~~500 of net proceeds (net of OID and legal fees) for each note and aggregate net proceeds of $95,000. The ~~Note~~Notes ~~bears~~ bear an interest rate of 812%, and isare due and payable on ~~April~~September 3012, 2018. The ~~Note~~Notes may be converted by the lender at any time into shares of Company’s common stock ~~(as determined in the Note)~~ at a price equal to 6562.5% of the ~~average of the~~ lowest ~~five~~ closing bid ~~prices~~price of the common stock for the 1015 prior trading days ~~ending~~including on the ~~latest~~day ~~complete~~upon ~~trading~~which ~~day~~a ~~prior~~notice toof ~~the~~ conversion ~~date~~is received by the Company. In connection with the issuance of the ~~note~~Notes, the Company recorded a premium of $2862,~~538~~400 as the ~~note~~notes isare considered stock settled debt under ASC 480, which was fully accreted upon note inception. As of December 31, 2017, the outstanding principal and interest ~~issuance~~on the note was $107,120. During the three months ended March 31, 2018, $55,284 of the ~~Note~~outstanding principal and interest of note was converted into 884,540 shares of common stock. As of ~~September~~March 3031, ~~2017~~2018, the outstanding principal and interest on the note was $5355,~~883~~120.

On ~~August~~October 82, 2017, the Company entered into a Securities Purchase Agreement (“SPA”) with a lender, providing for the purchase of a two Convertible Promissory ~~Note~~Notes in the aggregate principal amount of $55107,000 (the “Notes”), with the first note being in the amount of $53,500 (“Note I”)., ~~The~~and the second note being in the amount of $53,500 (“Note II”). ~~has~~Note ~~been~~I was funded on October 3, 2017, with the Company receiving $5045,000 of net proceeds (net of OID, legal and other fees). Note II will initially be paid for by the issuance of an offsetting $50,000 note issued to the Company by the Lender (the “Collateralized Note”). The funding of Note ~~bears~~II is subject to the mutual agreement of the lender and the Company which has not occurred as of yet. The lender is required to pay the principal amount of Note I in cash and in full prior to executing any conversions under Note II. The Notes bear an interest rate of 12%, and isare due and payable on ~~April~~October 82, 2018. The ~~Note~~Notes may be converted by the lender at any time into shares of Company’s common stock (as determined in the Notes) calculated at the time of conversion, except for Note II, which requires full payment of the Collateralized Note by the lender before conversions may be made. The Notes (subject to funding in the case of Note II) may be converted by the lender at aany time into shares of Company’s common stock price ~~equal~~on tothe date of the note or 62.5% of the lowest closing bid ~~prices~~price of the common stock for the 20 prior trading days including the day upon which a notice of conversion is received by the Company. In connection with the issuance of ~~the~~ note, ~~the~~ the Company recorded a ~~premium~~debt discount of $33,~~000~~514 asrelated to the ~~note~~embedded isconversion ~~considered~~option ~~stock~~derivative ~~settled~~liability. ~~debt~~The ~~under~~amortization expense ~~ASC~~related ~~480,~~to ~~which~~that discount recorded was ~~fully~~$8,005 ~~accreted~~and ~~upon issuance~~$8,286, ofduring the ~~Notes~~year ended December 31, 2017 and three months ended March 31, 2018, respectively. As of ~~September~~December 3031, 2017 and March 31, 2018, the outstanding principal and interest on the Note were $55,065 and 56,648. As the note conversion includes a “lesser of” pricing provision, a derivative liability of $33,514 was recorded when the Notes were entered into. The derivative liability is re-measured at each balance sheet date and reclassified to equity on a pro-rata basis upon conversion of the notes, the derivative liability balance for the note at March 31, 2018 was $5630,~~100~~732.

On August 11, 2017, the Company closed a Securities Purchase Agreement (“SPA”) with a lender, providing for the purchase of two Convertible Redeemable Notes in the aggregate principal amount of $94,500 (the “Notes”), with the first note being in the amount of $47,250 (“Note I”) and the second note being in the amount of $47,250 (“Note II”) with a maturity date of August 11, 2018. Note I was funded on September 11, 2017 and Note II was funded subsequent to the three months ended September 30, 2017 with the Company receiving, for each note, net proceeds of $40,000 (net of OID and legal fees) and an aggregate net proceeds of $80,000 (net of OID and legal fees). The Notes bear an interest rate of 12%; and may converted be at any time into shares of Company common stock, convertible at the lesser of a 37.5% discount to the common stock price on the date of the note or a 37.5% discount to the price of our common stock price at the time of conversion. The Notes also contain certain representations, warranties, covenants and events of default, and increases in the amount of the principal and interest rates under the Notes in the event of such defaults. In connection with the issuance of note, the Company recorded a debt discount of $30,699 related to the embedded conversion option derivative liability. The amortization expense related to that discount recorded was approximately $4,205 during the three months ended September 30, 2017. As of September 30, 2017, the outstanding principal and interest on the Notes was $48,198. As the note conversion includes a “lesser of” pricing provision, a derivative liability of $30,699 was recorded when the Notes were entered into. The derivative liability is re-measured at each balance sheet date and reclassified to equity on a pro-rata basis upon conversion of the notes, the derivative liability balance for the note at September 30, 2017 was $29,390.

POSITIVEID CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements

~~September~~March 3031, ~~2017~~2018

(Unaudited)

On ~~August~~October 2211, 2017, the Company entered into a Securities Purchase Agreement (“SPA”) with a lender, providing for the purchase of a two Convertible ~~Promissory~~Redeemable ~~Note~~Notes in the aggregate principal amount of $53104,000 (the “Notes”), with the first note being in the amount of $52,000 (“Note I”), and the second note being in the amount of $52,000 (“Note II”). ~~The~~Note I was funded on October 11, 2017 and Note ~~has~~II ~~been~~was funded on October 25, 2017, with the Company receiving $5095,000 of net aggregate proceeds (net of OID and legal fees). The ~~Note~~Notes ~~bears~~bear an interest rate of 812%, and isare due and payable on ~~May 30~~October 11, 2018. The ~~Note~~Notes may be converted by the lender at any time into shares of Company’s common stock (as determined in the ~~Note~~ Notes) at a price equal to 6562.5% of the ~~average of the~~ lowest ~~five~~ closing bid ~~prices~~price of the common stock for the 1020 prior trading days ~~ending~~including on the day ~~latest~~upon ~~complete~~which ~~trading~~a ~~day~~notice ~~prior~~of toconversion ~~the~~is ~~conversion~~received ~~date~~by the Company. In connection with the issuance of the ~~note~~Notes, the Company recorded a premium of $2862,~~538~~400 as the ~~note~~notes isare considered stock settled debt under ASC 480, which was fully accreted upon ~~issuance~~ ofnote ~~the Note~~inception. As of ~~September~~December 3031, 2017 and March 31, 2018, the outstanding principal and interest on the note ~~was~~were $53106,~~530~~470 and $109,590, respectively.

On ~~September~~November 119, 2017, the Company entered into a Securities Purchase Agreement (“SPA”) with a lender~~, providing~~ for the purchase of a ~~Secured~~ Convertible Promissory Note in the aggregate principal amount of ~~up to~~ $~~137~~53,~~500 (the~~000 (“Note”),. ~~with~~The ~~the~~Note ~~first~~was ~~tranche~~ funded on ~~September~~ November 15, 2017, with the Company receiving $~~75,000 of net proceeds (net of OID). A second tranche was funded subsequent to the three months ended September 30, 2017, with the Company receiving $~~50,000 of net proceeds (net of ~~OID~~fees) ~~(see Note 10)~~. The Note ~~has a 10% original issuance discount to offset transaction, diligence and legal costs. The Note~~ bears an interest rate of 108% and ~~matures12 months~~is ~~after~~due ~~the~~and payable ~~tranches~~on ~~are~~August ~~funded~~30, 2018. The Note may be converted by the lender at any time into shares of Company’s common stock (as determined in the Note) at a price equal to ~~62.5~~65% of the average of the lowest five closing bid ~~price~~prices ~~for~~of the ~~Company’s~~ common stock ~~during~~for the 10 20 trading days ~~immediately~~ ~~preceding~~ending aon the latest complete trading day prior to the conversion date. In connection with the issuance of the ~~note~~ Note, the Company recorded a premium of $4928,~~092~~538 as the ~~note~~Note is considered stock settled debt under ASC 480, which was fully accreted upon ~~issuance of the~~ note inception. As of ~~September~~ 30December 31, 2017 and March 31, 2018, the outstanding principal and interest on the note was $8253,~~161~~530 and $54,590, respectively.

On ~~September~~November 1213, 2017, the Company entered into a Securities Purchase Agreement (“SPA”) with a lender, providing for the purchase of two Convertible Redeemable Notes in the aggregate principal amount of $104,000 (the “Notes”), with the first note being in the amount of $52,000 (“Note I”), and the second note being in the amount of $52,000 (“Note II”). Note I ~~was~~and II were funded on ~~September~~November 1213, 2017 and ~~Note~~December ~~II was funded on September 27~~1, 2017, respectively, with the Company receiving $4795,~~500~~ 000 of net aggregate proceeds (net of OID and legal fees) ~~for each note and aggregate net proceeds of $95,000~~. The Notes bear an interest rate of 12%, and are due and payable on ~~September 12~~November 13, 2018. The Notes may be converted by the lender at any time into shares of Company’s common stock at a price equal to 62.5% of the lowest closing bid price of the common stock for the 1520 prior trading days including the day upon which a notice of conversion is received by the Company. In connection with the issuance of the Notes, the Company recorded a premium of $62,400 as the ~~note~~notes isare considered stock settled debt under ASC 480, which was fully accreted upon ~~issuance~~note ~~of the Notes~~inception. As of ~~September~~December 3031, 2017 and March 31, 2018, the outstanding principal and interest on the note ~~was~~were $~~104~~105,~~520~~300 and $108,420, respectively.

~~Other~~On ~~Financings~~November 21, 2017, the Company entered into a Securities Purchase Agreement (“SPA”) with a lender, providing for the purchase of a Secured Convertible Promissory Note in the aggregate principal amount of up to $137,500 (“Note”). The first and second tranche were funded on November 24, 2017 and December 15, 2017, respectively, with the Company receiving $75,000 of net total proceeds (net of OID). The Note bears an interest rate of 10%, which is payable in the Company’s common stock based on the conversion formula (as defined below), and the maturity date for each funded tranche will be 12 months from the date on which the funds are received by the Company and may be converted by the lender at any time into shares of Company’s common stock at a 37.5% discount to the lowest closing bid price for the Company’s common stock during the 20 trading days immediately preceding a conversion date. In connection with the issuance of the Note, the Company recorded a premium of $49,500 as the notes are considered stock settled debt under ASC 480, which was fully accreted upon note inception. As of December 31, 2017 and March 31, 2018, the outstanding principal and interest on the note were $83,016 and $85,078, respectively.

On ~~July~~November 921, ~~2012~~2017, the Company ~~issued~~entered into a ~~Secured~~Securities ~~Promissory~~Purchase ~~Note~~Agreement (~~the~~ “~~H&K Note~~SPA”) inwith ~~the~~a ~~principal~~lender, ~~amount~~providing offor ~~$849,510~~the topurchase ~~Holland~~of &a ~~Knight~~Convertible ~~LLP~~Redeemable ~~(“Holland~~Notes ~~& Knight”), its external legal counsel,~~ in ~~support~~the ofaggregate ~~amounts~~principal ~~due~~amount ~~and owing to Holland & Knight as~~ of ~~June 30~~$57,750 ~~2012~~(“Note”). The ~~H&K~~ Note iswas ~~non-interest~~funded on ~~bearing~~November 21, ~~and~~2017, ~~principal~~with on the ~~H&K~~Company ~~Note~~receiving is$50,000 ~~due and~~of ~~payable~~net asproceeds ~~soon~~(net asof ~~practicably~~OID ~~possible~~and bylegal ~~the Company~~fees). The ~~Company~~Note ~~has~~bears ~~agreed~~an tointerest rate ~~remit~~of ~~payment~~12% ~~against~~and ~~the~~is ~~H&K~~due ~~Note~~and ~~immediately upon~~payable ~~each~~on ~~occurrence~~August of21, ~~any~~2018. ofThe ~~the~~Note ~~following~~may ~~events:~~be ~~(a)~~converted ~~completion~~by ofthe anlender ~~acquisition~~at orany ~~disposition~~time ofinto ~~any~~shares of ~~the~~ Company’s ~~assets~~common or stock ~~or any of the Company’s subsidiaries’ assets or stock with gross proceeds in excess of $750,000,~~ (~~b) completion~~as ofdetermined ~~any financing with gross proceeds~~ in ~~excess of $1,500,000, (c~~Note) ~~receipt~~at ofa ~~any~~37.5% ~~revenue~~discount into ~~excess of $750,000 from~~ the ~~licensing~~lowest orclosing ~~development~~bid ofprice ~~any~~ of the ~~Company’s~~common orstock for the ~~Company’s~~20 ~~subsidiaries’ products, or (d) any liquidation~~prior ortrading ~~reorganization~~days ofincluding the ~~Company’s~~day ~~assets~~upon orwhich ~~liabilities.~~a ~~The~~notice ~~amount~~ of ~~payment~~conversion tois bereceived ~~remitted~~ by the Company. ~~shall~~In ~~equal one-third~~connection ofwith the ~~gross~~issuance ~~proceeds~~of the ~~received~~Note, by the Company ~~upon~~recorded ~~each~~a ~~occurrence~~premium of ~~any of the above events~~$34,650 ~~until~~as the ~~principal~~Note is ~~repaid~~ inconsidered ~~full.~~stock Ifsettled ~~the~~debt ~~Company~~under ~~receives~~ASC $3480,~~000,000~~ inwhich ~~gross~~was ~~proceeds in any one financing or licensing arrangement, the entire~~fully ~~principal~~accreted ~~balance~~upon ~~shall~~note ~~be paid in full~~inception. ~~The~~As ~~H&K Note was secured by substantially all~~ of ~~the~~December ~~Company’s~~31, ~~assets~~2017 ~~pursuant to a security agreement between the Company~~ and ~~Holland~~March &31, ~~Knight dated July 9~~2018, ~~2012. In conjunction with~~ the ~~TCA~~outstanding ~~Purchase Agreement~~principal and ~~the Boeing License Agreement, Holland & Knight agreed to terminate its security~~ interest. Ason ~~of September 30, 2017,~~ the ~~Company~~note ~~had repaid~~ were $~~588~~58,~~301~~520 ~~of the H&K Note~~ and ~~the outstanding balance was~~ $~~262~~60,~~209~~253, ~~which is included in notes payable on the consolidated balance sheet~~respectively.

POSITIVEID CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements

~~September~~March 3031, ~~2017~~2018

(Unaudited)

On ~~March~~December 166, ~~2016,~~2017 the Company entered into a ~~factoring~~Securities ~~agreement~~Purchase Agreement (“SPA”) with a lender ~~for $105~~,~~000~~ toproviding ~~fund working capital. The Company also paid $3,150 of origination fees. The agreement requires daily repayments of $862~~ for ~~an eight-month term, with~~ the ~~total~~ ~~amount~~purchase ~~repaid~~ of ~~$144,900.~~a AsConvertible ofRedeemable ~~September~~Notes ~~30,~~in ~~2016,~~ the ~~Company~~aggregate ~~has repaid the outstanding~~ principal ~~and~~amount ~~interest balance~~ of ~~this~~ ~~note. On June 7, 2016, the Company entered into a second factoring agreement with a lender for~~ $5138,~~000~~500 ~~to fund working capital~~(“Note”). ~~The~~ ~~Company also paid $1,020 of origination fees.~~ The ~~agreement~~Note ~~requires~~was ~~daily repayments of $419 for an eight-month term, with~~funded ~~the~~on ~~total amount to be repaid $70,380. As of~~ December 3113, ~~2016~~2017, ~~the~~with ~~Company has repaid~~ the ~~outstanding principal and interest balance of this note. On September 9, 2016, the~~ Company ~~entered~~receiving ~~into a third factoring agreement with a lender for~~ $~~105~~36,~~000~~120 ~~to fund~~of ~~working~~net ~~capital.~~proceeds ~~The~~(net ~~Company also paid $2,100~~ of ~~origination~~ fees). The ~~agreement~~Note ~~requires~~bears ~~daily repayments of $862 for~~ an ~~eight-month~~ ~~term,~~interest ~~with~~rate ~~the total amount to be repaid $144,900. As~~ of ~~March 31, 2017, the Company has repaid the outstanding principal~~10% and ~~interest~~is ~~balance~~due ofand ~~this~~payable ~~note.~~on OnDecember ~~November 17~~6, ~~2016, the Company entered into a fourth factoring agreement with a lender for $100,000 to fund working capital~~2018. The ~~Company~~Note ~~also~~may ~~paid~~be ~~$2,000~~converted ofby ~~origination~~the ~~fees.~~lender ~~The~~at ~~agreement~~any ~~requires~~time ~~daily~~into ~~repayments~~shares of Company’s ~~$821~~common ~~for~~stock an(as ~~eight-month~~determined ~~term,~~in ~~with~~Note) ~~the~~at ~~total~~a ~~amount to be repaid $138,000~~37.5% Asdiscount ofto ~~June 30, 2017,~~ the ~~Company~~lowest ~~has~~closing ~~repaid~~bid ~~the~~price ~~full amount~~ of the ~~outstanding~~common ~~principal~~stock ~~and~~for ~~interest~~the ~~balance~~20 ofprior trading ~~this~~days ~~note.~~including ~~On March 7, 2017,~~ the ~~Company~~day ~~entered~~upon ~~into~~which a ~~fifth~~notice ~~factoring agreement~~of ~~with~~conversion ais ~~lender~~received ~~for~~by ~~$105,000~~the ~~to fund working capital. The~~ Company ~~also paid $2,100 of origination fees~~. ~~The~~In ~~agreement requires~~connection ~~daily repayments of $1,034 for four and a half-month term,~~ with the ~~total~~issuance ~~amount to be repaid $144,900. During~~ of the ~~nine months ended September 30~~Note, ~~2017,~~ the Company ~~has~~recorded ~~repaid~~a ~~the~~premium ~~full amount~~ of ~~the outstanding principal and interest balance of this note. On May 8~~$23,100 ~~2017,~~as the ~~Company~~Note ~~entered~~is ~~into~~considered astock ~~sixth~~settled ~~factoring~~debt ~~agreement~~under ~~with~~ASC ~~a lender for $120~~480,~~000~~ towhich ~~fund~~was ~~working capital.~~fully ~~The~~accreted ~~Company~~upon ~~also~~note ~~paid $2,400 of origination fees~~inception. ~~The~~As ~~agreement requires daily repayments~~ of $1December 31,~~250~~ ~~for~~2017 ~~four~~ and aMarch ~~half-month term~~31, ~~with the total amount to be repaid $166~~2018,~~200.~~ ~~During~~ the ~~nine~~outstanding ~~months~~principal ~~ended~~and ~~September~~interest ~~30,~~on ~~2017,~~ the ~~Company~~note ~~has repaid a total~~were ~~amount of~~ $~~123~~38,~~713~~660 ~~of the total outstanding balance of the note~~ and $3839,~~874~~623, ~~remained outstanding which is included in notes payable on the consolidated balance sheet~~respectively.

On ~~May~~December 220, ~~2016~~2017, the Company, ~~through~~entered ~~its~~into ~~wholly~~a ~~owned~~Securities ~~subsidiary,~~Purchase ~~ENG~~Agreement ~~entered~~(“SPA”) ~~into~~with a ~~revolving~~lender, ~~line~~providing for the purchase of ~~credit~~a (Convertible Redeemable Notes in the ~~“Line”) with~~aggregate ~~California~~principal ~~Bank~~amount of ~~Commerce~~$52,000 (“~~CBC~~Note”). The ~~terms~~Note ofwas ~~the~~funded on ~~Line~~December ~~allow~~22, ~~ENG~~2017, towith ~~borrow~~the ~~against~~Company ~~its~~receiving ~~accounts~~$47,500 ~~receivable and~~of ~~inventory~~net toproceeds ~~manage~~(net ~~its~~of ~~project~~OID ~~based~~and ~~working~~legal ~~capital requirements~~fees). The ~~$350,000~~Note ~~Line~~bear ~~has~~an ainterest rate ~~maturity date~~ of ~~May~~12% 5,and ~~2018~~are due and ~~borrowings~~ ~~under~~payable ~~the~~on ~~Line~~December ~~bear~~20, ~~interest~~2018. atThe ~~the~~Note ~~Wall~~may ~~Street~~be ~~Journal~~converted ~~Prime~~by ~~Rate~~the ~~plus~~lender ~~1.5%~~at ~~(currently~~any ~~5.0%).~~time ~~The~~into ~~Company~~shares ~~has~~of ~~provided~~Company’s acommon ~~guaranty~~stock ofat ~~the~~a ~~Line~~price equal to ~~CBC~~62.5% ~~The~~of ~~Line~~the ~~also~~lowest ~~contains~~closing ~~certain~~bid ~~representations,~~price ~~warranties,~~of ~~covenants~~the ~~and~~common ~~events~~stock offor ~~default,~~the 15 prior trading days including the ~~requirement~~day toupon ~~maintain~~which ~~specified~~a ~~financial~~notice ~~ratios.~~of ~~ENG~~conversion ~~currently~~is ~~meets~~received ~~all~~by ~~such~~the ~~ratios~~Company. ~~Breaches~~In ofconnection ~~any~~with the issuance of ~~these~~the ~~terms~~Note, ~~could~~the Company ~~limit~~recorded ~~ENG’s~~a ~~ability~~premium toof ~~borrow~~$31,200 ~~under~~as the ~~Line~~Note ~~and~~is ~~result~~considered instock ~~increases~~settled indebt ~~the~~under ~~interest~~ASC ~~rate~~480, ~~under~~which ~~the~~was ~~Line.~~fully accreted upon note inception. As of ~~September 30~~December 31, 2017 and March 31, ~~$250~~2018,~~000~~ ~~was~~the ~~drawn~~outstanding ~~under~~principal and interest on the ~~Line~~note were $52,173 and $53,733, respectively.

~~During~~On ~~the~~January ~~year ended December 31~~2, ~~2016~~2018, the Company ~~issued~~entered ~~four~~into ~~separate~~a ~~convertible~~Securities ~~notes~~Purchase ~~(the~~Agreement (“~~Notes~~SPA”) towith a ~~consultant~~lender, providing for the ~~three~~purchase of ~~the~~a ~~notes~~Secured ~~had~~Convertible Promissory Note in the aggregate principal amount of $2082,~~000~~500 ~~each~~(the ~~and~~“Note”). ~~the~~The ~~fourth~~Note was ~~had~~funded aon ~~principal~~January ~~amount~~3, of2018, with the Company receiving $2275,~~500,~~000 ~~for~~in annet ~~aggregate principal~~proceeds ~~amount~~(net of ~~$82,500~~OID). ~~with~~The ~~maturity~~Note ~~dates~~has ~~between~~a ~~April~~10% 27OID to offset transaction, ~~2017~~diligence and ~~August~~legal 27costs. The Note bears an interest rate of 10%, ~~2017~~which is payable in the Company’s common stock based on the conversion formula (as defined below), ~~pursuant~~and tothe amaturity ~~consulting~~date ~~agreement.~~is 12 months from the date on which the funds were received by the Company. The ~~Notes~~Note ~~bear~~may ~~interest~~be converted by the lender at 8%any ~~per~~time ~~annum~~into ~~and~~shares ~~are~~of ~~convertible~~Company’s common stock at a 37.5% discount to the lowest closing bid price infor the 15Company’s common stock during the 20 trading days ~~prior~~immediately preceding toa conversion date. In connection with the issuance of the ~~Notes~~Note, the Company recorded a ~~total~~ premium of $49,500 as the Note ~~notes~~is ~~are~~ considered stock settled debt under ASC 480, which was fully accreted asupon ofnote ~~December 31, 2016~~inception. ~~During the nine months ended September 30, 2017, $36,716 of the outstanding principal and interest on Notes were converted into 3,468,233 shares of common stock.~~ As of ~~September~~March 3031, ~~2017~~2018, the outstanding principal and interest ofon the ~~Notes~~note was $2084,~~834~~563.

InOn ~~December~~January ~~2015~~8, 2018, the Company ~~leased~~issued a ~~specialized~~Convertible ~~equipment~~Promissory ~~under leases~~Note ~~classified~~in asthe ~~capital~~aggregate ~~leases~~principal amount of $78,125 (the “Note”) to a lender. The ~~interest~~Note ~~rate~~was ~~related~~funded toon January 10, 2018, with the ~~lease~~Company ~~obligation~~receiving is$75,000 8of net proceeds (net of OID).1 The Note bears an interest rate of 12% and is ~~amortized~~due ~~over~~and 4payable ~~years~~on ~~with~~ January 8, 2019. The Note may be converted by the ~~maturity~~lender ~~date~~at any time into shares of ~~November~~the ~~30,~~Company’s ~~2019~~common stock (as determined in the Note) at a 37.5% Asdiscount to the lowest price of ~~September~~the ~~30,~~common ~~2017,~~stock for the ~~outstanding~~15 ~~principal~~prior ~~and~~trading ~~interest~~days onincluding the ~~lease~~day ~~obligation~~upon which a notice of conversion is received by the Company. In connection with ~~was~~the ~~approximately~~issuance ~~$23~~of the Note,~~000,~~ ofthe ~~which~~Company ~~approximately~~recorded a premium of $1346,~~000~~875 as the Note is ~~classified~~considered stock settled debt under ~~notes~~ASC ~~payable~~480, which ~~and~~was ~~approximately~~fully ~~$10~~accreted upon note inception. As of March 31,~~000~~ is2018, ~~classified under~~the ~~long-term~~outstanding ~~loan~~principal ~~payable~~and interest on the ~~consolidated~~note ~~balance~~was ~~sheet~~$80,469.

InOn ~~December~~January ~~2015~~10, ~~and August 2016~~2018, the Company ~~issued~~entered ~~two~~into ~~separate convertible~~a ~~notes~~Securities ~~(the~~Purchase Agreement (“~~Notes~~SPA”) inwith ~~relation~~a tolender, ~~the~~providing ~~acquisitions~~for the purchase of ~~Thermomedics~~a ~~and~~Convertible ~~ENG.~~Redeemable ~~These~~ Notes ~~were amended~~ in the ~~beginning~~aggregate principal amount of ~~2017~~$41,600 ~~and~~(“Note”). ~~pursuant~~The toNote was funded on January 11, 2018, with the ~~amended~~Company ~~terms~~receiving $38,000 ~~are~~in nonet ~~longer~~proceeds ~~convertible~~(net ~~notes~~of fee and OID). AsThe Note bear an interest rate of 12% ~~June~~and ~~30,~~are ~~2017~~due and payable on January 10, 2019. The Note may be converted by the ~~remaining~~lender at any time into shares of Company’s ~~outstanding~~common ~~principal~~stock ~~and~~at ~~interest~~a ~~balance~~price onequal ~~one~~to 62.5% of the ~~notes~~lowest ~~was~~closing ~~paid~~bid inprice ~~full,~~of ~~from~~the common stock for the ~~proceeds~~15 onprior ~~sale~~trading ofdays ~~non-controlling~~including ~~interest~~the ~~(see~~day ~~Note~~upon 3)which a notice of conversion is received by the Company. AsIn connection with the issuance of ~~September~~the 30Note, ~~2017~~the Company recorded a premium of $24,960 as the ~~total~~Note ~~outstanding~~is ~~principal~~considered ~~and~~stock ~~interest~~settled ondebt ~~the~~under ~~remaining~~ASC ~~note~~480, which was ~~$58,528~~fully accreted upon note inception. ~~which~~As isof ~~included~~March in31, ~~notes~~2018, ~~payable~~the outstanding principal and interest on the ~~consolidated~~note ~~balance~~was ~~sheet~~$42,640.

~~The~~On January 12, 2018, the Company ~~has~~issued ~~approximately~~a Convertible Promissory Note in the aggregate principal amount of $353,000 (the “Note”) to a lender.9 ~~million~~The Note was funded on January 16, 2018, with the Company receiving $50,000 in net proceeds (net of ~~debt~~fees). ~~which~~The ~~are~~Note bears ~~past~~an ~~maturity~~interest rate of 8% and ~~subject~~is due and payable on October 30, 2018. The Note may be converted by the lender at any time into shares of Company’s common stock (as determined in the Note) at a price equal to 65% of the average of the lowest five closing bid prices of the common stock for the 10 trading days ending on the latest complete trading day prior to the conversion date. In connection with the issuance of the Note, the Company recorded a premium of $28,538 as the Note is considered stock settled debt under ASC 480, which was fully accreted upon note inception. As of ~~September~~March 3031, ~~2017~~2018, the outstanding principal and interest on the note was $53,833.

~~Embedded~~On ~~Conversion~~January ~~Option~~26, ~~Derivatives~~2018, the Company entered into a Securities Purchase Agreement (“SPA”) with a lender, providing for the purchase of a Convertible Redeemable Notes in the aggregate principal amount of $36,400 (“Note”). The Note was funded on January 26, 2018, with the Company receiving $33,000 in net proceeds (net of fee and OID). The Note bear an interest rate of 12% and are due and payable on January 26, 2019. The Note may be converted by the lender at any time into shares of Company’s common stock at a price equal to 62.5% of the lowest closing bid price of the common stock for the 15 prior trading days including the day upon which a notice of conversion is received by the Company. In connection with the issuance of the Note, the Company recorded a premium of $21,840 as the Note is considered stock settled debt under ASC 480, which was fully accreted upon note inception. As of March 31, 2018, the outstanding principal and interest on the note was $37,128.

Due to the conversion terms of certain promissory notes, the embedded conversion options met the criteria to be bifurcated and presented as derivative liabilities. The Company calculated the estimated fair values of the liabilities for embedded conversion option derivative instruments using the Monte Carlo option pricing model using the share prices of the Company’s stock on the dates of valuation and using the following ranges for volatility, expected term and the risk-free interest rate at each respective valuation date, no dividend has been assumed for any of the periods:

Note Inception Date

September 30, 2017

December 31, 2016

Volatility

195 - 438 %

147 - 472 %

360

Expected Term

0.4 - 1.50 years

0.17 – 1.13 years

0.01 - 1.34 years

Risk Free Interest Rate

0.21 – 1.06 %

0.50 – 76.00 %

0.45

POSITIVEID CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements

~~September~~March 3031, ~~2017~~2018

(Unaudited)

~~The~~On ~~following~~February ~~reflects~~2, 2018, the ~~initial~~Company ~~fair~~issued ~~value~~a onConvertible Promissory Note in the ~~note~~aggregate ~~inception~~principal ~~dates~~amount of $100,000 (the “Note”) to a lender. The Note bears an interest rate of 12% and ~~changes~~is due and payable on February 2, 2019. The Note was funded on February 2, 2018, with the Company receiving $100,000 in ~~fair~~proceeds. ~~value~~The ~~through~~Note ~~September~~may 30be converted by the lender at any time into shares of the Company’s common stock (as determined in the Note) at a 37.5% discount to the lowest price of the common stock as reported for the 15 prior trading days including the day upon which a notice of conversion is received by the Company. The Note also contains a demand right whereby the Holder, ~~2017:~~beginning 90 days after issuance may demand payment, for 115% of outstanding principal. In connection with the issuance of the Note, the Company recorded a premium of $60,000 as the Note is considered stock settled debt under ASC 480, which was fully accreted upon note inception. As of March 31, 2018, the outstanding principal and interest on the note was $102,000.

Balance, December 31, 2016	$	4,284,264
Note inception date fair value allocated to debt discount		472,097
Note inception date fair value allocated to other expense		40,332
Reclassification of derivative liability to equity upon debt conversion		(2,245,109	)
Change in fair value		62,900
Embedded conversion option liability fair value at September 30, 2017	$	2,614,484

On February 5, 2018, the Company issued a Convertible Promissory Note in the aggregate principal amount of $52,000 (the “Note”) to a lender. The Note was funded on February 6, 2018, with the Company receiving $50,000 in net proceeds (net of 4% OID). The Note bears an interest rate of 12% and is due and payable on November 5, 2018. The Note may be converted by the lender at any time into shares of the Company’s common stock (as determined in the Note) at a 37.5% discount to the lowest price of the common stock as for the 15 prior trading days including the day upon which a notice of conversion is received by the Company. In connection with the issuance of the Note, the Company recorded a premium of $31,200 as the Note is considered stock settled debt under ASC 480, which was fully accreted upon note inception. As of March 31, 2018, the outstanding principal and interest on the note was $53,040.

~~Fair~~On ~~Value~~February ~~Measurements~~5, 2018, the Company issued a Convertible Promissory Note in the aggregate principal amount of $35,200 (the “Note”) to a lender. The Note was funded on February 5, 2018, with the Company receiving $32,000 in net proceeds (net of OID). The Note bears an interest rate of 10%, which is payable in the Company’s common stock based on the conversion formula (as defined below), and the maturity date is nine months from the date on which the funds were received by the Company. The Note may be converted by the lender at any time into shares of Company’s common stock at a 37.5% discount to the lowest closing bid price for the Company’s common stock during the 20 trading days immediately preceding a conversion date. In connection with the issuance of the Note, the Company recorded a premium of $21,120 as the Note is considered stock settled debt under ASC 480, which was fully accreted upon note inception. As of March 31, 2018, the outstanding principal and interest on the note was $35,787.

WeOn ~~currently~~February ~~measure~~12, ~~and~~2018, ~~report~~the atCompany ~~fair~~issued ~~value~~a Convertible Promissory Note in the ~~liability~~aggregate ~~for~~principal ~~embedded~~amount ~~conversion~~of ~~option~~$53,000 ~~derivatives~~(the “Note”) to a lender. The ~~fair~~Note ~~value~~was ~~liabilities for~~funded ~~price~~on ~~adjustable~~February ~~convertible~~14, ~~debt~~2018, ~~instruments~~with ~~have~~the ~~been~~Company ~~recorded~~receiving as$50,000 ~~determined~~in ~~utilizing~~net ~~the~~proceeds ~~Monte~~(net ~~Carlo~~of ~~option~~fee). ~~pricing~~The ~~model~~Note asbears ~~previously~~an ~~discussed~~interest rate of 8% and is due and payable on November 30, 2018. The ~~following~~Note ~~tables~~may ~~summarize~~be ~~our~~converted ~~financial~~by ~~assets~~the ~~and~~lender ~~liabilities~~at ~~measured~~any time into shares of Company’s common stock (as determined in the Note) at ~~fair~~a ~~value~~price equal to 65% of the average of the lowest five closing bid prices of the common stock for the 10 trading days ending on athe ~~recurring~~latest complete trading day prior to the conversion ~~basis~~date. In connection with the issuance of the Note, the Company recorded a premium of $28,538 as the Note is considered stock settled debt under ASC 480, which was fully accreted upon note inception. As of ~~December~~March 31, ~~2016~~2018, the outstanding principal and ~~September~~interest on ~~30,~~the ~~2017:~~note was $53,530.

			Quoted Prices in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs
			(Level 1)		(Level 2)		(Level 3)
Balance at December 31, 2016:
Liabilities:
Fair value of liability for embedded conversion option derivative instruments	$	4,284,264	$	-	$	-	$	4,284,264
Balance at September 30, 2017:
Liabilities:
Fair value of liability for embedded conversion option derivative instruments	$	2,614,484	$	-	$	-	$	2,614,484

On February 19, 2018, PositiveID Corporation (the “Company”) issued a Convertible Promissory Note in the aggregate principal amount of $75,000 (the “Note”) to a lender. The Note was funded on February 23, 2018, with the Company receiving $75,000 of proceeds. The Note bears an interest rate of 12% and is due and payable on February 19, 2019. The Note may be converted by the lender at any time into shares of the Company’s common stock (as determined in the Note) at a 37.5% discount to the lowest price of the common stock for the 15 prior trading days including the day upon which a notice of conversion is received by the Company. The Note also contains a demand right whereby the Holder, beginning 90 days after issuance may demand payment, for 105% of outstanding principal and interest. In connection with the issuance of the Note, the Company recorded a premium of $45,000 as the Note is considered stock settled debt under ASC 480, which was fully accreted upon note inception. As of March 31, 2018, the outstanding principal and interest on the note was $75,750.

5On March 2, 2018, the Company entered into a Securities Purchase Agreement (“SPA”) with a lender, providing for the purchase of a Convertible Redeemable Notes in the aggregate principal amount of $39,000 (“Note”). The Note was funded on March ~~Stockholder~~2, 2018, with the Company receiving $35,500 in net proceeds (net of fee and OID). The Note bear an interest rate of 12% and are due and payable on March 2, 2019. The Note may be converted by the lender at any time into shares of Company’s ~~Deficit~~common stock at a price equal to 62.5% of the lowest closing bid price of the common stock for the 15 prior trading days including the day upon which a notice of conversion is received by the Company. In connection with the issuance of the Note, the Company recorded a premium of $23,400 as the Note is considered stock settled debt under ASC 480, which was fully accreted upon note inception. As of March 31, 2018, the outstanding principal and interest on the note was $39,390.

Authorized Common Stock

On January 30, 2017, the Company filed the First Amendment to the Company’s Third Amended and Restated Certificate of Incorporation with the State of Delaware, to increase the Company’s authorized capital stock from 3.9 billion shares to 20 billion shares (19.995 billion common) and to change the par value of the Company’s Common Stock from $0.001 to $0.0001. On May 19, 2017, the Company filed the Second Amendment to the Third Amended and Restated Certificate of Incorporation, as amended, with the State of Delaware, to implement a 1-for-3,000 reverse stock split of the Company’s outstanding Common Stock, which became effective on May 23, 2017. The reverse stock split affected the outstanding Common Stock as well as all Common Stock underlying convertible notes, warrants, convertible preferred stock and stock options outstanding immediately prior to the reverse stock split. The number of authorized shares was not adjusted. All share and per share amounts in the accompanying historical consolidated financial statements have been adjusted retroactively to reflect the change in the par value of the Common Stock and the 1-for-3,000 reverse stock split.

Conversion of Convertible Notes

During the three and nine months ended September 30, 2017, approximately 72.7 million and 82.7 million shares were issued, respectively, in connection with conversion of approximately $0.6 million and $1.9 million of convertible promissory notes, respectively (see Note 4).

Sale of Non-Controlling Interest

During the quarter ended June 30, 2017, the Company issued 1,300,000 shares of the Company’s common stock as a fee in relation to the sale of a non- controlling interest (see Note 3) with grant date fair value of $78,000.

POSITIVEID CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements

~~September~~March 3031, ~~2017~~2018

(Unaudited)

~~Series~~On IMarch 2, 2018, the Company entered into a Securities Purchase Agreement (“SPA”) with a lender, providing for the purchase of a Secured Convertible Promissory Note in the aggregate principal amount of $55,000 (the “Note”). The Note was funded on March 2, 2018, with the Company receiving $50,000 in net proceeds (net of OID). The Note has a 10% OID to offset transaction, diligence and ~~Series~~legal IIcosts. ~~Preferred~~The ~~Stock~~Note bears an interest rate of 10%, which is payable in the Company’s common stock based on the conversion formula (as defined below), and the maturity date is 12 months from the date on which the funds were received by the Company. The Note may be converted by the lender at any time into shares of Company’s common stock at a 37.5% discount to the lowest closing bid price for the Company’s common stock during the 20 trading days immediately preceding a conversion date. In connection with the issuance of the Note, the Company recorded a premium of $33,000 as the Note is considered stock settled debt under ASC 480, which was fully accreted upon note inception. As of March 31, 2018, the outstanding principal and interest on the note was $55,458.

On ~~September~~March 3019, ~~2013~~2018, the ~~Board~~Company ofentered ~~Directors~~into ~~authorized~~a ~~and~~Securities inPurchase ~~November~~Agreement ~~2013,~~(“SPA”) ~~the~~with ~~Company~~a ~~filed~~lender, ~~with~~providing for the purchase ~~State~~ of ~~Delaware,~~ a ~~Certificate of~~Secured ~~Designations~~Convertible ofPromissory ~~Preferences,~~Note ~~Rights~~in ~~and~~the ~~Limitations~~aggregate ofprincipal ~~Series~~amount Iof ~~Preferred~~$41,250 ~~Stock~~(the “Note”). The ~~Series~~Note was Ifunded ~~Preferred~~on ~~Stock~~March ~~ranks~~19, ~~junior to~~2018, with the Company’s ~~Series~~receiving F$37,500 ~~Preferred~~in ~~Stock~~net ~~and~~proceeds to(net ~~all~~of ~~liabilities~~OID). ofThe ~~the~~Note ~~Company~~has ~~and~~a is10% ~~senior~~OID to ~~the~~offset transaction, ~~Common~~diligence ~~Stock~~ and ~~any other~~legal ~~preferred stock~~costs. The ~~Series~~Note Ibears ~~Preferred~~an ~~Stock~~interest ~~has a stated value per share of $1,000, a dividend~~ rate of 610% ~~per annum~~, ~~voting rights~~which onis anpayable ~~as-converted~~in ~~basis and a conversion price equal to~~ the ~~closing bid price of the~~ Company’s ~~Common~~common stock ~~Stock~~based on the ~~date~~ ofconversion ~~issuance.~~formula ~~The Series I Preferred Stock is required to be redeemed~~ (atas ~~stated~~defined ~~value~~below), ~~plus~~and ~~any accrued dividends) by~~ the ~~Company~~ ~~after~~maturity ~~three~~date ~~years~~is or9 ~~any~~months ~~time~~from ~~after one year,~~ the ~~Company~~date ~~may~~on atwhich ~~its option, redeem~~ the ~~shares~~funds ~~subject~~were received toby athe ~~ten-day~~Company. ~~notice (to~~The ~~allow~~Note ~~holder~~may ~~conversion).~~be ~~The~~converted ~~Series~~by Ithe ~~Preferred~~lender ~~Stock~~at isany ~~convertible~~time into ~~the~~shares of Company’s ~~Common~~common ~~Stock,~~stock at ~~stated value~~a ~~plus~~37.5% ~~accrued~~discount ~~dividends,~~to at the lowest closing bid price onfor ~~September 30, 2013, any time at~~ the ~~option of the holder and by the~~ Company ~~in the event that the Company~~’s ~~closing~~common stock ~~price~~during ~~exceeds 400% of~~ the ~~conversion~~20 ~~price~~trading ~~for~~days ~~twenty~~immediately ~~consecutive trading~~preceding ~~days.~~a ~~The~~conversion ~~Company~~date. ~~has~~In ~~classified~~connection with the ~~Series~~issuance Iof ~~Preferred Stock as a liability in~~ the ~~consolidated~~Note, ~~balance sheet due to~~ the ~~mandatory redemption~~Company ~~feature.~~recorded ~~The~~a ~~Series~~premium Iof ~~Preferred~~$24,750 ~~Stock~~as ~~has voting rights equal to~~ the ~~number~~Note ofis ~~shares~~considered stock ofsettled ~~Common~~debt ~~Stock~~under ~~that~~ASC ~~Series~~480, ~~I Preferred~~which ~~Stock~~was isfully ~~convertible~~accreted ~~into,~~upon ~~times~~note ~~twenty-five~~inception. ~~This~~As ~~provision gave the holders~~ of ~~Series~~March I31, ~~Preferred~~2018, ~~Stock~~the ~~voting~~outstanding ~~control~~principal inand ~~situations~~interest ~~requiring~~on ~~shareholder~~the ~~vote~~note was $41,442.

On ~~November~~March 519, ~~2013~~2018, the Company ~~filed~~entered aninto ~~Amended~~a ~~and~~Securities ~~Restated~~Purchase ~~Certificate~~Agreement of(“SPA”) ~~Designation~~with a lender, providing for the purchase of ~~Series~~a IConvertible ~~Preferred~~Redeemable ~~Stock~~Notes (in the ~~“Amended Certificate~~aggregate principal amount of ~~Designation~~$39,000 (“Note”). The ~~Amended~~Note ~~Certificate~~was offunded on ~~Designation~~March ~~was~~19, ~~filed~~2018, towith ~~clarify~~the ~~and~~Company ~~revise~~receiving ~~the~~$35,500 ~~mechanics~~in net proceeds (net of ~~conversion~~ fee and ~~certain~~OID). ~~conversion~~The ~~rights~~Note ofbear ~~the~~an ~~holders~~interest rate of 12% ~~Series~~and Iare ~~Preferred~~due ~~Stock.~~and Nopayable ~~other~~on ~~rights~~March ~~were~~19, ~~modified~~2019. orThe ~~amended~~Note inmay be converted by the ~~Amended Certificate~~lender at any time into shares of ~~Designation~~Company’s common stock at a price equal to 62.5% Onof ~~January~~the 8,lowest ~~2015,~~closing bid price of the ~~Company~~common ~~filed~~stock anfor ~~amendment~~the to15 prior trading days including the ~~Amended~~day ~~Certificate~~upon which a notice of ~~Designation~~conversion tois ~~increase~~ received by the ~~authorized~~Company. ~~shares~~In connection with the issuance of ~~Series~~the INote, ~~Convertible~~the ~~Preferred~~Company recorded ~~Stock~~a ~~from~~premium 1of $23,~~000~~400 ~~shares~~as tothe 2Note is considered stock settled debt under ASC 480,~~500~~ ~~shares.~~which Nowas ~~other~~fully ~~terms~~accreted ~~were~~upon ~~modified~~note inception. orAs ~~amended~~of inMarch 31, 2018, the ~~Amended~~outstanding ~~Certificate~~principal ofand ~~Designation~~interest on the note was $39,195.

On ~~July~~March 2528, ~~2016~~2018, the ~~Board~~Company ~~authorized~~entered into a ~~Certificate~~Securities ofPurchase ~~Designations~~Agreement of(“SPA”) ~~Preferences~~with a lender, ~~Rights~~providing ~~and~~for ~~Limitations~~the purchase of ~~Series~~a IISecured Convertible ~~Preferred~~ ~~Stock.~~Promissory ~~The~~Note ~~Certificate~~in ~~was filed with~~ the ~~State~~aggregate ofprincipal ~~Delaware~~amount ~~Secretary~~ of ~~State on July 25~~$38,500 ~~2016~~(the “Note”). The ~~Series II Preferred~~Note ~~ranks:~~was ~~(a)~~funded ~~senior~~on ~~with~~March ~~respect~~19, to2018, ~~dividends and right of liquidation~~ with the ~~common~~Company ~~stock;~~receiving ~~(b)~~$35,000 ~~pari~~in ~~passu~~net ~~with~~proceeds ~~respect~~(net ~~to dividends and right~~ of ~~liquidation~~OID). ~~with~~The ~~the~~Note ~~Company’s~~has ~~Series~~a I10% ~~Preferred~~OID ~~and~~to ~~Series J Convertible Preferred Stock; and (c) junior~~offset totransaction, ~~all~~diligence ~~existing~~ and ~~future~~legal ~~indebtedness of the Company~~costs. The ~~Series~~Note IIbears ~~Preferred~~an ~~has~~interest arate ~~stated~~of ~~value~~10%, ~~per~~which ~~share~~is ofpayable ~~$1,000,~~in ~~subject to~~the ~~adjustment~~Company’s ascommon stock ~~provided~~based inon the ~~Certificate~~conversion formula (~~the~~as ~~“Stated~~defined ~~Value”~~below), and athe ~~dividend~~maturity ~~rate~~date ofis 6%9 ~~per~~months ~~annum~~from of the ~~Stated Value.~~date Ason ~~with~~which the ~~Series~~funds Iwere received ~~Preferred,~~by the ~~Series II Preferred has 25 votes per common share equivalent~~Company. The ~~Series~~Note IImay ~~Preferred is~~be ~~subject~~converted toby ~~redemption~~the (lender at ~~Stated Value, plus~~ any ~~accrued,~~time ~~but~~into ~~unpaid~~shares ~~dividends~~of ~~(the~~Company’s ~~“Liquidation~~common ~~Value”))~~stock byat ~~the~~a ~~Company~~37.5% nodiscount ~~later~~to ~~than~~the ~~three~~lowest ~~years~~closing ~~after~~bid aprice ~~Deemed~~for ~~Liquidation Event and at~~ the Company’s ~~option~~common ~~after~~stock ~~one~~during ~~year from~~ the ~~issuance date~~20 oftrading ~~the~~days ~~Series~~immediately ~~II Preferred, subject to~~ preceding a ~~ten-day notice (to allow holder~~ conversion) date. ~~The~~In ~~Series~~connection IIwith ~~Preferred is convertible at~~ the ~~option~~issuance of ~~a holder or if~~ the ~~closing~~Note, ~~price of~~ the ~~common~~Company ~~stock~~recorded ~~exceeds 400% of the Conversion Price for~~ a ~~period~~premium of ~~twenty consecutive trading days~~$23,100 atas the ~~option~~Note ofis ~~the~~considered stock ~~Company.~~settled ~~Conversion~~debt ~~Price~~under ~~means~~ASC a480, ~~price~~which ~~per~~was ~~share~~fully ofaccreted ~~the~~upon ~~common~~note ~~stock~~inception. ~~equal~~As ~~to 100%~~ of ~~the~~March ~~lowest~~31, ~~daily~~2018, ~~volume weighted average price of~~ the ~~common~~outstanding ~~stock~~principal and ~~during~~interest ~~the~~on ~~subsequent 12 months following~~ the ~~date the~~note ~~Series II Preferred~~ was ~~issued~~$38,500.

~~From~~On ~~September~~March 30, ~~2013~~2018, ~~through~~the ~~April~~Company 6,entered ~~2016,~~into ~~the~~a ~~Company~~Securities ~~issued~~Purchase 2Agreement (“SPA”) with a lender,~~025~~ ~~shares~~providing for the purchase of ~~Series~~a IConvertible ~~Preferred~~Redeemable ~~Stock~~Notes toin ~~its~~the ~~officers~~aggregate principal amount of $36,400 ~~directors~~(“Note”). The Note was funded on March 30, 2018, with the Company receiving $33,000 in net proceeds (net of fee and ~~management~~OID). ~~for~~The ~~management~~Note bear an interest rate of 12% and ~~director~~are ~~compensation~~due and ~~payment~~payable ofon ~~deferred~~March ~~obligations~~30, 2019. ~~Each~~The ofNote may be converted by the ~~Series~~lender Iat ~~preferred~~any ~~is convertible~~time into ~~the~~shares of Company’s common ~~Common~~stock ~~Stock,~~ at ~~stated~~a ~~value~~price ~~plus~~equal ~~accrued~~to ~~dividends,~~62.5% atof the lowest closing bid price onof the ~~issuance date,~~common ~~any~~stock ~~time~~for atthe 15 prior trading days including the ~~option~~day upon which a notice of ~~the~~conversion ~~holder~~is ~~and~~received by the Company. inIn connection with the ~~event~~issuance ~~that~~of the ~~Company’s~~Note, ~~closing~~the ~~stock~~Company recorded ~~price~~a ~~exceeds 400%~~premium of ~~the~~$21,840 ~~conversion~~as ~~price~~the ~~for~~Note ~~twenty~~is ~~consecutive~~considered ~~trading~~stock ~~days.~~settled ~~The~~debt ~~Series~~under IASC ~~Preferred~~480, ~~Stock~~which ~~has~~was ~~voting~~fully ~~rights~~accreted ~~equivalent~~upon tonote inception. ~~twenty-five~~As ~~votes~~of ~~per~~March ~~common~~31, ~~share~~2018, ~~equivalent~~the outstanding principal and interest on the note was $36,400.

OnOther August 11, 2016, the Board of PositiveID agreed to exchange 2,025 shares of its Series I Preferred, which have a stated value of $2,025,000 and redemption value of $2,261,800, for 2,262 shares of Series II Preferred, which have a stated value of $2,262,000. Pursuant to the Exchange each existing holder of Series I Preferred exchanged their Series I Preferred shares for Series II Preferred shares having equivalent per share stated value, maintaining the same voting rights as they had as holders of the Series I Preferred. The Series II have an aggregate stated value equivalent to the redemption value of the Series I at the exchange date. Both the Series I Preferred and the Series II Preferred have a stated value per share of $1,000, and a dividend rate of 6% per annum. All shares of Series I Preferred previously issued have become null and void and any and all rights arising thereunder have been extinguished. The Series II Preferred is only forfeitable after the exchange date up to January 1, 2019 upon termination for cause and is subject to acceleration in the event of conversion, redemption and certain events.Financings

~~Accounting~~On ~~guidance~~July ~~under~~9, ~~ASC~~2012, ~~718~~the ~~dictates~~Company ~~that~~issued a Secured Promissory Note (the ~~incremental~~“H&K ~~difference~~Note”) in ~~fair~~the ~~value~~principal amount of ~~Series~~$849,510 to IIHolland ~~and~~& ~~Series~~Knight ILLP ~~should~~(“Holland be& ~~recorded~~Knight”), asits external legal counsel, in support of amounts due and owing ~~stock~~to Holland & Knight as of June 30, 2012. The H&K Note is non-~~based~~interest ~~compensation~~bearing, ~~expense~~and principal on the H&K Note is due and payable as soon as practicably possible by the Company. AsThe aCompany ~~result~~has agreed to remit payment against the H&K Note immediately upon each occurrence of any of the ~~independent~~following ~~valuation~~events: ~~performed,~~(a) wecompletion ~~have~~of ~~recorded~~an acquisition or disposition of any of the ~~Series~~Company’s assets IIor atstock or any of the ~~fair~~Company’s subsidiaries’ assets or stock with gross proceeds in excess of $750,000, (b) ~~value~~completion of any financing with gross proceeds in excess of $21,~~306~~500,~~345~~000, at(c) receipt of any revenue in excess of $750,000 from the ~~date~~licensing or development of ~~issuance~~any of the Company’s or the Company’s subsidiaries’ products, or (d) any liquidation or reorganization of the Company’s assets or liabilities. The ~~Series~~amount Iof ~~had~~payment ato ~~fair~~be ~~value~~remitted by the Company shall equal one-third of ~~$281~~the gross proceeds received by the Company upon each occurrence of any of the above events,~~345,~~ ~~resulting~~until the principal is repaid in afull. ~~charge~~If ofthe Company receives $23,~~025~~000,000 ~~recorded~~in gross proceeds in any one financing or licensing arrangement, the entire asprincipal ~~stock~~balance ~~based~~shall ~~compensation~~be paid in ~~2016~~full. ~~Additionally~~The H&K Note was secured by substantially all of the Company’s assets pursuant to a security agreement between the Company and Holland & Knight dated July 9, 2012. In conjunction with the ~~Series~~TCA IPurchase Agreement ~~liability~~and ~~was~~the ~~reclassified~~Boeing License Agreement, Holland & Knight agreed to ~~additional~~terminate ~~paid-in-capital~~its security interest. As of December 31, 2017 and March 31, 2018, the Company had repaid $598,301 of the H&K Note and the outstanding balance was $252,209 which is included in notes payable on the consolidated balance sheet.

POSITIVEID CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements

~~September~~March 3031, ~~2017~~2018

(Unaudited)

During 2016, the Company issued four separate convertible notes (the “Notes”) to a consultant, three of the notes had the principal amount of $20,000 each and the fourth had a principal amount of $22,500, for an aggregate principal amount of $82,500 with maturity dates between April 27, 2017 and August 27, 2017, pursuant to a consulting agreement. The Notes bear interest at 8% per annum and are convertible at a 37.5% discount to lowest closing bid price in the 15 trading days prior to conversion. In connection with the issuance of the Notes, the Company recorded a total premium of $49,500 as the notes are considered stock settled debt under ASC 480, which was fully accreted as of in 2016. During 2016 and 2017, $30,000 and $43,716 of the outstanding principal and interest on Notes, respectively were converted into 23 and 5,002 shares of common stock, respectively. As of December 31, 2017 and March 31, 2018, the outstanding principal and interest of the Notes was $14,634.

On December 2015, the Company leased a specialized equipment under leases classified as capital leases. The interest rate related to the lease obligation is 8.1% and is amortized over 4 years with the maturity date of November 30, 2019. As of December 31, 2017, the outstanding principal and interest on the lease obligation was approximately $21,000, of which approximately $13,000 is classified under notes payable and approximately $8,000 is classified under long-term loan payable on the consolidated balance sheet. As March 31, 2018, the outstanding principal and interest on the lease obligation was approximately $18,000, of which approximately $18,000 is classified under notes payable on the consolidated balance sheet.

On December 2015, the Company issued a convertible note (the “Note”) in relation to the acquisitions of Thermomedics. The Note was amended in the beginning of 2017 and pursuant to the amended terms, is no longer a convertible note. As of December 31, 2017 and March 31, 2018, the total outstanding principal and interest on the Note was $44,168 and $34,639, respectively, which is included in notes payable on the consolidated balance sheet.

On January 30, 2018, in connection with the deconsolidation of ENG and to settle certain amounts due to ENG by PositiveID Corporation, the Company issued a non-convertible note (the “Note”) payable to ENG for $54,000 (see note 3). As of March 31, 2018, the total outstanding principal on the Note was $54,000 which is included in notes payable on the consolidated balance sheet.

Embedded Conversion Option Derivatives

	Note Inception Date			March 31, 2018			December 31, 2017
Volatility		195 - 383	%		562	%		231 – 383	%
Expected Term		0.4 - 1.50 years			0.10 – 1.42 years			0.17 – 1.41 years
Risk Free Interest Rate		0.21 - 2.1	%		2.08	%		1.39 – 1.76	%

The following reflects the initial fair value on the note inception dates and changes in fair value through March 31, 2018:

Balance, January 1, 2018	$	2,650,111
Note inception date fair value allocated to debt discount		26,307
Note inception date fair value allocated to other expense		216
Reclassification of derivative liability to equity upon debt conversion		(525,328	)
Change in fair value		1,440,422
Embedded conversion option liability fair value as of March 31, 2018	$	3,591,728

Fair Value Measurements

We currently measure and report at fair value the liability for embedded conversion option derivatives. The fair value liabilities for price adjustable convertible debt instruments have been recorded as determined utilizing the Monte Carlo option pricing model as previously discussed. The following tables summarize our financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2017 and March 31, 2018:

POSITIVEID CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements

March 31, 2018

(Unaudited)

			Quoted Prices in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs
			(Level 1)		(Level 2)		(Level 3)
Balance at December 31, 2017:
Liabilities:
Fair value of liability for embedded conversion option derivative instruments	$	2,650,111	$	-	$	-	$	2,650,111

Balance at March 31, 2018:
Liabilities:
Fair value of liability for embedded conversion option derivative instruments	$	3,591,728	$	-	$	-	$	3,591,728

7. Stockholder’s Deficit

Authorized Common Stock

On April 13, 2018, the Company filed an amendment to its Third Amended and Restated Certificate of Incorporation, as amended, with the State of Delaware, to implement a 1-for-1,000 reverse stock split of the Company’s outstanding common stock, which became effective on April 18, 2018.

The reverse stock split affected the outstanding common stock as well as all Common Stock underlying convertible notes, warrants, convertible preferred stock and stock options outstanding immediately prior to the reverse stock splits. The number of authorized shares was not adjusted. All share and per share amounts in the accompanying historical consolidated financial statements have been retroactively adjusted to reflect the April 18, 2018 reverse stock split.

Conversion of Convertible Notes

During the three months ended March 31, 2018, approximately 5.0 million shares were issued in connection with conversion of approximately $1.0 million of convertible promissory notes (see Note 6).

Series II Preferred Stock

On July 25, 2016, the Board authorized a Certificate of Designations of Preferences, Rights and Limitations of Series II Convertible Preferred Stock. The Certificate was filed with the State of Delaware Secretary of State on July 25, 2016. The Series II Preferred ranks: (a) senior with respect to dividends and right of liquidation with the common stock; (b) pari passu with respect to dividends and right of liquidation with the Company’s Series I Preferred and Series J Convertible Preferred Stock; and (c) junior to all existing and future indebtedness of the Company. The Series II Preferred has a stated value per share of $1,000, subject to adjustment as provided in the Certificate (the “Stated Value”), and a dividend rate of 6% per annum of the Stated Value. As with the Series I Preferred, the Series II Preferred has 25 votes per common share equivalent. The Series II Preferred is subject to redemption (at Stated Value, plus any accrued, but unpaid dividends (the “Liquidation Value”)) by the Company no later than three years after a Deemed Liquidation Event and at the Company’s option after one year from the issuance date of the Series II Preferred, subject to a ten-day notice (to allow holder conversion). The Series II Preferred is convertible at the option of a holder or if the closing price of the common stock exceeds 400% of the Conversion Price for a period of twenty consecutive trading days, at the option of the Company. Conversion Price means a price per share of the common stock equal to 100% of the lowest daily volume weighted average price of the common stock during the subsequent 12 months following the date the Series II Preferred was issued.

On August 11, 2016, the Board of PositiveID agreed to exchange 2,025 shares of its Series I Preferred, which have a stated value of $2,025,000 and redemption value of $2,261,800 for 2,262 shares of Series II Preferred, which have a stated value of $2,262,000. Pursuant to the Exchange each existing holder of Series I Preferred exchanged their Series I Preferred shares for Series II Preferred shares having equivalent per share stated value, maintaining the same voting rights as they had as holders of the Series I Preferred. The Series II have an aggregate stated value equivalent to the redemption value of the Series I at the exchange date. Both the Series I Preferred and the Series II Preferred have a stated value per share of $1,000, and a dividend rate of 6% per annum. All shares of Series I Preferred previously issued have become null and void and any and all rights arising thereunder have been extinguished. The Series II Preferred is only forfeitable after the exchange date up to January 1, 2019 upon termination for cause and is, subject to acceleration in the event of conversion, redemption and certain events.

POSITIVEID CORPORATION AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements

March 31, 2018

(Unaudited)

Accounting guidance under ASC 718 dictates that the incremental difference in fair value of Series II and Series I should be recorded as stock-based compensation expense. As a result of the independent valuation performed, we have recorded the Series II at the fair value of $2,306,345 at the date of issuance. The Series I had a fair value of $281,345, resulting in a charge of $2,025,000 recorded as stock-based compensation in 2016. Additionally, the Series I liability was reclassified to additional paid-in-capital.

On March 29, 2017, the Company, filed a Certificate of Elimination (the “Certificate of Elimination”) for its Series I Convertible Preferred Stock (“Series I”) with the Delaware Secretary of State to eliminate from its Third Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”), all references to the Company’s Series I. No shares of the Series I were issued or outstanding upon filing of the Certificate of Elimination.

On March 29, 2017, the Company filed an Amended Restated Certificate of Designations of Preferences, Rights and Limitations of Series II Convertible Preferred Stock (the “Amended Certificate of Designation”). The Amended Certificate of Designation was filed to increase the authorized shares of Series II Convertible Preferred Stock from 3,000 shares to 4,000 shares. No other terms were modified or amended in the Amended Certificate of Designation.

On March 29, 2017, the Company issued shares of Series II Convertible Preferred shares (“Series II”) as follows: (i) 50 shares of Series II ~~Preferred~~ were issued to each of three independent board members as a component of their 2017 compensation (150 shares total); and (ii) 685 shares of Series II ~~Preferred~~ were issued to the Company’s management as a component of their 2016 incentive compensation at a stated value of $1,000 per share. These Series II ~~Preferred~~is ~~shares are~~ only forfeitable after the exchange date up to January 1, 2019 upon termination for cause and is, subject to acceleration in the event of conversion, redemption and certain events. In connection with the issuance of the 835 Series II ~~Preferred~~ shares, the Company charged $841,594 to stock -based ~~compensation~~ compensation expense in 2017 (which is $10,000 less than ~~the~~ total cost as $10,000 was accrued in fiscal 2016) to reflect the Series II ~~Preferred~~ fair value of $1,020 per share. As of ~~September~~December 3031, 2017 and March 31, 2018, 3,097 shares of Series II were issued and outstanding.

Series J Preferred Stock

On December 4, 2015, the Board of Directors authorized and on December 7, 2015, the Company filed with the State of Delaware, a Certificate of Designations of Preferences, Rights and Limitations of Series J Preferred Stock where 1,700 ~~shares~~ of Series J Preferred Stock ~~were~~ was authorized. The Series J Preferred Stock ranks; (a) senior with respect to dividends and right of liquidation with the Company’s common stock (b) pari passu with respect to dividends and right of liquidation with the Company’s Series I Convertible Preferred Stock; and (c) junior with respect to dividends and right of liquidation to all existing and future indebtedness of the Company. Without the prior written consent of Holders holding a majority of the outstanding shares of Series J Preferred Stock, the Company may not issue any Preferred Stock that is senior to the Series J Preferred Stock in right of dividends and liquidation. At any time after the date of the issuance of shares of Series J Preferred Stock, the Corporation will have the right, at the Corporation’s option, to redeem all or any portion of the shares of Series J Preferred Stock at a price per share equal to 100% of the $1,000 per share stated value of the shares being redeemed. Series J Preferred Stock is not entitled to dividends, interest and voting rights. The Series J Preferred Stock is convertible into the Company’s common stock, at stated value, at a conversion price equal to 100% of the arithmetic average of the VWAP of the common stock for the fifteen trading days prior to the six-month anniversary of the Issuance Date.

On August 25, 2016, PositiveID completed the acquisition and entered into an agreement with Sanomedics and Thermomedics (the “August Agreement”), which amends certain terms of the Purchase Agreement and terminates the Control Agreement. As a result, the 125 shares of Preferred Series J stock originally issued shall be released from escrow as follows: 71 shares to Sanomedics and 54 shares returned to the Company’s treasury. As of ~~September~~December 3031, 2017 and March 31, 2018, the 71 shares of Series J ~~were~~preferred stock ~~issued~~is ~~and~~convertible ~~outstanding~~into 55 of the Company’s common shares at fixed conversion price of $1,280 (based on the stated value of $1,000 per share) as determined by the agreement (see Note 2).

Warrants

From time to time the Company issues warrants both for compensatory purposes to consultants and advisors, and to financial institutions in conjunction with financing activities. No warrants were issued during the ~~nine~~three months ended ~~September~~March 3031, ~~2017~~2018. Due to the April 2018 reverse stock split, there were in substance no warrants issued or outstanding as of March 31, 2018.

As of September 30, 2017, 890 warrants to purchase the Company’s common stock have been granted outside of the Company’s plans and remain outstanding as of September 30, 2017. These warrants were granted at exercise prices in excess of $9.00 per share, are fully vested and are exercisable for a period of five years from the date of grant.31

~~Stock~~POSITIVEID ~~Option~~CORPORATION ~~Plans~~AND SUBSIDIARIES

On August 26, 2011, the Company’s stockholders approved and adopted the PositiveID Corporation 2011 Stock Incentive Plan (the “2011 Plan”). The 2011 Plan provides for awards of incentive stock options, nonqualified stock options, restricted stock awards, performance units, performance shares, SARs and other stock-based awards to employees and consultants. Under the 2011 Plan, up to 1 million shares of common stock may be granted pursuant to awards. Approximately 1.0 million remaining shares may be granted under the 2011 Plan. Awards to employees under the Company’s stock option plans generally vest over a two-year period, with pro-rata vesting upon the anniversary of the grant. Awards of options have a maximum term of ten years and the Company generally issues new shares upon exercise. As of September 30, 2017, the Company had 1,207 stock options in total, under the 2011 plan and outside the plan, issued and outstanding.

POSITIVEID CORPORATION

Notes to the Condensed Consolidated Financial Statements

~~September~~March 3031, ~~2017~~2018

(Unaudited)

~~On December 4, 2015, the Company’s Board of Directors approved and adopted the Thermomedics, Inc. 2015 Flexible~~ Stock ~~Plan~~ ~~(“Thermomedics~~Option 2015 Plan”). The Thermomedics 2015 Plan provides for awards of incentive stock options, nonqualified stock options, restricted stock awards, performance units, performance shares, SARs and other stock-based awards to employees and consultants. Under the Thermomedics 2015 Plan, up to 5 million shares of common stock may be granted pursuant to awards. As of June 30, 2017, 342,500 options were previously issued under the Thermomedics 2015 plan to employees and consultant. These options have vested and were fully expensed as of the nine months ended September 30, 2017.Plans

On August 26, 2011, the Company’s stockholders approved and adopted the PositiveID Corporation 2011 Stock Incentive Plan (the “2011 Plan”). The 2011 Plan provides for awards of incentive stock options, nonqualified stock options, restricted stock awards, performance units, performance shares, SARs and other stock-based awards to employees and consultants. Under the 2011 Plan, up to 1 million shares of common stock may be granted pursuant to awards. Approximately 1.0 million remaining shares may be granted under the 2011 Plan. Awards to employees under the Company’s stock option plans generally vest over a two-year period, with pro-rata vesting upon the anniversary of the grant. Awards of options have a maximum term of ten years and the Company generally issues new shares upon exercise. As of March 31, 2018, due to the April 2018 reverse stock split, there were in substance no options issued or outstanding to employees and consultant under the 2011 Plan or outside the plan.

On December 4, 2015, the Company’s Board of Directors approved and adopted the Thermomedics, Inc. 2015 Flexible Stock Plan (“Thermomedics 2015 Plan”). The Thermomedics 2015 Plan provides for awards of incentive stock options, nonqualified stock options, restricted stock awards, performance units, performance shares, SARs and other stock-based awards to employees and consultants. Under the Thermomedics 2015 Plan, up to 5 million shares of common stock may be granted pursuant to awards. As of March 31, 2018, 342,500 options were previously issued under the Thermomedics 2015 plan to employees and consultant. These options have vested and were fully expensed as of the three months ended March 31, 2017.

There are inherent uncertainties in making estimates about forecasts of future operating results and identifying comparable companies and transactions that may be indicative of the fair value of the Company’s securities. The Company believes that the estimates of the fair value of its common stock options at each option grant date were reasonable under the circumstances.

The Black-Scholes model, which the Company uses to determine compensation expense, requires the Company to make several key judgments including:

●	the value of the Company’s common stock;
●	the expected life of issued stock options;
●	the expected volatility of the Company’s stock price;
●	the expected dividend yield to be realized over the life of the stock option; and
●	the risk-free interest rate over the expected life of the stock options.

The Company’s computation of the expected life of issued stock options was determined based on historical experience of similar awards giving consideration to the contractual terms of the stock-based awards, vesting schedules and expectations about employees’ future length of service. The interest rate was based on the U.S. Treasury yield curve in effect at the time of grant. The computation of volatility was based on the historical volatility of the Company’s common stock.

Stock-Based Compensation Expense

Stock-based compensation expense for awards granted to employees is recognized on a straight-line basis over the requisite service period based on the grant-date fair value. Forfeitures are estimated at the time of grant and require the estimates to be revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company recorded compensation expense related to stock options, restricted stock and preferred shares of approximately $6022,000 and $~~200~~922,000 for the three months ~~ended~~ ~~September~~ended ~~30,~~March ~~2017 and 2016~~31, ~~respectively~~2018 and ~~approximately $1.0 million and $0.8 million for the nine months ended September 30,~~ 2017 ~~and 2016~~, respectively.

68. Taxes

In July 2008, the Company completed the sale of all of the outstanding capital stock of Xmark to Stanley. In January 2010, Stanley received a notice from the Canadian Revenue Agency (“CRA”) that the CRA would be performing a review of Xmark’s Canadian tax returns for the periods 2005 through 2008. This review covers all periods that the Company owned Xmark. The review performed by CRA resulted in an assessment of approximately $1.4 million, in 2011.

During 2012, the Company received an indemnification claim notice from Stanley related to the matter. The Company did not agree with the position taken by the CRA, and filed a formal appeal related to the matter. In addition, Stanley received assessments for withholding taxes on deemed dividend payments in respect of the disallowed management fee totaling approximately $0.2 million, for which we filed a formal appeal. In connection with the filing of the appeals, Stanley was required to remit an upfront payment of a portion of the tax reassessment totaling approximately $950,000. The Company has also filed a formal appeal related to the withholding tax assessments, pursuant to which Stanley was required to remit an additional upfront payment of approximately $220,000. The Company has agreed to repay Stanley for the upfront payments, plus interest and the upfront payments made by Stanley is reflected as a liability on the accompanying consolidated balance sheet as “Tax Liability”.

As of ~~September~~March 3031, ~~2017~~2018, the Company had paid a total amount of $~~694~~704,~~360~~061 of the liability. In addition, Stanley had received a total refund of $148,325 from the CRA which was deducted from the recorded liability. Based on management’s estimate, including reconciling to Stanley’s accounts, the Company has a recorded tax liability of approximately $~~110~~100,000, and $98,963 as of December 31, 2017 and March 31, 2018, respectively, reflected as a liability on the accompanying consolidated balance sheet ~~as of September 30, 2017~~.

~~7. Commitments and Contingencies~~32

~~Lease~~POSITIVEID ~~Commitments~~CORPORATION AND SUBSIDIARIES

The Company leases certain office space under non-cancelable operating leases, including the Company’s corporate offices in Delray Beach, Florida under a lease scheduled to expire in October 18, 2018, laboratory and office space in Pleasanton, California a lease scheduled to expire in September 30, 2018 and office and manufacturing space in Concord, California which is currently on a month-to-month commitment for approximately $7,600 per month. Rent expense under operating leases totaled approximately $183,000 and $184,000 for the nine months ended September 30, 2017 and 2016, respectively.

LG Capital Funding Litigation

POSITIVEID CORPORATION

Notes to the Condensed Consolidated Financial Statements

~~September~~March 3031, ~~2017~~2018

(Unaudited)

9. Commitments and Contingencies

Lease Commitments

The Company leases certain office space under non-cancelable operating leases, including the Company’s corporate offices in Delray Beach, Florida under a lease scheduled to expire in October 18, 2018, laboratory and office space in Pleasanton, California a lease scheduled to expire in September 30, 2018. Rent expense under operating leases totaled approximately $46,000 and $54,000 for the three months ended March 31, 2018 and 2017, respectively.

LG Capital Funding Litigation

On March 7, 2017, LG Capital Funding, LLC (“LG”), filed a complaint in the U.S. District Court of the Eastern District of New York (the “Court”), related to a 10% Convertible Redeemable Note issued by us to LG on July 7, 2016 in the amount of $66,150 (the “LG Note”). The LG Note provides that LG is entitled to convert all or any amount of the outstanding balance and accrued interest of the LG Note into shares of our Common Stock. The complaint alleges breach of contract and anticipatory breach of contract, asserting among other things, that we failed to deliver shares of stock to LG pursuant to a notice of conversion, and failed to reserve a sufficient number of shares of stock issuable under the terms of the LG Note. On July 12, 2017, the Court denied LG’s motion for Order to Show Cause and Request for an Injunction. The Company will continue to answer and defend against this complaint. Under ASC 450, the Company has determined that it is reasonably possible but not probable that the outcome of the litigation might be unfavorable. Based on the Company’s analysis of the outcome of the litigation, the range of potential outcomes are between $0 and $250,000. As such, the Company has recorded a loss contingency it believes reflects the most likely outcome of the litigation.

Other Legal Proceedings

The Company is a party to certain legal actions, as either plaintiff or defendant, arising in the ordinary course of business, none of which is expected to have a material adverse effect on the Company’s business, financial condition or results of operations. However, litigation is inherently unpredictable, and the costs and other effects of pending or future litigation, governmental investigations, legal and administrative cases and proceedings, whether civil or criminal, settlements, judgments and investigations, claims or charges in any such matters, and developments or assertions by or against the Company relating to the Company or to the Company’s intellectual property rights and intellectual property licenses could have a material adverse effect on the Company’s business, financial condition and operating results.

~~Distributor~~10. Employment Contracts and ~~Supplier~~Stock ~~Agreements~~Compensation to Related Parties

~~Under~~On ~~certain~~April ~~agreements~~8, 2016, the Company ~~may~~entered beinto ~~subject~~employment contracts with both Mr. Caragol and Mr. Probst, effective January 1, 2016. The terms of Mr. Caragol’s employment contract include a three-year term and a salary of $275,000. Mr. Caragol’s salary will automatically adjust to ~~penalties~~$350,000 ifat ~~they~~the ~~are~~time ~~unable~~that PositiveID’s common stock is listed on a national exchange. Mr. Caragol is eligible for annual bonuses. Mr. Caragol is also entitled to ~~supply~~the ~~products~~use ~~under~~of ~~its~~a ~~obligations~~Company car and related expenses and an unaccountable expense allowance of $25,000. ~~Since~~The terms of Mr. Probst’s employment contract include a three-year term and a salary of $200,000. ~~inception~~Mr. Probst’s salary will automatically adjust to $250,000 at the ~~Company~~time ~~has~~that ~~never~~PositiveID’s ~~incurred~~common ~~any~~stock ~~such~~is ~~penalties~~listed on a national exchange. Mr. Probst is eligible for annual bonuses.

8If either Mr. Caragol or Mr. Probst’s employment is terminated prior to the expiration of the term of his employment agreement, ~~Employment~~certain ~~Contracts~~significant payments become due. The amount of such payments depends on the nature of the termination. In addition, the employment agreement contains a change of control provision that provides for the payment of 2.0 times and ~~Stock~~2.95 ~~Compensation~~times in the case of Mr. Probst and Mr. Caragol, respectively of the then current base salary and the same multipliers of the highest bonus paid to ~~Related~~the ~~Parties~~executive during the three calendar years immediately prior to the change of control. Any outstanding stock options or restricted shares held by the executive as of the date of his termination or a change of control become vested and exercisable as of such date and remain exercisable during the remaining life of the option. The employment agreement also contains non-compete and confidentiality provisions which are effective from the date of employment through two years from the date the employment agreement is terminated.

OnFrom ~~April~~time 8,to ~~2016,~~time ~~the~~during ~~Company~~these ~~entered~~agreements ~~into employment contracts with~~ both Mr. Caragol and Mr. Probst, ~~effective~~have ~~January~~deferred 1,their ~~2016~~salaries. ~~The~~ ~~terms~~As of ~~Mr.~~the ~~Caragol’s~~filing ~~employment contract include a three-year term and a salary~~ of ~~$275,000.~~this ~~Mr. Caragol’s salary~~report ~~will~~both ~~automatically adjust to $350,000 at the time that PositiveID’s common stock is listed on a national exchange~~Mssrs. ~~Mr.~~ Caragol is ~~eligible for annual bonuses~~ and was granted 167 stock options, which vest; (i) 57 on January 1, 2017; (ii) 55 on January 1, 2018; (iii) 55 on January 1, 2019. These options will expire on January 1, 2021. Mr. Caragol is also entitled to the use of a Company car and related expenses and an unaccountable expense allowance of $25,000. The terms of Mr. Probst’s ~~employment contract~~are ~~include~~deferring a ~~three-year~~portion ~~term and a salary~~ of ~~$200,000.~~their ~~Mr. Probst’s~~ salary ~~will automatically adjust to $250,000 at the time that PositiveID’s common stock is listed on a national exchange~~. Mr. Probst is eligible for annual bonuses and was granted 100 stock options, which vest; (i) 34 on January 1, 2017; (ii) 33 on January 1, 2018; (iii) 33 on January 1, 2019. These options will expire on January 1, 2021.

If either Mr. Caragol or Mr. Probst’s employment is terminated prior to the expiration of the term of his employment agreement, certain significant payments become due. The amount of such payments depends on the nature of the termination. In addition, the employment agreement contains a change of control provision that provides for the payment of 2.0 times and 2.95 times in the case of Mr. Probst and Mr. Caragol, respectively of the then current base salary and the same multipliers of the highest bonus paid to the executive during the three calendar years immediately prior to the change of control. Any outstanding stock options or restricted shares held by the executive as of the date of his termination or a change of control become vested and exercisable as of such date, and remain exercisable during the remaining life of the option. The employment agreement also contains non-compete and confidentiality provisions which are effective from the date of employment through two years from the date the employment agreement is terminated.33

9.POSITIVEID ~~Segments~~CORPORATION AND SUBSIDIARIES

The Company operates in three business segments: Molecular Diagnostics, Medical Devices, and Mobile Labs.

Molecular Diagnostics

The Company develops molecular diagnostic systems for rapid medical testing and bio-threat detection. The Company’s fully automated pathogen detection systems are designed to detect a range of biological threats. The Company’s M-BAND (Microfluidic Bio-agent Autonomous Networked Detector) system is an airborne bio-threat detection system developed for the homeland defense industry to detect biological weapons of mass destruction. The Company is developing the FireflyDX family of products, automated point-of-need pathogen detection systems for rapid diagnostics.

Medical Devices

Through its wholly owned Thermomedics subsidiary, the Company markets and sells the Caregiver product. Caregiver is an FDA-cleared for clinical use, infrared thermometer that measures forehead temperature in adults, children and infants, without contact. Caregiver is the world’s first clinically validated, non-contact thermometer for the healthcare providers market, which includes hospitals, physicians’ offices, medical clinics, nursing homes and other long-term care institutions, and acute care hospitals. Our Caregiver thermometer with TouchFree™ technology is less likely to transmit infectious disease than devices that require even minimal contact. It therefore saves medical facilities the cost of probe covers (up to $0.10 per temperature reading), storage space and disposal costs.

POSITIVEID CORPORATION

Notes to the Condensed Consolidated Financial Statements

~~September~~March 3031, ~~2017~~2018

(Unaudited)

11. Segments

The Company operates in three business segments which are Molecular Diagnostics, Medical Devices, and Mobile Labs (see Note 3).

Molecular Diagnostics

The Company develops molecular diagnostic systems for rapid medical testing and bio-threat detection. The Company’s fully automated pathogen detection systems are designed to detect a range of biological threats. The Company’s M-BAND (Microfluidic Bioagent Autonomous Networked Detector) system is an airborne bio-threat detection system developed for the homeland defense industry to detect biological weapons of mass destruction. The Company is developing the FireflyDX family of products, automated point-of-need pathogen detection systems for rapid diagnostics.

Medical Devices

Through its wholly owned Thermomedics subsidiary, the Company markets and sells the Caregiver® product. Caregiver® is an FDA-cleared for clinical use, infrared thermometer that measures forehead temperature in adults, children and infants, without contact. Caregiver® is the world’s first clinically validated, non-contact thermometer for the healthcare providers market, which includes hospitals, physicians’ offices, medical clinics, nursing homes and other long-term care institutions, and acute care hospitals. Our Caregiver® thermometer with TouchFree™ technology is less likely to transmit infectious disease than devices that require even minimal contact. It therefore saves medical facilities the cost of probe covers (up to $0.10 per temperature reading), storage space and disposal costs.

Mobile Labs

~~Our majority-owned subsidiary,~~ ENG ~~(see Note 3)~~, is a leader in the specialty technology vehicle market, with a focus on mobile laboratories, command and communications applications, and mobile cellular systems. ENG builds mobile laboratories specifically designed for chemical and biological detection, monitoring and analysis. ENG also provides specialty vehicle manufacturing for TV news vans and trucks, emergency response trailers, mobile command centers, infrared inspection, ~~utilities inspection,~~ and other special purpose vehicles. ENG was a consolidated subsidiary through January 30, 2018, at which point ENG became a significant investment accounted for pursuant to the equity method of accounting (see Note 3 and Note 5).

The following is the selected segment data as of and for the three ~~and nine~~ months ended ~~September~~March 3031, ~~2017~~2018 and ~~2016~~2017 (in thousands):

	Three months ended September 30, 2017
	Three months ended March 31, 2018
	Molecular Diagnostics			Medical Devices			Mobile Labs (January 1, 2018 through January 30, 2018)			Corporate			Total
Revenue	$	17—		$	77177		$	~~1,373~~243		$	—		$	~~1,467~~420
Operating (loss)	$	(~~201~~202	)	$	(~~114~~28	)	$	(990	)	$	(~~566~~709	)	$	(~~890~~1,029	)
Depreciation and amortization	$	(2	)	$	(27	)	$	(214	)	$	—		$	(5033	)
Interest and other income (expense)	$	1011		$	—		$	(32	)	$	(1,~~018~~838	)	$	(1,~~011~~829	)
Net loss	$	(190	)	$	(115	)	$	(12	)	$	(1,584	)	$	(1,901	)
(Loss) before provision for income taxes	$	(191	)	$	(28	)	$	(92	)	$	(2,592	)	$	(2,903	)
Goodwill	$	510		$	91		$	~~199~~—		$	—		$	~~800~~601
Segmented assets	$	~~548~~540		$	~~413~~356		$	~~1,380~~—		$	35317		$	21,~~376~~213
Expenditures for property and equipment	$	—		$	—		$	(112	)	$	—		$	~~(11~~—	)

	Three months ended September 30, 2016
	Three months ended March 31, 2017
	Molecular Diagnostics			Medical Devices			Mobile Labs			Corporate			Total
Revenue	$	5263		$	~~145~~95		$	~~868~~1,069		$	—		$	1,~~065~~227
Operating (loss)	$	(~~165~~130	)	$	(81113	)	$	(~~167~~205	)	$	(21,~~991~~385	)	$	(31,~~404~~833	)
Depreciation and amortization	$	(42	)	$	(2627	)	$	(21	)	$	—		$	(5150	)
Interest and other income (expense)	$	46		$	(581	)	$	(21	)	$	(12,~~023~~022	)	$	(12,~~079~~016	)
Net loss	$	(162	)	$	(141	)	$	(167	)	$	(4,013	)	$	(4,483	)
(Loss) before provision for income taxes	$	(106	)	$	(115	)	$	(203	)	$	(3,425	)	$	(3,849	)
Goodwill	$	510		$	91		$	199		$	—		$	800
Segmented assets	$	~~600~~608		$	~~583~~518		$	1,~~234~~383		$	~~195~~118		$	2,~~612~~627
Expenditures for property and equipment	$	—		$	—		$	—(15	)	$	—		$	—(15	)

	Nine months ended September 30, 2017
	Molecular Diagnostics			Medical Devices			Mobile Labs			Corporate			Total
Revenue	$	142		$	349		$	3,428		$	—		$	3,919
Operating (loss)	$	(554	)	$	(231	)	$	(373	)	$	(2,463	)	$	(3,621	)
Depreciation and amortization	$	(6	)	$	(81	)	$	(64	)	$	—		$	(151	)
Interest and other income (expense)	$	23		$	(3	)	$	—		$	(3,071	)	$	(3,051	)
Net loss	$	(531	)	$	(234	)	$	(374	)	$	(5,533	)	$	(6,672	)
Goodwill	$	510		$	91		$	199		$	—		$	800
Segmented assets	$	548		$	413		$	1,380		$	35		$	2,376
Expenditures for property and equipment	$	—		$	—		$	(26	)	$	—		$	(26	)

	Nine months ended September 30, 2016
	Molecular Diagnostics			Medical Devices			Mobile Labs			Corporate			Total
Revenue	$	52		$	346		$	4,180		$	—		$	4,578
Operating (loss)	$	(710	)	$	(356	)	$	(52	)	$	(4,929	)	$	(6,047	)
Depreciation and amortization	$	(110	)	$	(81	)	$	(60	)	$	—		$	(251	)
Interest and other income (expense)	$	17		$	(59	)	$	(2	)	$	(4,226	)	$	(4,270	)
Net loss	$	(726	)	$	(415	)	$	(54	)	$	(9,122	)	$	(10,317	)
Goodwill	$	510		$	91		$	199		$	—		$	800
Segmented assets	$	600		$	583		$	1,234		$	195		$	2,612
Expenditures for property and equipment	$	(1	)	$	—		$	(7	)	$	—		$	(8	)

POSITIVEID CORPORATION AND SUBSIDIARIES

POSITIVEID CORPORATION

Notes to the Condensed Consolidated Financial Statements

~~September~~March 3031, ~~2017~~2018

(Unaudited)

1012. Subsequent Events

On ~~October~~April 213, ~~2017~~2018, the Company ~~entered~~filed ~~into~~an aamendment ~~Securities~~to ~~Purchase~~its ~~Agreement~~Third ~~(“SPA”)~~Amended ~~with~~and aRestated ~~lender,~~Certificate ~~providing for the purchase~~ of ~~two Convertible Promissory Notes in the aggregate principal amount of $107~~Incorporation,~~000~~ ~~(the~~as ~~“Notes”)~~amended, with ~~the~~ ~~first note being in~~ the ~~amount~~State of ~~$53~~Delaware,~~500~~ ~~(“Note I”), and the second note being in the amount of $53,500 (“Note II”). Note I was funded subsequent~~ to ~~September~~implement ~~30,~~a ~~2017, with the Company receiving $45,000 of net proceeds (net of OID, legal and other fees). Note II will initially be paid~~ 1-for ~~by the issuance of an offsetting $50~~-1,000 ~~note~~reverse ~~issued~~stock tosplit ~~the Company by the Lender~~ (the “~~Collateralized~~Reverse ~~Note~~Stock Split”). ~~The funding~~ of ~~Note II is subject to~~ the ~~mutual agreement of the lender and the~~ Company~~. The lender is required to pay the principal amount of Note I in cash and in full prior to executing any conversions~~’s ~~under~~outstanding ~~Note~~Common ~~II. The Notes bear an interest rate of 12%~~Stock, ~~and~~which ~~are~~became ~~due~~effective ~~and payable~~ on ~~October~~April 218, 2018. The ~~Notes~~reverse ~~may~~stock besplit ~~converted by~~affected the ~~lender~~outstanding atCommon ~~any~~Stock as ~~time~~well ~~into shares of Company’s common stock (~~as ~~determined~~all inoutstanding ~~the~~Common ~~Notes)~~Stock ~~calculated~~underlying atconvertible ~~the time of conversion~~notes, ~~except~~ ~~for Note II~~warrants, ~~which~~convertible ~~requires~~preferred ~~full~~stock ~~payment~~and ofstock ~~the~~options immediately ~~Collateralized~~prior ~~Note~~to by the ~~lender~~reverse ~~before~~stock ~~conversions may be made~~split. The ~~Notes (subject~~number ~~to funding in the case~~ of ~~Note~~authorized ~~II) may be converted by the lender at any time into~~ shares ofwas ~~Company’s~~not ~~common~~adjusted. ~~stock at~~All ashare ~~price~~and ~~equal to the lower of $0.0175~~ per share, ~~or 62.5% of the lowest closing bid price of the common stock for the 20 prior~~amounts ~~trading~~in ~~days including~~ the ~~day~~accompanying ~~upon~~historical ~~which~~consolidated afinancial ~~notice~~statements ofhave ~~conversion~~been isretroactively ~~received~~adjusted byto ~~the~~reflect ~~Company. As~~ the ~~note~~Reverse ~~conversion includes a~~Stock ~~“lesser~~Split ~~of”~~(see ~~pricing provision, the Company will record a derivative liability in connection with the issuance of~~ Note I 1).

OnThe ~~October 11, 2017, the~~ Company ~~entered into a Securities Purchase Agreement (“SPA”) with a lender~~, providing for the purchase of two Convertible Redeemable Notes in the aggregate principal amount of $104,000 (the “Notes”), with the first note being in the amount of $52,000 (“Note I”), and the second note being in the amount of $52,000 (“Note II”). The Notes were funded subsequent to ~~September 30, 2017, with~~ the ~~Company~~three ~~receiving~~months ~~$95,000~~ended ofMarch ~~net proceeds (net of OID and legal fees). The Notes bear an interest rate of 12%~~31, ~~and are due and payable on October 11,~~ 2018. The Notes may be converted by the lender at any time into shares of Company’s common stock (as determined in the Notes) at a price equal to 62.5% of the lowest closing bid price of the common stock for the 20 prior trading days including the day upon which a notice of conversion is received by the Company. In connection with the issuance of the Notes, the Company will record a premium as the notes are considered stock settled debt under ASC 480.:

On November 9, 2017, the Company entered into a Securities Purchase Agreement (“SPA”) with a lender for the purchase of a Convertible Promissory Note in the aggregate principal amount of $53,000 (the “Note”). The Company expects the Note to be funded within 5 business days after the close, with the Company receiving $50,000 of net proceeds (net of fees). The Note bears an interest rate of 8%, and is due and payable on August 30, 2018. The Note may be converted by the lender at any time into shares of Company’s common stock (as determined in the Note) at a price equal to 65% of the average of the lowest five closing bid prices of the common stock for the 10 trading days ending on the latest complete trading day prior to the conversion date. In connection with the issuance of the Note, the Company will record a premium as the notes are considered stock settled debt under ASC 480.

●	received approximately $107,000 of net proceeds (net of legal fees and OID) from note payables in the aggregate principal amount of approximately $212,000. These notes payable have; (i) interest rates between 10% to 12%; (ii) conversion discounts of 37.5% and; (iii) maturity dates between nine to twelve months from the date it was funded. In connection with the issuance of these notes, the Company will record a premium as these notes are considered stock settled debt under ASC 480.

●	issued approximately 4.1 million shares of common stock in connection with the conversion of notes with a principal and interest value of approximately $98,000.

On November 13, 2017, the Company entered into a Securities Purchase Agreement (“SPA”) with a lender, providing for the purchase of two Convertible Redeemable Notes in the aggregate principal amount of $104,000 (the “Notes”), with the first note being in the amount of $52,000 (“Note I”), and the second note being in the amount of $52,000 (“Note II”). The Company expects Note I to be funded within 5 business days after the close, with the Company receiving $47,500 of net proceeds (net of OID and legal fees). The funding of Note II is subject to the mutual agreement of the lender and the Company. The lender is required to pay the principal amount of Note I in cash and in full prior to executing any conversions under Note II. The Notes bear an interest rate of 12%, and are due and payable on November 13, 2018. The Notes may be converted by the lender at any time into shares of Company’s common stock (as determined in the Notes) calculated at the time of conversion, except for Note II, which requires full payment of Note II by the lender before conversions may be made. The Notes (subject to funding in the case of Note II) may be converted by the lender at any time into shares of Company’s common stock at a price equal to the 62.5% of the lowest closing bid price of the common stock for the 20 prior trading days including the day upon which a notice of conversion is received by the Company. In connection with the issuance of the Notes, the Company will record a premium as the notes are considered stock settled debt under ASC 480.35

In addition to the new notes discussed above, the Company, subsequent to September 30, 2017:

	●	received $260,250 of net proceeds (net of OID and legal fees) from the funding of notes under existing SPAs and back-end notes (see Note 4).
	●	issued approximately 66.1 million shares of common stock in connection with the conversion of notes with a principal and interest value of approximately $429,000.

Special Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10Q (this “Report”) contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that reflect our current estimates, expectations and projections about our future results, performance, prospects and opportunities. Forward-looking statements include, without limitation, statements about our market opportunities, our business and growth strategies, our projected revenue and expense levels, possible future consolidated results of operations, the adequacy of our available cash resources, our financing plans, our competitive position and the effects of competition and the projected growth of the industries in which we operate, as well as the following statements:

● the expectation that operating losses will continue for the near future, and that until we are able to achieve profits, we intend to continue to seek to access the capital markets to fund the development of our products; ● that we seek to structure our research and development on a project basis to allow management of costs and results on a discrete short-term project basis, the expectation that doing so may result in quarterly expenses that rise and fall depending on the underlying project status, and the expectation that this method of managing projects may allow us to minimize our firm fixed commitments at any given point in time; ● that we intend to continue to explore strategic opportunities, including potential acquisition opportunities of businesses that are complementary to ours; ● that we do not anticipate declaring any cash dividends on our common stock; ● that our ability to continue as a going concern is dependent upon our ability to obtain financing to fund the continued marketing, sales and development of our products and working capital requirements; ● that after consideration of our current cash resources, our expected access to capital under existing financing arrangements, and, if necessary, delaying and/or reducing certain research, development and related activities and costs, ~~that~~ we will have sufficient funds available to meet our working capital requirements for the near-term future; ● that our products have certain technological advantages, but maintaining these advantages will require continual investment in research and development, and later in sales and marketing; ● that if any of our manufacturers or suppliers were to cease supplying us with system components, we would be able to procure alternative sources without material disruption to our business, and that we plan to continue to outsource any manufacturing requirements of our current and under development products; ● that the medical application of our ~~Caregiver~~FireflyDX ~~thermometer~~products ~~with~~will ~~TouchFree~~require ~~technology~~FDA isclearance ~~less~~or ~~likely~~CLIA waiver; ● that FireflyDX would enable accurate diagnostics leading to ~~transmit~~more ~~infectious~~rapid ~~disease~~and effective treatment than ~~devices~~what ~~that~~is ~~require~~currently ~~even~~available ~~minimal~~with ~~contact.~~existing systems; ● that wethe consideration to be paid by ExcitePCR to the Company pursuant to the APA, will be ~~able~~10,500,000 shares of common stock of ExcitePCR, and the Company will own approximately 91% of the outstanding shares of ExcitePCR post-closing of the sale (prior to any financing); ● that as a condition to the Company’s obligation to close the transaction, ExcitePCR shall have completed a financing transaction with net proceeds to ExcitePCR of at least $3 million; ● that M-BAND was developed in accordance with DHS guidelines; ● that our Caregiver thermometer with TouchFree™ technology is less likely to transmit infectious disease than devices that require even minimal contact.

This Report also contains forward-looking statements attributed to third parties relating to their estimates regarding the size of the future market for products and systems such as our products and systems, and the assumptions underlying such estimates. Forward-looking statements include all statements that are not historical facts and can be identified by forward-looking statements such as “may,” “might,” “should,” “could,” “will,” “intends,” “estimates,” “predicts,” “projects,” “potential,” “continue,” “believes,” “anticipates,” “plans,” “expects” and similar expressions. Forward-looking statements are only predictions based on our current expectations and projections, or those of third parties, about future events and involve risks and uncertainties.

Although we believe that the expectations reflected in the forward-looking statements contained in this Report on are based upon reasonable assumptions, no assurance can be given that such expectations will be attained or that any deviations will not be material. In light of these risks, uncertainties and assumptions, the forward-looking statements, events and circumstances discussed in this Report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Important factors that could cause our actual results, level of performance or achievements to differ materially from those expressed or forecasted in, or implied by, the forward-looking statements we make in this Report are discussed in our Annual Report on Form 10-K for the year ended December 31, 2016 filed with the SEC on March 31, 2017 under “Item 1A. Risk Factors” and elsewhere and include:36

●Although we ~~our~~believe ~~ability~~that ~~to predict~~ the ~~extent~~expectations ofreflected ~~future~~in ~~losses~~the orforward-looking ~~when~~statements wecontained ~~will~~in ~~become~~this ~~profitable;~~Report ●on ~~our~~are ~~ability~~based toupon ~~continue~~reasonable assumptions, asno aassurance ~~going~~can ~~concern;~~be ●given ~~our~~that ~~ability~~such toexpectations ~~successfully~~will ~~consider,~~be ~~review,~~attained ~~and~~or ifthat ~~appropriate,~~any ~~implement~~deviations ~~other~~will ~~strategic~~not ~~opportunities;~~be ●material. ~~our~~In light ~~expectation~~of ~~that~~these werisks, ~~will~~uncertainties ~~incur~~and ~~losses~~assumptions, onthe aforward-looking ~~consolidated basis~~statements, ~~for~~events ~~the~~and ~~foreseeable~~circumstances ~~future;~~discussed ●in ~~our~~this Report ~~ability~~may tonot ~~fund~~occur ~~our operations~~ and ~~continued~~actual ~~development~~results ofcould ~~our~~differ ~~products,~~materially ~~including~~and ~~FireflyDX;~~adversely ●from ~~our~~those ~~ability~~anticipated toor ~~target~~implied in the ~~bio~~forward-~~threat~~looking statements. ~~detection,~~Important ~~real-time~~factors ~~PCR,~~that ~~professional~~could ~~healthcare~~cause ~~and~~our ~~specialty~~actual ~~technology~~results, ~~vehicle~~level ~~markets;~~of ●performance ~~our~~or ~~ability~~achievements to ~~obtain~~differ ~~and~~materially ~~maximize~~from those ~~the~~expressed ~~amount~~or offorecasted ~~capital~~in, ~~that~~or weimplied ~~will~~by, ~~have~~the ~~available~~forward-looking tostatements ~~pursue~~we ~~business~~make ~~opportunities;~~in ●this ~~our~~Report ~~ability~~are todiscussed ~~obtain~~in ~~patents~~our Annual Report on ~~our~~Form ~~products,~~10-K for the ~~validity~~year ended December 31, ~~scope~~2017 ~~and~~filed ~~enforceability~~with ofthe ~~our~~SEC ~~patents~~on April 2, ~~and~~2018 ~~the~~under ~~protection~~“Item ~~afforded~~1A. byRisk ~~our~~Factors” and ~~patents;~~elsewhere and include:

34● our ability to predict the extent of future losses or when we will become profitable; ● our ability to continue as a going concern; ● our ability to successfully consider, review, and if appropriate, implement other strategic opportunities; ● our expectation that we will incur losses, on a consolidated basis, for the foreseeable future; ● our ability to fund our operations and continued development of our products, including FireflyDX; ● our ability to close the asset purchase agreement with ExcitePCR; ● our ability to target the bio-threat detection, real-time PCR, and professional healthcare markets; ● our ability to obtain and maximize the amount of capital that we will have available to pursue business opportunities; ● our ability to obtain patents on our products, the validity, scope and enforceability of our patents, and the protection afforded by our patents; ● the potential for costly product liability claims and claims that our products infringe the intellectual property rights of others; ● our ability to comply with current and future regulations relating to our businesses; ● the potential for patent infringement claims to be brought against us asserting that we are violating another party’s intellectual property rights; ● our ability to be awarded government contracts; ● our ability to establish and maintain proper and effective internal accounting and financial controls; ● our ability to pay obligations when due which may result in an event of default under our financing arrangements; ● our ability to successfully identify strategic partners or acquirers for the breath glucose detection system; ● our ability to successfully integrate our acquisitions; ● our ability to recover or monetize the convertible notes receivable and warrants with VeriTeQ; ● our ability to defend against litigation.

● the potential for costly product liability claims and claims that our products infringe the intellectual property rights of others; ● our ability to comply with current and future regulations relating to our businesses; ● the potential for patent infringement claims to be brought against us asserting that we are violating another party’s intellectual property rights; ● our ability to be awarded government contracts; ● our ability to establish and maintain proper and effective internal accounting and financial controls; ● our ability to pay obligations when due which may result in an event of default under our financing arrangements; ● our ability to close the transaction with ExcitePCR; and ● our ability to defend against pending or future litigation.

You should not place undue reliance on any forward-looking statements. In addition, past financial or operating performance is not necessarily a reliable indicator of future performance, and you should not use our historical performance to anticipate future results or future period trends. Except as otherwise required by federal securities laws, we disclaim any obligation or undertaking to disseminate any updates or revisions to any forward-looking statement contained in this Report to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based. All forward-looking statements attributable to us, or persons acting on our behalf, are expressly qualified in their entirety by the cautionary statements included in this Quarterly Report.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the accompanying unaudited condensed ~~consolidated~~ financial statements and related notes included in Item 1 of this Quarterly Report on Form 10-Q as well as our Annual Report on Form 10-K for the year ended December 31, ~~2016~~2017.

Overview

PositiveID is a life sciences and technology company focused primarily on the healthcare and homeland security markets.

PositiveID is currently developing the FireflyDX family of products, which are, automated, point-of-care pathogen detection systems for rapid diagnostics. PositiveID has a substantial portfolio of intellectual property related primarily to sample preparation and rapid medical testing applications. PositiveID’s operations are focused around its three segments, which include the operations of PDI/ExcitePCR and our FireflyDX platform (our Molecular Diagnostics segment), the operations of Thermomedics and our Caregiver product (our Medical Devices segment), and through our investment in ENG Mobile Systems (a Mobile Labs segment).

On January 30, ~~2017~~2018, ~~the~~ENG, ~~Company~~in ~~filed~~order ~~the First Amendment~~ to ~~the~~raise ~~Company’s~~working ~~Third~~capital, ~~Amended~~sold ~~and~~additional ~~Restated~~ownership ~~Certificate~~ of ~~Incorporation with~~ENG ~~the State of Delaware,~~ to ~~increase~~a ~~the~~strategic ~~Company’s~~investor ~~authorized~~who held ~~capital~~a ~~stock from 3~~49.98% ~~billion~~interest ~~shares~~in ~~to 20 billion shares (19~~ENG.~~995~~ ~~billion~~As ~~common)~~a ~~and~~result toof ~~change~~this ~~the~~transaction ~~par value of~~ the Company’s ~~Common~~equity ~~Stock~~interest ~~from~~in ~~$0.001~~ENG decreased to ~~$0.0001.~~approximately ~~On May~~24% ~~19,~~and ~~2017,~~ the Company ~~filed~~deconsolidated the ~~Second~~balance ~~Amendment~~sheet, toresults ~~the~~of ~~Third~~operations ~~Amended~~ and ~~Restated Certificate~~cash flows of ~~Incorporation,~~ENG asin ~~amended,~~its consolidated ~~with~~financial ~~the~~statements ~~State~~and ofaccounted ~~Delaware,~~for toENG ~~implement a~~under ~~1-for-3,000~~the ~~reverse~~equity ~~stock~~method ~~split~~ of ~~the~~accounting ~~Company’s~~in ~~outstanding~~accordance ~~Common~~with ~~Stock, which~~ASC ~~became~~323. ~~effective~~At ~~on May 23~~December 31, 2017. ~~The reverse stock split affected~~ the ~~outstanding~~Company ~~Common Stock~~owned as50.2% ~~well~~of asENG ~~all~~and ~~Common~~controlled ~~Stock~~ENG’s ~~underlying~~assets. ~~convertible~~These ~~notes,~~assets ~~warrants,~~represented ~~convertible~~between ~~preferred~~50% ~~stock~~ and ~~stock~~55% ~~options~~of the ~~outstanding~~Company’s ~~immediately~~overall ~~prior~~assets. toAs the ~~reverse~~result ~~stock~~of ~~split.~~the ~~The~~Company ~~number~~owning ofapproximately ~~authorized~~24% ~~shares~~of ~~was~~ENG, ~~not~~as ~~adjusted.~~of ~~All~~January ~~share~~30, ~~values~~2018, ~~and~~no ~~amounts~~longer incontrolled ~~the~~ENG’s ~~accompanying~~assets, ~~historical~~the ~~consolidated~~Company ~~financial~~deconsolidated ~~statements~~the ~~have~~results ~~been~~of ~~adjusted~~ENG, tocomprising ~~reflect~~a ~~the~~significant ~~change~~amount inof the ~~par value~~Company’s ofassets, ~~the~~as ~~Common~~of ~~Stock~~January ~~and the 1-for-3~~30,~~000~~ ~~reverse stock split~~2018.

On August 24, 2017, the Company and its wholly-owned subsidiary PositiveID Diagnostics, Inc. (collectively, the “Seller”), entered into an Asset Purchase Agreement (“APA”) with ExcitePCR Corporation (“ExcitePCR”). Pursuant to the APA, at closing, the Seller will sell and deliver to ExcitePCR all right, title and interest in all assets used or useful in connection with the operation of the FireflyDX technology, which consists of the FireflyDX intellectual property and that of its predecessor, the Dragonfly Dx technology and products, along with patents, the applicable know how used in the development of the FireflyDX and Dragonfly Dx technology, and breadboard prototypes of both products (the “Firefly Technology”). The consideration to be paid by ExcitePCR to the Seller pursuant to the APA, will be 10,500,000 shares of common stock of ExcitePCR, and the Company will own approximately 91% of ExcitePCR post-closing of the sale (prior to any financing). As a condition to the Seller’s obligation to close the transaction, ExcitePCR shall have completed a financing transaction with net proceeds to ExcitePCR of at least $3 million. Additional conditions and deliverables at closing include a patent assignment agreement, accounting services agreement, license agreement, and certain required consents from third parties. As of November 7, 2017, ExcitePCR and the Company had not yet closed the transaction.

The Company believes that the Firefly Technology has significant potential value to stockholders. The parties have entered into the APA so ExcitePCR can secure financing and then independently pursue the development, improvement and commercialization of the Firefly Technology. The current stockholders of ExcitePCR include two third-party individuals, who are working with ExcitePCR to develop and execute the business plan of ExcitePCR. Lyle L. Probst (the Company’s President) is the Chief Executive Officer of ExcitePCR, Dr. Kimothy Smith (the Company’s Chief Technology Advisor) is the Chief Science Officer of ExcitePCR. William J. Caragol (the Company’s Chairman and CEO), is the Chairman of ExcitePCR.

Results of Operations

~~Three~~The ~~Months~~Company ~~Ended~~operates ~~September~~in ~~30,~~three ~~2017~~business ~~Compared~~segments towhich ~~Three~~are ~~Months~~Molecular ~~Ended~~Diagnostics, ~~September~~Medical 30Devices, ~~2016~~and Mobile Labs.

~~The~~Three ~~following~~Months isEnded ~~the~~March ~~selected~~31, ~~segment~~2018 ~~data~~Compared ~~for~~to ~~the~~Three ~~three~~Months ~~and~~Ended ~~months~~March ~~ended September 30~~31, 2017 ~~and 2016.~~

	Three Months Ended September 30, 2017
	Molecular Diagnostics			Medical Devices			Mobile Labs			Corporate			Total
Revenue	$	17		$	77		$	1,373		$	—		$	1,467
Cost of revenue		7			13			922			—			942
Gross profit		10			64			451			—			525
Selling, general and administrative		132			119			460			566			1,277
Research and development		79			59			—			—			138
Total operating expenses		211			178			460			566			1,415
Operating (loss)	$	(201	)	$	(114	)	$	(9	)	$	(566	)	$	(890	)

The following is the selected segment data for the three months ended March 31, 2018 and 2017 (in thousands).

	Three Months Ended September 30, 2016
	Three Months Ended March 31, 2018
	Molecular Diagnostics			Medical Devices			Mobile Labs (January 1, 2018 through January 30, 2018)			Corporate			Total
Revenue	$	52—		$	~~145~~177		$	~~868~~243		$	—		$	~~1,065~~420
Cost of revenue		1—			2554			~~501~~174			—			~~527~~228
Gross profit		51—			~~120~~123			~~367~~69			—			~~538~~192
Selling, general and administrative		~~177~~83			53112			~~534~~159			~~2,991~~709			31,~~755~~063
Research and development		39119			~~148~~39			—			—			~~187~~158
Total operating expenses		~~216~~202			~~201~~151			~~534~~159			~~2,991~~709			31,~~942~~221
Operating (loss)	$	(~~165~~202	)	$	(8128	)	$	(~~167~~90	)	$	(~~2,991~~709	)	$	(31,~~404~~029	)

	Three Months Ended March 31, 2017
	Molecular Diagnostics			Medical Devices			Mobile Labs			Corporate			Total
Revenue	$	63		$	95		$	1,069		$	—		$	1,227
Cost of revenue		—			25			779			—			804

Gross profit		63			70			290			—			423

Selling, general and administrative		143			132			495			1,385			2,155
Research and development		50			51			—			—			101

Total operating expenses		193			183			495			1,385			2,256
Operating (loss)	$	(130	)	$	(113	)	$	(205	)	$	(1,385	)	$	(1,833	)

Revenue

We reported revenue of $10.54 million and $1.12 million for the three months ended ~~September~~March 3031, ~~2017~~2018 and ~~2016~~2017, respectively. ~~The~~Historically, the majority of the Company’s ~~current~~ revenues ~~are~~were ~~primarily~~ generated from its Mobile Labs segment. Such revenue is recorded at the completion and delivery of mobile lab and telecommunications vehicles. As individual projects ~~may~~are beusually material, revenues ~~from quarter to quarter~~ can vary materially period to period based on the timing of such deliveries., ~~The~~and ~~increase~~quarterly in revenue, isas ~~attributable~~a toresult, ~~increased~~may ~~deliveries~~not ofreflect ~~mobile~~results ~~labs~~projected ~~and~~over ~~other~~an ~~specialty~~annual ~~vehicles~~period. inThe ~~the~~decreased ~~three~~revenue ~~months~~from ~~ended~~the ~~September~~first ~~30,~~quarter of 2017 ~~compared~~ to 2018 was primarily driven by the ~~three~~deconsolidation of ~~months~~the ~~ended~~Mobile ~~September~~Labs segment on January 30, ~~2016~~2018.

Cost of Revenue and Gross Profit

Cost of revenue ~~consists~~consist of inventory cost and compensation expense for employees and consultants working directly on the Company’s revenue generating products and agreements. Cost of revenue was $0.92 million and $0.58 million for three months ended ~~September 30~~March 31, 2018 ~~2017~~ and ~~2016~~2017, respectively. Gross profit decreased from $~~538~~423,000 in the three months ended ~~September~~March 3031, ~~2016~~2017 to $~~525~~192,000 in the three months ended ~~September~~March 3031, ~~2017~~2018. AsThe ~~individual projects may be material, revenues from quarter to quarter can vary materially based on the timing of such deliveries which resulted in the~~ decrease in cost of revenue and gross profit. ~~The increase in cost of revenue~~ was ~~attributable~~primarily todriven by the ~~increase~~deconsolidation ~~in revenue discussed above. The decrease in gross profit and margin is attributable~~of to the ~~change~~Mobile inLabs ~~revenue~~segment ~~mix~~on ~~and~~January ~~specifically~~30, ~~a decrease in revenue in the medical device segment~~2018.

Selling, General and Administrative Expense

Selling, general and administrative expense consists primarily of compensation for employees in executive, sales, marketing and operational functions, including finance and accounting and corporate development. Included in selling, general and administrative expense is all non-cash, equity -based compensation. Other significant costs include depreciation and amortization, professional fees for accounting and legal services, consulting fees and facilities costs.

Selling, general and administrative expense decreased by ~~approximately~~ $21.51 million, or 6651%, for the three months ended ~~September~~March 3031, ~~2017~~2018 compared to the three months ended ~~September~~March 3031, ~~2016~~2017. This ~~decreased~~decrease was primarily ~~driven~~attributable byto athe ~~decrease~~non-cash initem ~~stock~~charged to stock-based compensation ~~expense.~~ Inexpense ~~2016,~~in ~~approximately~~connection ~~$2.0~~with ~~million,~~the aissuance ~~one-time~~of ~~non-cash~~835 ~~expense,~~shares ~~was~~of ~~charged~~Series toII preferred stock ~~based~~during ~~expense~~the inthree ~~connection~~months ~~with~~ended ~~the~~March ~~exchange~~31, 2017 ofand ~~Series~~by Ithe ~~Preferred~~deconsolidation ~~shares~~of tothe ~~Series~~Mobile IILabs ~~preferred~~segment ~~shares~~on January 30, 2018.

Research and Development

Our research and development expense ~~consists~~consist primarily of labor (both internal and contract) and materials costs associated with ~~various~~ various development projects, including testing, developing prototypes and related expenses. Our research and development costs ~~include~~ include payments to our development partners and acquisition of in process research and development. We seek to structure our ~~research~~ research and development on a project basis to allow the management of costs and results on a discrete short-term project basis. This may result in quarterly expenses that rise and fall depending on the underlying project status. We expect this method of ~~managing~~ managing projects to allow us to minimize our firm fixed commitments at any given point in time.

Research and development expense ~~decreased~~increased by approximately $4957,000, or 2656%, for the three months ended ~~September~~March 3031, ~~2017~~2018 compared to ~~the~~ the three months ended ~~September~~March 3031, ~~2016~~2017. The ~~decrease~~increase was primarily attributable to the ~~decrease~~increase in labor, and engineering costs ~~related~~ related to the development of ~~FireflyDX~~the ~~products~~Bluetooth capable Caregiver product.

Change in Fair Value of Embedded Conversion Option Liability

The ~~change in~~ fair value of embedded conversion option liability ~~changed~~increased by approximately $10.59 million or ~~143~~152%, for the three months ended March ~~September 30~~31, ~~2017~~2018 compared to the three months ended ~~September~~March 3031, ~~2016~~2017. The ~~change~~increase was primarily attributed to the revaluation of ~~the fair value~~ of the embedded conversion option liability ~~charged~~at toMarch ~~other expense and the change in the fair-value of the derivative liability in the three months ended September 30~~31, ~~2017~~2018. This is a non-cash income/expense item.

Interest Expense

Interest expense decreased by approximately $10.7 million or 7547%, for the three months ended ~~September~~March 3031, ~~2017~~2018 compared to the three months ended ~~September~~March 3031, ~~2016~~2017. The decrease was primarily attributed to the ~~lower~~ amortization of fair value premiums and debt discounts ~~related~~ related to the ~~decreased level of~~ borrowing, through convertible notes, insome ~~the~~of ~~three~~which ~~months~~were ~~ended~~fully ~~September~~expensed ~~30,~~in 2017. The amortization of fair value premiums and debt discounts are non-cash income/expense items.

~~Nine~~Loss ~~Months~~on ~~Ended~~Investment ~~September~~in ~~30,~~ENG ~~2017~~Mobile ~~Compared to Nine Months Ended September 30, 2016~~Systems

~~The~~As ~~following~~a isresult of the ~~selected~~dilution ~~segment~~of ~~data~~the ~~for~~Company’s ~~the~~interest ~~nine~~in ~~months~~ENG ~~ended~~on ~~September~~January 30, ~~2017~~2018, the Company deconsolidated ENG and ~~2016~~accounted for its investment in ENG using the equity method of accounting in accordance with ASC 323 (see Note 2). The fair value of the ENG investment on the deconsolidation date was recorded as separate line item in the Company’s consolidated balance sheet under “Investment in ENG Mobile Systems” and was adjusted to reflect the “Loss on investment in ENG Mobile Systems”, recorded as separate line item the statement of operations. The Company recognized $45,088 loss on investment in ENG Mobile Systems during the quarter ended March 31, 2018.

	Nine Months Ended September 30, 2017
	Molecular Diagnostics			Medical Devices			Mobile Labs			Corporate			Total
Revenue	$	142		$	349		$	3,428		$	—		$	3,919
Cost of revenue		39			78			2,380			—			2,497
Gross profit		103			271			1,048			—			1,422
Selling, general and administrative		421			347			1,421			2,463			4,652
Research and development		236			155			—			—			391
Total operating expenses		657			502			1,421			2,463			5,043
Operating (loss)	$	(554	)	$	(231	)	$	(373	)	$	(2,463	)	$	(3,621	)

Gain on Deconsolidation

	Nine Months Ended September 30, 2016
	Molecular Diagnostics			Medical Devices			Mobile Labs			Corporate			Total
Revenue	$	52		$	346		$	4,180		$	—		$	4,578
Cost of revenue		1			75			2,798			—			2,874
Gross profit		51			271			1,382			—			1,704
Selling, general and administrative		505			474			1,434			4,929			7,342
Research and development		256			153			—			—			409
Total operating expenses		761			627			1,434			4,929			7,751
Operating (loss)	$	(710	)	$	(356	)	$	(52	)	$	(4,929	)	$	(6,047	)

The decrease of the Company’s ownership in ENG on January 30, 2018 and the resulting deconsolidation resulted in the recognition of a $387,692 gain during the three months ended March 31, 2018. Effective January 30, 2018, the Company began to account for its investment in ENG using the equity method of accounting. See “Loss on investment in ENG Mobile Systems” above for details.

3739

Revenue

We reported revenue of $3.9 million and $4.6 million for the nine months ended September 30, 2017 and 2016, respectively. The Company’s current revenues are primarily generated from its Mobile Labs segment. Such revenue is recorded at the completion and delivery of mobile lab and telecommunications vehicles. As individual projects may be material, revenues from quarter to quarter can vary materially based on the timing of such deliveries. The decrease in revenue was primarily attributable to larger revenues in the first six months of 2016 compared to the first six months of 2017. Management believes that this is the result of a large backlog of business as of the December 24, 2015 acquisition date, which was recognized in the first half of 2016.

Cost of Revenue and Gross Profit

Cost of revenue consist of inventory cost and compensation expense for employees and consultants working directly on the Company’s revenue generating products and agreements. Cost of revenue was $2.5 million and $2.9 million for nine months ended September 30, 2017 and 2016, respectively. Gross profit decreased from $1.7 million in the nine months ended September 30, 2016 to $1.4 million in the nine months ended September 30, 2017. As individual projects may be material, revenues from quarter to quarter can vary materially based on the timing of such deliveries which resulted in the decrease in cost of revenue and gross profit. The decrease in cost of revenue and gross profit are the result of lower revenues in the first half of 2017, as discussed above.

Selling, General and Administrative Expense

Selling, general and administrative expense consists primarily of compensation for employees in executive, sales, marketing and operational functions, including finance and accounting and corporate development. Included in selling, general and administrative expense is all non-cash, equity based compensation. Other significant costs include depreciation and amortization, professional fees for accounting and legal services, consulting fees and facilities costs.

Selling, general and administrative expense decreased by $2.7 million, or 37%, for the nine months ended September 30, 2017 compared to the nine months ended September 30, 2016. This decreased was primarily driven by a decrease in stock based compensation expense. In 2016, approximately $2.0 million, a one-time non-cash expense, was charged to stock based expense in connection with the exchange of Series I Preferred shares to Series II preferred shares.

Research and Development

Our research and development expense consists primarily of labor (both internal and contract) and materials costs associated with various development projects, including testing, developing prototypes and related expenses. Our research and development costs include payments to our development partners and acquisition of in process research and development. We seek to structure our research and development on a project basis to allow the management of costs and results on a discrete short-term project basis. This may result in quarterly expenses that rise and fall depending on the underlying project status. We expect this method of managing projects to allow us to minimize our firm fixed commitments at any given point in time.

Research and development expense decreased by approximately $18,000, or 4%, for the nine months ended September 30, 2017 compared to the nine months ended September 30, 2016. The decrease was primarily attributable to the decrease in labor, and engineering costs related to the development of FireflyDX products.

Change in Fair Value of Embedded Conversion Option Liability

The change in fair value of embedded conversion option liability changed by approximately $1.5 million or 107%, for the nine months ended September 30, 2017 compared to the nine months ended September 30, 2016. The change was primarily attributed to the revaluation of the fair value of the embedded conversion option liability charged to other expense and the change in the fair-value of the derivative liability in the nine months ended September 30, 2017. This is a non-cash income/expense item.

Interest Expense

Interest expense decreased by approximately $2.8 million or 48%, for the nine months ended September 30, 2017 compared to the nine months ended September 30, 2016. The decrease was primarily attributed to the amortization of fair value premiums and debt discounts related to the decreased level of borrowing, through convertible notes, the nine months ended September 30, 2017. The amortization of fair value premiums and debt discounts are non-cash income/expense items.

Liquidity and Capital Resources

As of ~~September~~March 3031, ~~2017~~2018, cash totaled $2549,000 compared to cash of $40181,000 at December 31, ~~2016~~2017.

Cash Flows from Operating Activities

Net cash used in operating activities totaled approximately $21.40 million and $20.93 million during the ~~nine~~three months ended ~~September~~March 3031, ~~2017~~2018 and ~~2016~~2017, respectively, primarily to fund operating losses. This ~~decrease~~increase in cash used in operating activities, which totaled $0.7 million, was primarily the result of ~~the~~changes ~~Company’s~~in ~~continued~~operating ~~efforts~~assets toand ~~reduce~~liabilities. ~~its~~Such ~~operating~~changes ~~burn~~represent timing changes in working capital.

Cash Flows from Investing Activities

Net cash provided by and (used in) ~~and provided by~~ investing activities totaled approximately $~~1.4~~97,000 ~~million~~ and $(811,000), ~~respectively,~~ during the ~~nine~~ three months ended March ~~September 30~~31, ~~2017~~2018 and ~~2016~~2017, respectively. The increase in cash ~~proceeds~~provided ~~for~~by ~~2017~~investing ~~primarily~~activities ~~resulted~~was ~~from~~primarily the ~~net~~result ~~cash~~of ~~inflows~~the ~~from~~deconsolidation ~~the sale~~ of aENG ~~non-controlling~~during ~~interest~~the inthree ~~one~~months ofended ~~the~~March ~~Company’s~~31, ~~subsidiaries~~2018.

Cash Flows from Financing Activities

Financing activities provided ~~net~~ cash of approximately $1.0.8 million and $20.96 million, net of payments, during the ~~nine~~three months ended ~~September 30~~March 31, ~~2017~~2018 and ~~2016~~ 2017, respectively, primarily related to proceeds from the issuance of convertible notes ~~and debentures~~.

Financial Condition

As of ~~September~~March 3031, ~~2017~~2018, we had a working capital deficit, stockholders’ deficit and accumulated deficit of approximately $1011.3 8 million, $910.07 million and $~~164~~168.6 million, respectively, compared to a working capital deficit, stockholders’ deficit ~~and~~ and accumulated deficit of approximately $10.36 million, $8.9.7 million and $~~157~~165.8 million, respectively, as of December 31, ~~2016~~2017. The increase in the working capital deficit iswas primarily ~~the~~due ~~result~~to ofcapital ~~the~~raised ~~Company’s~~through convertible debt financings that was spent on operations.

We have incurred operating losses and net cash used in operating activities since the merger that created PositiveID in 2009. The current ~~2017~~2018 operating losses are the result of research and development expenditures, selling, general and administrative expenses related to our molecular diagnostics and detection and Caregiver products. We expect our operating losses to continue through ~~2017~~ 2018. It’s management’s opinion that these conditions raise substantial doubt about our ability to continue as a going concern for a period of one year from the date of this filing.

Our ability to continue as a going concern is dependent upon our ability to obtain financing to fund the continued development of our products and to support working capital requirements. Until we are able to achieve operating profits, we will continue to seek to access the capital markets. In fiscal ~~2016~~2017 and for the first ~~nine~~three months of ~~2017~~2018, we raised approximately $32.87 and $10.9 million, respectively primarily from the issuance of convertible debt. In addition, during the nine months ended September 30, 2017, we received approximately $1.4 million of net proceeds from the sale of non-controlling interest in one of our subsidiaries to a strategic investor.

Off-Balance Sheet Arrangements

None.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

As a “Smaller Reporting Company,” we are not required to provide the information required by this item.

Item 4. Controls and Procedures.

3940

Disclosure Controls and Procedures

Evaluation of Disclosure Controls. We evaluated the effectiveness of the design and operation of our “disclosure controls and procedures” as defined in Rule 13a-15(e) under the Exchange Act as of ~~September~~March 3031, ~~2017~~2018. This evaluation (the “disclosure controls evaluation”) was done under the supervision and with the participation of management, including the person(s) performing the function of our chief executive officer (“CEO”) and acting chief financial officer (“CFO”). Rules adopted by the SEC require that in this section of this Report we present the conclusions of the CEO and CFO about the effectiveness of our disclosure controls and procedures as of ~~September~~March 3031, ~~2017~~2018 based on the disclosure controls evaluation.

Objective of Controls. Our disclosure controls and procedures are designed so that information required to be disclosed in our reports filed under the Exchange Act, such as this Report, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Our disclosure controls and procedures are also intended to ensure that such information is accumulated and communicated to our management, including the CEO and acting CFO, as appropriate to allow timely decisions regarding required disclosure. There are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives, and management necessarily is required to use its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures.

Conclusion. Based upon the disclosure controls evaluation, our CEO and acting CFO had concluded that, as of ~~September~~March 3031, ~~2017~~2018 our disclosure controls and procedures were effective to provide reasonable assurance that the foregoing objectives are achieved.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Rule 13a-15 under the Exchange Act that occurred during the quarter ended ~~September~~March 3031, ~~2017~~2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II — OTHER INFORMATION

Item 1. Legal Proceedings.

The Company is a party to certain legal actions, as either plaintiff or defendant, arising in the ordinary course of business, with the exception of the LG Capital litigation described below, none of which is expected to have a material adverse effect on its business, financial condition or results of operations. However, litigation is inherently unpredictable, and the costs and other effects of pending or future litigation, governmental investigations, legal and administrative cases and proceedings, whether civil or criminal, settlements, judgments and investigations, claims or charges in any such matters, and developments or assertions by or against the Company relating to it or to its intellectual property rights and intellectual property licenses could have a material adverse effect on the Company’s business, financial condition and operating results.

LG Capital Funding Litigation

On March 7, 2017, LG Capital Funding, LLC (“LG”), filed a complaint in the U.S. District Court of the Eastern District of New York (the “Court”), related to a 10% Convertible Redeemable Note issued by us to LG on July 7, 2016 in the amount of $66,150 (the “LG Note”). The LG Note provides that LG is entitled to convert all or any amount of the outstanding balance and accrued interest of the LG Note into shares of our Common Stock. The complaint alleges breach of contract and anticipatory breach of contract, asserting, among other things, that we failed to deliver shares of stock to LG pursuant to a notice of conversion, and failed to reserve a sufficient number of shares of stock issuable under the terms of the LG Note. On July 12, 2017, the Court denied LG’s motion for ~~summary~~Order ~~judgment~~to Show Cause and Request for an Injunction. The Company will continue to answer and defend against this complaint. Under ASC 450, the Company has determined that it is reasonably possible but not probable that the outcome of the litigation might be unfavorable. Based on the Company’s analysis of the outcome of the litigation, the range of potential outcomes are between $0 and $250,000. As such, the Company has recorded a loss contingency it believes reflects the most likely outcome of the litigation.

Item 1A. Risk Factors.

Information regarding risk factors appears under the caption “SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS” at the beginning of Part I Item 2 of this quarterly report on Form 10-Q and in Part I — Item 1A of our Annual Report on Form 10-K for the year ended December 31, ~~2016~~2017 filed with the SEC on ~~March~~April 312, ~~2017~~2018. There have been no material changes to such risk factors during the three months ended ~~September~~March 3031, ~~2017 other than the following additional risk factor:~~2018.

We may be unable to successfully close the ExcitePCR transaction and, if we do not, we may be unable to further develop the Firefly Technology.

We believe that the Firefly Technology has significant potential value to stockholders. As a condition to our obligation to close the APA, ExcitePCR shall have completed a financing transaction with net proceeds to ExcitePCR of at least $3 million. Additional conditions and deliverables at closing include a patent assignment agreement, accounting services agreement, license agreement, and certain required consents from third parties. As of November 7, 2017, ExcitePCR and the Company had not yet closed the transaction.

The parties have entered into the APA so ExcitePCR can secure financing and then independently pursue the development, improvement and commercialization of the Firefly Technology. If we are unable to close the transaction with ExcitePCR, we may unable to further develop the Firefly Technology due to potential partners and/or investors key to the completion and commercialization of the Firefly Technology preferring to not partner with a highly leveraged company such as ours. Our failure to develop the Firefly Technology could have a material adverse effect on our business, financial condition, or results of operations.

Item 2. Unregistered Sale of Equity Securities.

During the three months ended ~~September~~March 3031, ~~2017~~2018, we issued shares of our common stock that were not registered under the Securities Act, and were not previously disclosed in a Current Report on Form 8-K as follows:

1. During the three months ended ~~September~~March 3031, ~~2017~~2018, we issued approximately 8.6 million shares of our common stock to a lender in connection with their conversion of convertible promissory notes. The notes were converted at an average price per share of $0.01. 2. During the quarter ended September 30, 2017, we issued approximately 1.~~1 million shares of our common stock to a second lender in connection with their conversion of convertible promissory notes. The notes were converted at an average price per share of $~~0~~.01.~~ ~~3. During the quarter ended September 30, 2017, we issued approximately 23.3~~ million shares of our common stock to a ~~third~~ lender in connection with ~~their conversion of convertible promissory notes. The notes were converted at an average price per share of $0.01. 4. During~~ the ~~quarter ended September 30, 2017, we issued approximately 11.6 million shares of our common stock to a fourth lender in connection with their~~ conversion of ~~convertible~~ promissory notes. The notes were converted at an average price per share of $0.01271. 5. During the quarter ended September 30, 2017, we issued approximately 0.6 million shares of our common stock to a fifth lender in connection with their conversion of convertible promissory notes. The notes were converted at an average price per share of $0.01. 6. During the quarter ended September 30, 2017, we issued approximately 2.5 million shares of our common stock to a note holder in connection with their conversion of convertible promissory notes. The notes were converted at an average price per share of $0.01 7. During the quarter ended September 30, 2017, we issued approximately 18.3 million shares of our common stock to a sixth lender in connection with their conversion of convertible promissory notes. The notes were converted at an average price per share of $0.01 8. During the quarter ended September 30, 2017, we issued approximately 6.6 million shares of our common stock to a seventh lender in connection with their conversion of convertible promissory notes. The notes were converted at an average price per share of $0.01

The securities described in this Item 2 were issued without registration in reliance upon the exemption provided, among others, by Section 4(a)(2) of the Securities Act of 1933, as amended, as transactions not involving any public offering. Our reliance on Section 4(a)(2) of the Securities Act was based upon the following factors: (a) the transactions did not involve a public offering; (b) there were only a limited number of offerees; (c) there were no subsequent or contemporaneous public offerings of the securities by us; (d) the securities were not broken down into smaller denominations; and (e) the negotiations for the sales of the securities took place directly between the offerees and us.41

2.	During the three months ended March 31, 2018, we issued approximately 2.3 million shares of our common stock to a second lender in connection with the conversion of promissory notes. The notes were converted at an average price per share of $0.179.

3.	During the three months ended March 31, 2018, we issued approximately 0.7 million shares of our common stock to a third lender in connection with the conversion of promissory notes. The notes were converted at an average price per share of $0.283.

4.	During the three months ended March 31, 2018, we issued approximately 0.8 million shares of our common stock to a fourth lender in connection with the conversion of promissory notes. The notes were converted at an average price per share of $0.063.

5.	During the three months ended March 31, 2018, we issued approximately 0.1 million shares of our common stock to a fifth lender in connection with the conversion of promissory notes. The notes were converted at an average price per share of $0.274.

6.	During the three months ended March 31, 2018, we issued approximately 19,500 shares of our common stock to a sixth lender in connection with the conversion of promissory notes. The notes were converted at an average price per share of $1.188.

7.	During the three months ended March 31, 2018, we issued approximately 43,000 shares of our common stock to a seventh lender in connection with the conversion of promissory notes. The notes were converted at an average price per share of $1.278.

The disclosure regarding the Securities Purchase Agreements entered into and convertible notes issued on January 10, January 12, January 26, February 5, February 12, March 2 (twice), March 19 (twice), March 28, and March 30, 2018 listed in Note 6 to the unaudited condensed consolidated financial statements under the headings “Other Convertible Debt Financings” is incorporated herein by reference.

The shares of stock described in this Item 2 were issued without registration in reliance upon the exemption provided, among others, by Section 4(a)(2) of the Securities Act of 1933, as amended, as a transaction not involving any public offering. Our reliance on Section 4(a)(2) of the Securities Act was based upon the following factors: (a) the transaction did not involve a public offering; (b) there were only a limited number of offerees; (c) there were no subsequent or contemporaneous public offerings of the securities by us; (d) the securities were not broken down into smaller denominations; and (e) the negotiations for the sale of the stock took place directly between the offeree and us.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

~~None~~Item 1.01 Entry into a Material Definitive Agreement.

Item 2.03 Creation of Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

Item 3.02 Unregistered Sales of Equity Securities

Item 6. Exhibits.

We have listed the exhibits by numbers corresponding to the Exhibit Table of Item 601 in Regulation S-K on the Exhibit list attached to this report.

4142

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	POSITIVEID CORPORATION (Registrant)
Date: November 13, 2017	By:	/s/ William J. Caragol
Date: May 18, 2018	By:	/s/ William J. Caragol
		William J. Caragol
		Chairman of the Board, Chief Executive Officer and Acting Chief Financial Officer (Principal Executive Officer and Acting Principal Financial Officer)

4243

Exhibit Index

		Incorporated by Reference			Filed or
Exhibit		Incorporated by Reference			Filed or Furnished
Exhibit Number	Exhibit Description	Form	Exhibit	Filing Date	Furnished Herewith
Number	Exhibit Description	Form	Exhibit	Filing Date	Herewith
4.1*	Example of Convertible Promissory Note	8-K	4.1	7/21/2017
3.1	Third Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation of PositiveID Corporation	8-K	3.1	04/17/2018
4.2	Form of 12% Convertible Redeemable Note, dated September 12, 2017, with Union Capital, LLC	8-K	4.2	9/15/2017
4.1*	Form of Secured Convertible Promissory Note	8-K	4.1	02/03/2017
4.3	Form of 12% Convertible Redeemable Back-End Note, dated September 12, 2017, with Union Capital, LLC	8-K	4.3	9/15/2017
4.2*	Form of Convertible Promissory Note	8-K	4.1	01/12/2018
10.1*	Example of Securities Purchase Agreement entered into in connection with issuance of Convertible Redeemable Notes	8-K	10.1	7/21/2017
4.3*	Form of Demand Convertible Promissory Note	8-K	4.1	02/02/2018
10.2	Asset Purchase Agreement, dated as of August 24, 2017, among PositiveID Corporation, PositiveID Diagnostics, Inc., and ExcitePCR Corporation	8-K	10.1	8/28/2017
4.4*	Form of Convertible Redeemable Note	8-K	4.1	10/13/2017
10.3	Form of Securities Purchase Agreement, dated September 12, 2017, with Union Capital, LLC	8-K	10.2	9/15/2017
10.1*	Example of Securities Purchase Agreement entered into in connection with issuance of Convertible Notes	8-K	10.1	01/05/2018
10.4	Form of Union Capital, LLC Collateralized Secured Promissory Note, dated September 12, 2017, with PositiveID Corporation	8-K	10.3	9/15/2017
10.2	Form of Stock Purchase Agreement dated January 30, 2018, between PositiveID Corporation, Holdings ENG, LLC and E-N-G Mobile Systems, Inc.	8-K	10.1	02/02/2018
10.5	Form of PowerUp Lending Group Ltd 8% Convertible Redeemable Note, dated November 9, 2017, with PositiveID Corporation				X
10.6	Form of Securities Purchase Agreement, dated November 9, 2017, with PowerUp Lending Group Ltd				X
10.7	Form of 12% Convertible Redeemable Note, dated November 13, 2017, with Union Capital, LLC				X
10.8	Form of 12% Convertible Redeemable Back-End Note, dated November 13, 2017, with Union Capital, LLC				X
10.9	Form of Securities Purchase Agreement, dated November 13, 2017, with Union Capital, LLC				X
31.1	Certification of Principal Executive Officer and Principal Financial Officer, pursuant to 18 U. S. C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.				X
32.1**	Certification of Principal Financial Officer, pursuant to 18 U. S. C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.				X
101.INS	XBRL Instance.				X
101.SCH	XBRL Schema.				X
101.CAL	XBRL Calculation.				X
101.DEF	XBRL Definition.				X
101.LAB	XBRL Label.				X
101.PRE	XBRL Presentation.				X

* During the three months ended ~~September~~March 3031, ~~2017~~2018, PositiveID ~~entered~~issued ~~into~~ substantially similar: ~~securities~~(a) ~~purchase~~secured ~~agreements and~~convertible ~~issued~~promissory ~~substantially~~notes on ~~similar~~January ~~convertible~~2, ~~redeemable~~March ~~notes~~2, onMarch ~~July~~19, 17 and ~~August~~March 2128, 2018; (8%b) ~~interest~~convertible -promissory ~~PowerUp~~notes ~~Lending~~on ~~Group~~January ~~Ltd.~~8, January 12, February 5 (twice), ~~August~~and 8February (12%; ~~interest~~(c) -demand ~~Fidelis~~convertible ~~Capital,~~promissory ~~LLC),~~notes on February 2 and ~~September~~February 1119; and (d) convertible redeemable notes on January 10%, ~~interest~~January -26, ~~GHS~~March ~~Investments~~2, ~~LLC)~~March 19, and March 30.

** In accordance with SEC Release 33-8238, Exhibit 32.1 is being furnished and not filed.

4344

Filing Compare · POSITIVEID Corp